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Confocal microscope image:  
Immunohistochemistry – fluorescence staining for mutant ataxin-3 (Ab 1H9, red) 
localization upon co-expression with calpastatin (Ab H300, green) in the striatum of 
adult mice, 2 months post-injection. Nuclear marker (DAPI, blue) was used. 
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Summary 
 
 Machado-Joseph disease, also known as spinocerebellar ataxia type 3 
(MJD/SCA3), is the most frequent autosomal dominantly-inherited ataxia worldwide. 
MJD is caused by a CAG expansion within the coding region of MJD1 gene mapped to 
chromosome 14q32.1, resulting the mutation in an abnormal polyglutamine tract at the 
C-terminal of the ataxin-3 protein. 
 According to the toxic fragment hypothesis, MJD neurodegeneration might 
derive from the proteolysis of the mutant protein to liberate toxic fragments, which can 
then initiate the aggregation process associated with inclusion formation. Furthermore, 
a nuclear localization is predicted to be required for the manifestation of MJD 
symptoms. Understanding the cellular protease(s) responsible for the proteolytic 
mechanism and how ataxin-3 translocates from cytoplasm to nucleus could reveal 
potential targets for therapy. In this sense, we set out to investigate in animal mouse 
models whether and how are calpains involved in MJD pathogenesis. 
 In chapter 1, a review of the importance of ataxin-3 proteolysis and nuclear 
localization in polyglutamine diseases, particularly the case of MJD, is presented. 
 In chapter 2, we modulated calpain activity in a lentiviral mouse model of MJD 
by overexpression of calpastatin, an endogenous calpain-specific inhibitor, with adeno-
associated viral vectors (AAV). We provide evidence that calpains are the proteases 
involved in mutant ataxin-3 proteolysis at amino acids 154, 220, 60 and 260 leading to 
the formation of putative fragments: a ~26 kDa fragment, C and N-terminal, and a ~34 
kDa fragment, only C-terminal. Inhibition of calpains prevents the formation of both 
fragments, reducing the size and number of neuronal intranuclear inclusions of mutant 
ataxin-3, while mediating neuroprotection. Accordingly, upon three progressively 
increasing levels of calpastatin, we observed that the mean diameter of mutant ataxin-3 
intranuclear inclusions was reduced, suggesting that, calpain-mediated proteolysis is 
required for ataxin-3 translocation to the nucleus and aggregation. Our results show 
that calpain overactivation and thus MJD progression could be propelled by depletion 
of calpastatin. In agreement, reduced levels of calpastatin were detected in MJD 
lentiviral and transgenic mouse models and, importantly, in MJD patients post mortem 
tissue. 
 In chapter 3, a systemic strategy of calpain inhibition able to reach a broader 
distribution, while minimizing invasiveness was used. Our data show that an oral low 
molecular weight drug termed BDA-410 administered daily to a lentiviral mouse model 
is able to promote, by calpain inhibition, a decrease of mutant ataxin-3 fragments, full-
length and aggregate levels, an effect that does not result from reduction of mRNA 
   VIII   
expression. Preservation of DARPP-32 immunoreactivity, a regulator of dopamine 
receptor signalling, and reduced number of shrunken hyperchromatic nuclei are 
indicative of the neuroprotective effect provided by BDA-410. Our results also show 
that mutant ataxin-3 aggregates of specific size have different toxic properties. 
Accordingly, we found that larger aggregates colocalize significantly more with cleaved 
caspase-3 than smaller aggregates. BDA-410 calpain inhibition reduces the number of 
mutant ataxin-3 positive cells co-expressing cleaved caspase-3, contributing to a 
decrease in cytotoxicity. 
 In chapter 4, a transgenic mouse model of MJD was used to evaluate calpain 
inhibitory effects after onset of neuropathology. Calpastatin overexpression through 
AAV vectors decreased mutant ataxin-3 full-length levels, stabilizing the fragments 
formation, and inhibited ataxin-3 translocation to the nucleus and consequent 
aggregation in the calpastatin-transduced area of seven months old transgenic mice. 
Moreover, in this chapter, to answer the question of what is the trigger of ataxin-3 
proteolysis in MJD: calpains overactivation or calpastatin depletion, we analyzed non-
injected transgenic mice at different ages. Our results show that ataxin-3 proteolysis 
increases with age. Nevertheless, the distinction of this event between wild-type and 
transgenic mice occurred at a younger age, being significantly increased in the latter 
mice, suggesting that proteolysis as a pathogenic mechanism is an early event. As 
calpastatin depletion in transgenic mice is age-dependent we can conclude that it is 
downstream to proteolysis. Unexpectedly, we could not prove that calpain inhibition 
can alleviate motor incoordination, probably due to a restricted calpain inhibitory effect 
in a specific region, which did not reach other affected brain regions, and due to a late 
calpain inhibition. 
 In conclusion, this thesis provides evidence that calpains are the proteases 
involved in mutant ataxin-3 proteolysis and translocation to the nucleus. Furthermore, 
our results show that calpain inhibition either by viral transduction or oral administration 
mediates neuroprotection and might be considered an effective therapeutic strategy for 
MJD. 
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Resumo 
 
 A doença de Machado-Joseph, também conhecida por ataxia espinocerebelosa 
tipo 3 (MJD/SCA3), é a ataxia autossómica dominante mais comum a nível mundial. A 
MJD é causada por uma expansão CAG na região codificante do gene MJD1 
localizado no cromossoma 14q32.1, sendo a mutação traduzida numa cadeia de 
poliglutaminas anormal no terminal carboxílico da proteína ataxina-3. 
 De acordo com a hipótese dos fragmentos tóxicos, a neurodegenerescência na 
MJD pode derivar da proteólise da proteína mutante conduzindo à formação de 
fragmentos tóxicos, que por sua vez iniciam o processo de agregação com formação 
de inclusões. Acresce que, para haver manifestação dos sintomas na MJD parece ser 
necessária a localização da ataxina-3 no núcleo. A compreensão do mecanismo 
proteolítico, em particular da(s) protease(s) celular(es) e dos fragmentos de clivagem 
da ataxina-3 e consequente transporte do citoplasma para o núcleo pode revelar 
potenciais alvos terapêuticos. Neste sentido, investigámos em modelos roedores 
animais se e como as calpaínas estão envolvidas na patogénese de MJD. 
 No capítulo 1, é apresentado um resumo bibliográfico da importância da 
proteólise da ataxina-3 e sua localização nuclear nas doenças de poliglutaminas, em 
particular no caso da MJD. 
 No capítulo 2, modulámos a actividade das calpaínas no modelo lentiviral 
murino da MJD sobreexpressando a calpastatina, o inibidor endógeno específico das 
calpaínas, através de vectores virais adeno-associados (AAV). Evidenciámos que as 
calpaínas são as proteases envolvidas na proteólise da ataxina-3 mutante nos 
aminoácidos 154, 220, 60 e 260 conduzindo à formação de fragmentos: um fragmento 
de ~26 kDa, C e N-terminal, e um fragmento de ~34 kDa, apenas C-terminal. A 
inibição das calpaínas previne a formação dos dois fragmentos, reduzindo o tamanho 
e o número de inclusões intranucleares da ataxina-3 mutante e promovendo 
neuroprotecção. Em conformidade, observámos que em três níveis crescentes de 
calpastatina, o diâmetro médio das inclusões intranucleares de ataxina-3 mutante 
decrescia, sugerindo que a proteólise mediada pelas calpaínas é determinante para o 
transporte da ataxina-3 para o núcleo e agregação. Os nossos resultados demonstram 
que a sobreactivação das calpaínas e por isso a progressão da MJD pode ser 
promovida pela deplecção da calpastatina. Na verdade, foram detectados níveis 
reduzidos de calpastatina nos modelos murinos lentiviral e transgénico e, mais 
importante, em tecido post mortem de doentes MJD. 
 No capítulo 3, foi usada uma estratégia de inibição de calpaínas capaz de 
alcançar uma distribuição mais ampla minimizando o procedimento invasivo. Os 
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nossos resultados demonstram que um fármaco de baixo peso molecular designado 
por BDA-410 administrado diariamente ao modelo lentiviral murino promove por 
inibição das calpaínas um decréscimo dos níveis de fragmentos, proteína não clivada 
e agregados de ataxina-3 mutante, efeito que não decorre dos níves de mRNA. A 
preservação da imunoreactividade da proteína DARPP-32, um regulador da 
sinalização dos receptores de dopamina, e uma redução do número de núcleos 
hipercromáticos condensados são indicativos de um efeito neuroprotector 
proporcionado pela administração do inibidor BDA-410.  
Os nossos resultados demonstram também que agregados de ataxina-3 
mutante de diferente tamanho têm diferentes propriedades tóxicas. Neste sentido, 
verificámos que agregados maiores apresentam um aumento significativo na 
colocalização com a caspase-3 clivada. A inibição das calpaínas reduz o número de 
células imunoreactivas para ataxina-3 que co-expressam a caspase-3 clivada, 
contribuindo para o decréscimo de citotoxicidade.  
 No capítulo 4, recorreu-se a um modelo de murganho transgénico de MJD para 
avaliar os efeitos inibidores das calpaínas após início da neuropatologia. A 
sobreexpressão da calpastatina por vectores AAV reduziu os níveis da ataxina-3 
mutante não clivada, estabilizando a formação de fragmentos. Simultaneamente, a 
inibição das calpaínas em murganhos transgénicos de sete meses de idade inibiu o 
transporte da ataxina-3 para o núcleo e consequente agregação na área transduzida 
pela inibição das calpaínas. Neste capítulo, investigou-se ainda em murganhos 
transgénicos não tratados a origem do estímulo que desencadeia a proteólise da 
ataxina-3 na MJD: se a sobreactivação das calpaínas, se a deplecção da calpastatina. 
Os nossos resultados sugerem que a proteólise da ataxina-3 aumenta com a idade. 
No entanto, a distinção deste evento entre murganhos transgénicos e normais ocorre a 
uma idade inferior, estando aumentada nos murganhos transgénicos, o que sugere 
que a proteólise como mecanismo patogénico é um evento precoce. Como a 
deplecção de calpastatina é dependente da idade podemos concluir que ocorre 
posteriormente à proteólise. Inesperadamente, não conseguimos provar que a inibição 
das calpaínas pode prevenir a descoordenação motora, provavelmente por o efeito 
inibitório das calpaínas ter sido restrito ao estriado, não tendo incluído outras regiões 
afectadas do cérebro determinantes para o comprometimento da função motora, e 
possivelmente por a inibição das calpaínas ter sido efectuada tardiamente, tendo em 
conta que se observou que a sobreactivação da proteólise pela ataxina-3 mutante 
ocorre de forma precoce. 
 Em resumo, esta tese demonstra que a proteólise da ataxina-3 mutante e o seu 
transporte para o núcleo é mediado pelas calpaínas. Para além disso, os nossos 
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resultados demonstram que a inibição das calpaínas quer por transdução viral quer 
por administração oral promove neuroprotecção e pode ser considerada uma 
estratégia terapêutica eficaz para MJD. 
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Introduction 
  3 
1.1. Polyglutamine diseases 
 
In 1991, the first CAG triplet repeat disease, named spinal and bulbar muscular 
atrophy (SBMA), was described (La Spada et al., 1991). Since then, eight other 
disorders were identified, including Huntington’s disease (HD), dentatorubral-
pallidoluysian atrophy (DRPLA) and spinocerebellar ataxias (SCA) types 1, 2, 3, 6, 7 
and 17. All derive from a CAG codon over-repetition in each respective gene, which 
translates into an elongated polyglutamine (polyQ) tract within the affected proteins. 
With the exception of SBMA, an X-linked recessive disease, all other polyQ diseases 
are autosomal dominant (Zoghbi and Orr, 2000) (Table I). 
 
Table I. Polyglutamine Diseases 
Disease Protein Protein function Brain regions most affected 
SBMA Androgen receptor testosterone-activated steroid receptor anterior horn and bulbar neurons, dorsal root ganglia 
HD Huntingtin 
intracellular transport, transcription, 
possible scaffold protein in different 
pathways 
striatum, cerebral cortex 
DRPLA Atrophin-1 possible transcriptional co-repressor cerebellum, cerebral cortex, basal ganglia, Luys body 
SCA1 Ataxin-1 transcriptional co-repressor cerebellar Purkinje cells, dentate nucleus, brainstem 
SCA2 Ataxin-2 component of RNA processing and translational regulation pathways 
cerebellar Purkinje cells, brainstem, 
frontotemporal lobes 
MJD/SCA3 Ataxin-3 deubiquitinating enzyme involved in protein quality control 
cerebellar dentate nucleus, basal 
ganglia, brainstem, spinal cord 
SCA6 P/Q-type calcium channel subunit !1A 
voltage-sensitive calcium-channel 
subunit 
cerebellar Purkinje cells, dentate 
nucleus, inferior olive 
SCA7 Ataxin-7 
component of histone acetyltransferase 
complex (TFTC/STAGA) and 
transcriptional regulation pathways 
cerebellum, brainstem, macula, 
visual cortex 
SCA17 TATA box binding protein 
component of core transcriptional 
complex TFIID 
cerebellar Purkinje cells, inferior 
olive 
The nine known polyQ diseases are listed along with their causative proteins, their putative functions and 
brain regions most affected. Table was adapted from (Shao and Diamond, 2007; Williams and Paulson, 
2008). 
 
The proteins affected in polyglutamine diseases are unrelated in terms of their 
amino acid sequence, structure and function, being neurodegeneration selective to 
specific brain regions (see Table I). However, common features include a progressive 
neuronal cell loss and decline in physical and psychological functions (Gatchel and 
Zoghbi, 2005). In general, the age of onset inversely correlates with the number of 
CAG repeats (Maciel et al., 1995; van de Warrenburg et al., 2002). Furthermore, as 
repeats are unstable and tend to further expand, successive generations may present 
an earlier onset and a more severe phenotype – a phenomenon called anticipation 
(Myers et al., 1982). 
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1.1.1. Pathogenesis of polyglutamine diseases 
 
 To date, the mechanism by which the CAG repeat mutation drives pathogenesis 
remains to be established. PolyQ-expanded proteins may undergo proteolysis into 
cleavage fragments that misfold, leading to toxic effects in multiple targets such as the 
transcriptional machinery, mitochondria and quality control systems, accumulating into 
inclusions within the cytoplasm and the cell nucleus (Fig. 1.1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Molecular mechanisms underlying pathogenesis of polyQ diseases. Proteolytic 
cleavage to generate toxic fragments has been implicated in some of the polyQ diseases. 
Expanded polyQ proteins may then exert toxicity as a misfolded monomer or toxic oligomers, 
which can assemble into intranuclear inclusions. Toxic effects may include alterations in protein 
normal function, transcription, RNA toxicity, failure of quality control system or mitochondrial 
dysfunction. 
 
1.1.1.1. PolyQ sequence 
 
The unstable polyQ sequence expansion plays an important role in the 
pathogenesis of this group of disorders. In fact, several transgenic models expressing 
expanded CAG repeats outside the natural gene context present a neurodegenerative 
phenotype similar to polyQ disorders (Ikeda et al., 1996; Mangiarini et al., 1996; 
Ordway et al., 1997). 
 Although extensive work has been directed to protein toxicity, RNA toxicity 
might also represent a pathogenic mechanism for polyQ disorders, in accordance to 
other repeat expansion diseases like myotonic dystrophy type 1 and SCA8, both CUG 
repeat RNA expansion diseases. Accordingly, Li et al. (2008) provided evidence for a 
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pathogenic role of the CAG repeat RNA in polyQ toxicity in a MJD/SCA3 fly model. Not 
only the interruption of the long series of CAG repeats with CAA codons led to a 
significant reduction in neurodegeneration, being predicted that the interrupted RNA 
sequence encoded the same mutant protein, but also the expression of an untranslated 
CAG repeat of pathogenic length conferred toxicity, indicating that the RNA itself might 
have a pathogenic role (Li et al., 2008). 
 
1.1.1.2. Loss of normal protein function 
 
 Recent studies suggest that the polyQ expansion might lead to perturbation of 
normal function of the polyQ-carrying protein, which could promote toxicity. In fact, 
overexpression of wild-type huntingtin in transgenic mice can rescue mutant huntingtin 
toxicity (Leavitt et al., 2001). In addition, duplication of ataxin-1-like gene suppresses 
SCA1 neuropathology in mice (Bowman et al., 2007). However, multiple knockout 
models of polyQ diseases did not present the disease phenotype (Duyao et al., 1995; 
Matilla et al., 1998; Rodrigues et al., 2010; Schmitt et al., 2007). Furthermore, in 
contrast to what was observed in a MJD/SCA3 fly model (Warrick et al., 2005), non-
expanded ataxin-3 could not mitigate polyQ-induced degeneration in MJD/SCA3 
mouse and rat models (Alves et al., 2010; Hubener and Riess, 2010).  
 
1.1.1.3. Intracellular inclusions 
 
Protein aggregates containing the mutant protein were described in transgenic 
disease models and more importantly in patients, being considered a hallmark of all 
polyQ diseases. Indeed, the term neuronal intranuclear inclusions (NIIs) became widely 
used in these disorders (Becher et al., 1998; Holmberg et al., 1998; Paulson et al., 
1997b; Skinner et al., 1997), although in SCA2 and SCA6 NIIs formation is not 
prominent, being inclusions preferentially cytoplasmic (Ishikawa et al., 2001; Koyano et 
al., 1999). Whether these inclusions are pathogenic or protective is a matter of debate 
(Kitamura and Kubota, 2010; Ross and Poirier, 2005; Shao and Diamond, 2007; 
Takahashi et al., 2010). 
Initially, it was proposed that these large inclusions were the proximal cause of 
neurodegeneration. PolyQ-expanded proteins are structurally unstable and thus tend to 
aggregate (Scherzinger et al., 1997) and interact with other proteins via exposed 
hydrophobic surfaces, leading to perturbation of cellular activities, as several functional 
proteins become trapped in aggregates, such as transcription factors (McCampbell et 
al., 2000; Nucifora et al., 2001; Schaffar et al., 2004), proteasome components (Chai et 
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al., 1999b), chaperones (Muchowski et al., 2000; Schmidt et al., 2002) and ubiquitin 
(Donaldson et al., 2003). Evidences of disruption of axonal transport, through motor 
protein titration or physical interruption have also been reported (Gunawardena et al., 
2003). However, recent studies have dissociated the appearance of inclusions from the 
pathogenic process, consistent with the idea that such inclusions represent an end-
stage of the adaptive cellular response to large quantities of misfolded protein. In fact, 
distribution of such aggregates does not perfectly match with neuronal loss (Gutekunst 
et al., 1999; Kuemmerle et al., 1999; Paulson et al., 1997b; Slow et al., 2005; Trottier et 
al., 1998). Furthermore, inclusion body formation was correlated to protection and cell 
survival by decrease of the levels of toxic diffuse forms (Arrasate et al., 2004; 
Takahashi et al., 2008). Indeed, accumulating evidence suggests that soluble species, 
including fragments and oligomers, are more toxic than large insoluble aggregates or 
inclusions, which is described as the toxic fragment hypothesis, whereby smaller 
proteolytic fragments of expanded polyQ proteins containing the glutamine repeat show 
enhanced propensity for toxicity and aggregation, and may underlie neuronal 
dysfunction and neurological phenotype (DiFiglia et al., 1997; Haacke et al., 2006; 
Ikeda et al., 1996; Kim et al., 2001; Tarlac and Storey, 2003; Wellington et al., 1998).  
This search for toxic species is not consensual by the fact that different 
experimental paradigms using either full-length polyQ mutant proteins or polyQ protein 
fragments can lead to divergent results. 
 
1.1.1.4. Proteolytic cleavage 
 
Evidence from human tissue as well as animal and cell models suggests that 
cleavage is a relevant event in the natural turnover of polyQ proteins (Tarlac and 
Storey, 2003), as reviewed in Table II. 
In misfolded proteins the exposure of usually hidden moieties, such as 
hydrophobic surfaces or main chain NH and CO groups, is much greater in the 
monomeric and oligomeric states than in the inclusion state under conditions where the 
number of misfolded proteins per cell is identical (Kitamura and Kubota, 2010; Ross 
and Poirier, 2005). This alteration, as well as other post-translational modifications of 
amino acid residues including phosphorylation, ubiquitination, sumoylation and 
palmitoylation, might result in aberrant interactions with other proteins and may alter 
the properties of causative proteins, including stability (Takahashi et al., 2010). 
According to the proteolytic hypothesis, neurotoxicity might depend on the formation of 
oligomers, and therefore on the proteolysis of the host protein to liberate a polyQ 
fragment, which might translocate into the nucleus and promote toxic effects (Peters et 
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al., 1999; Yang et al., 2002). Sanchez and colleagues showed that inhibition of the 
oligomerization process by infusion of Congo red into a transgenic mouse model of HD 
exerted marked protective effects on survival, weight loss and motor function (Sanchez 
et al., 2003).  
Specific pathological topography according to brain regions affected in each 
disorder could be governed by distribution of a specific protease or its recognition 
through a novel conformation conferred by the expanded polyQ tract, allowing 
recognition of hidden domains or sequences, as stated above, or its specific activation 
due to a characteristic cellular context (Tarlac and Storey, 2003). Actually, tissue-
specific proteolysis has been demonstrated in HD brains, where an increase in 
huntingtin N-terminal fragments was observed in affected striatum, when compared 
with the cerebral cortex (Mende-Mueller et al., 2001). 
Even though many cellular processes, such as embryogenesis, gene 
expression, cell cycle, programmed cell death, intracellular protein targeting and 
endocrine/neural functions are regulated by limited proteolysis of precursor proteins 
(Hyman and Yuan, 2012), a wide variety of proteases has been engaged in necrotic 
cell death and neurodegeneration. These include cytosolic cysteine and aspartyl 
proteases, lysosomal proteases, microglial proteases and the ubiquitin proteasome 
system (Artal-Sanz and Tavernarakis, 2005). A better understanding of the proteolytic 
mechanisms and the proteases involved could reveal potential targets for therapeutic 
action to battle neurodegenerative disorders. 
 
1.1.1.5. Protein subcellular localization 
 
 The subcellular localization of polyQ proteins is highly regulated, depending on 
the sequence and structure of the proteins, presence of internal localization signals, 
post-translational modifications, protein-protein interactions and specific cellular 
conditions (Antony et al., 2009; Breuer et al., 2010; Macedo-Ribeiro et al., 2009; 
Mueller et al., 2009; Orr, 2001; Reina et al., 2010). Despite the stated regulation, the 
nucleus might be an important player in the pathogenesis of polyQ diseases (Table II). 
In fact, the importance of nuclear localization was emphasised by Yang et al, who 
showed that simple polyQ aggregates localized to the cytoplasm had little impact on 
cell viability, but led to dramatic cell death when localized to nuclei (Yang et al., 2002). 
Toxicity may then be initiated by the adequate nuclear environment followed by 
numerous downstream events including apoptotic activation, misfolding, aggregation 
and sequestration of other proteins (Walsh et al., 2005). Actually, many transcriptional 
factors/regulators, including CREB-binding protein, TAFII130, Sp1 and p53, have been 
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found in inclusion bodies and shown to interact with polyQ proteins, suggesting that 
these interactions might perturb gene expression through transcriptional dysregulation 
(Luthi-Carter et al., 2002; Okazawa, 2003). 
Enhanced nuclear transport upon polyQ expansion might be mediated by 
interference with the nuclear matrix (Skinner et al., 1997) or by proteolytic cleavage, 
either because it occurs between specific nuclear localization signals (NLS) and 
nuclear export signals (NES) (Pemberton and Paschal, 2005) or because smaller 
fragments are more likely to enter the nucleus through passive diffusion (Marfori et al., 
2011). Further understanding the nucleocytoplasmic shuttling, particularly in the case 
of cytoplasmic polyQ proteins, could help to elucidate disease pathogenesis. 
 
Table II. Subcellular localization and evidence of proteolysis of polyglutamine proteins 
Disease 
Subcellular localization Required for toxicity Proteases 
identified References Protein Inclusions Nuclear localization Proteolysis 
SBMA 
cytoplasm 
and 
nucleus 
nucleus + + caspases 
(Ellerby et al., 1999b; Katsuno 
et al., 2002; Kobayashi et al., 
1998; LaFevre-Bernt and 
Ellerby, 2003; Li et al., 1998; 
Merry et al., 1998; Wellington 
et al., 1998) 
HD 
cytoplasm 
and 
nucleus 
cytoplasm 
and 
nucleus 
+ + 
caspases, calpains, 
bleomycin 
hydrolase, 
cathepsin Z, matrix 
metalloproteinases 
(Gafni and Ellerby, 2002; Gafni 
et al., 2004; Graham et al., 
2010; Graham et al., 2006; 
Miller et al., 2010; Ratovitski et 
al., 2011; Tebbenkamp et al., 
2011; Warby et al., 2008; 
Wellington et al., 2002; 
Wellington et al., 1998; 
Wellington et al., 2000) 
DRPLA 
cytoplasm 
and 
nucleus 
nucleus + + caspases 
(Ellerby et al., 1999a; Nucifora 
et al., 2003; Ross et al., 1999; 
Wellington et al., 1998) 
SCA1 
cytoplasm 
and 
nucleus 
nucleus + -  (Klement et al., 1998) 
SCA2 cytoplasm 
cytoplasm 
and 
nucleus 
- -  (Huynh et al., 2000) 
MJD/SCA3 
cytoplasm 
and 
nucleus 
nucleus + + caspases, calpains 
(Berke et al., 2004; 
Bichelmeier et al., 2007; 
Haacke et al., 2007; Jung et 
al., 2009; Koch et al., 2011; 
Wellington et al., 1998) 
SCA6 cytoplasm 
cytoplasm 
and 
nucleus 
+ + not identified (Kordasiewicz et al., 2006; Kubodera et al., 2003) 
SCA7 
cytoplasm 
and 
nucleus 
nucleus + + caspases 
(Cancel et al., 2000; Garden et 
al., 2002; Mookerjee et al., 
2009; Young et al., 2007; Yvert 
et al., 2001; Yvert et al., 2000) 
SCA17 nucleus nucleus - -  (Nakamura et al., 2001) 
+ or -, evidence that nuclear localization or proteolysis of polyQ proteins is or is not required for polyQ 
toxicity, respectively. 
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1.1.1.6. Failure of quality control system  
 
 Because cells produce a large amount of misfolded proteins in nature, a 
functional quality control system is crucial for cellular viability. Impairment of this 
system leads to the accumulation of misfolded proteins, resulting in dysfunction and 
cell death of neurons (Ciechanover and Brundin, 2003; Shao and Diamond, 2007; 
Takahashi et al., 2010).  
 As previously mentioned, inclusion bodies of polyQ diseases are ubiquitinated 
and contain proteasome components, which suggested that the ubiquitin proteasome 
system could be disrupted by expanded polyQ proteins (Chai et al., 1999b; Donaldson 
et al., 2003; Schmidt et al., 2002). Problems might also arise from an inability of 
proteasome to fully digest soluble expanded polyQ proteins and from the generation of 
their fragments (Holmberg et al., 2004; Venkatraman et al., 2004). Additionally, 
aggregated proteins may also sequester chaperones, compromising the ability of the 
cell to evolve an appropriate folding response (Behrends et al., 2006; Muchowski et al., 
2000; Schmidt et al., 2002). Quality control ubiquitin ligases, including CHIP, parkin 
and E4B, have recently emerged as modifiers of various neurodegenerative disorders, 
as they constitute a scaffold that gathers components of protein refolding with ubiquitin 
machinery (Williams and Paulson, 2008). An increased turnover of these E3 ubiquitin 
ligases may contribute to pathogenesis by interference with protein degradation 
(Durcan et al., 2011; Jana et al., 2005; Miller et al., 2005). 
 Furthermore, autophagy, which refers to a catabolic process in which cell 
constituents, such as organelles and proteins, are delivered to the lysosomal 
compartment for degradation, has been linked to polyQ expansion diseases. This 
correlation was first established when mutant huntingtin was found to be associated 
with accumulated autophagic vacuoles in patients with HD (Kegel et al., 2000; Nagata 
et al., 2004). Hallmarks of autophagy impairment have now been reported in animal 
models of other polyQ diseases, including SCA1, MJD/SCA3, SCA7 and SBMA (La 
Spada and Taylor, 2010; Montie et al., 2009; Nascimento-Ferreira et al., 2011; Vig et 
al., 2009; Zander et al., 2001). 
 
1.1.1.7. Mitochondrial dysfunction 
 
 Evidence that mitochondrial dysfunction contributes to polyQ 
neurodegeneration comes primarily from studies of HD. Toxic effects include 
compromised energy metabolism and increased oxidative damage, which eventually 
contribute to neuronal dysfunction and death. In fact, HD patients exhibit metabolic 
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defects, including reduced glucose metabolism and decreased mitochondrial complex 
activity. Furthermore, mitochondria from patients required lower calcium loads for 
depolarization and showed lower membrane potentials (Antonini et al., 1996; Browne 
et al., 1997; Grafton et al., 1992). Impaired mitochondrial function may further mitigate 
cytosolic and mitochondrial calcium homeostasis, rendering neurons especially 
sensitive to excitotoxicity (Brouillet et al., 1995). In addition, because protein quality 
control pathways are ATP-dependent, impaired mitochondrial function could 
exacerbate problems in protein folding or decrease the degradation of expanded polyQ 
proteins (Gines et al., 2003). Mitochondrial dysfunction has also been implicated in the 
pathogenesis of SBMA  (Beauchemin et al., 2001), SCA1 (Kish et al., 1999), DRPLA 
(Lodi et al., 2000) and more recently of MJD, by compromising mitochondrial complex 
II activity (Chou et al., 2006; Laco et al., 2012; Tsai et al., 2004). There is evidence that 
polyQ expansion in ataxin-3 is essential for mitochondrial membrane anchoring, as 
truncated forms without the expanded stretch were only detected in the mitochondrial 
matrix. Interestingly, while both wild-type and mutant ataxin-3 could be observed in 
mitochondrial membranes, only the fragment of the mutant protein could also be 
detected in the membranes, but not the fragments originated from the wild-type protein. 
Mitochondrial damage could derive from aggregation in the matrix or through the 
formation of channels in the membrane (Pozzi et al., 2008).  
 
 
 
  1.2. Machado-Joseph Disease 
 
  Spinocerebellar ataxia type 3 (SCA3) is also known as Machado-Joseph 
disease (MJD), as it was initially described in Northern American families, emigrants 
from the Portuguese Azorean islands São Miguel (Machado family) and Flores (Joseph 
family) (Nakano et al., 1972; Rosenberg et al., 1976). The subsequent identification of 
the families in Portugal led to the unification of the disease. MJD was then considered 
a single genetic disease, although with variable phenotypic expression (Coutinho and 
Andrade, 1978). Nowadays, MJD is considered the most frequent form among the 
autosomal dominantly inherited cerebellar ataxias in Europe, Japan and United States 
(Riess et al., 2008). 
  MJD is associated with an expanded CAG repeat in the coding region of MJD1 
gene mapped to the long arm of chromosome 14, region 14q32.1 (Kawaguchi et al., 
1994; Takiyama et al., 1993). The mutation results in a polyQ tract at the C-terminus of 
ataxin-3 (Durr et al., 1996), ranging the number of CAG repeats, in healthy population, 
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from 12 to 44, while in MJD patients it varies between 61 to 87 (Maciel et al., 2001). 
Although intermediate size alleles are rare, there are a few reports of disease-
associated alleles containing 45-56 CAG repeats (Padiath et al., 2005; Takiyama et al., 
1997; van Alfen et al., 2001). 
  MJD neurodegeneration involves neuronal loss in selective brain regions, 
including the cerebellum (spinocerebellar pathways and dentate nucleus), brainstem 
(pons and medulla oblongata), basal ganglia (globus pallidus, caudate and putamen, 
substantia nigra) and spinal cord (Alves et al., 2008b; Durr et al., 1996; Klockgether et 
al., 1998; Rub et al., 2008; Sudarsky and Coutinho, 1995; Wullner et al., 2005). 
Progressive cerebellar ataxia, pyramidal signs, as well as ophtalmoplegia, dystonia, 
dysphagia and facial and lingual fasciculation-like movements are common features of 
MJD (D'Abreu et al., 2010; Lima and Coutinho, 1980). 
  Regarding MJD treatment, effective causative approaches are still lacking, 
being available only symptomatic strategies: extrapyramidal syndromes resembling 
parkinsonism and symptoms of restless legs syndrome may respond to levodopa or 
dopamine agonists (Buhmann et al., 2003; Schols et al., 1998; Tuite et al., 1995); 
spasticity, drooling, and sleep disturbance respond variably to baclofen, atropine-like 
drugs, and hypnotic agents; dystonia can be treated with botulinum toxin (Freeman and 
Wszolek, 2005); daytime fatigue may respond to psychostimulants used in narcolepsy; 
accompanying depression should be treated with antidepressants (Cecchin et al., 
2007). Non-pharmacological approaches, such as physiotherapy, physical aids, such 
as walkers and wheelchairs, regular speech therapy as well as occupational therapy 
help patients to cope with disability and dysphagia, and assist in their everyday 
activities (D'Abreu et al., 2010). However, identification of affected pathways that could 
reverse cellular defects or target the expression, processing or conformation of the 
pathogenic protein, may provide ways to slow or block disease progression 
(Bettencourt and Lima, 2011; Shao and Diamond, 2007). See Table III for an outline of 
potential therapeutic strategies that have shown efficacy in experimental models of 
MJD. 
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Table III. Development of therapeutic strategies for Machado-Joseph disease 
Therapeutic 
pathway 
Mechanism 
(Compound) MJD model Result Reference 
Transcription 
regulation 
HDAC inhibitor (sodium 
butyrate) transgenic mice 
delayed onset of ataxic 
symptoms, ameliorated 
neurological phenotypes, 
improved survival rate 
(Chou et al., 2011) 
HDAC inhibitor (valproic 
acid) 
Caenorhabditis 
elegans 
reduced aggregation and 
motor dysfunction 
(Teixeira-Castro et 
al., 2011) 
Calcium 
neuronal 
signalling 
Ca2+ signalling stabilizer 
(dantrolene) transgenic mice 
improved motor 
performance, prevented 
neuronal cell loss 
(Chen et al., 2008) 
Gene 
expression 
RNA interference by 
lentiviral-mediated 
expression of shRNAs 
lentiviral rat model reduced aggregation and neuronal dysfunction 
(Alves et al., 2008a; 
Alves et al., 2010) 
PNA and LNA antisense 
oligomers 
patient-derived 
fibroblast cell lines 
reduced ataxin-3 
expression 
(Hu et al., 2011; Hu 
et al., 2009) 
Ataxin-3 
clearance 
and folding 
autophagy inducer 
(temsirolimus) transgenic mice 
reduced aggregation and 
improved motor 
performance 
(Menzies et al., 
2010) 
autophagy inducer 
(beclin-1) lentiviral rat model 
reduced aggregation and 
neuronal dysfunction 
(Nascimento-Ferreira 
et al., 2011) 
heat shock response 
inducer (Hsp90 inhibitor 
17-DMAG) 
Caenorhabditis 
elegans 
reduced aggregation and 
motor dysfunction 
(Teixeira-Castro et 
al., 2011) 
Rho kinases inhibitor (Y-
27632) 
mouse 
neuroblastoma cell 
line (Neuro2a) 
reduced aggregation (Bauer et al., 2009) 
Hsp40 chaperone 
rat adrenal 
pheochromocytoma 
cell line (PC12) 
suppressed aggregation 
and decreased 
neurotoxicity 
(Chai et al., 1999a) 
Hsp70 chaperone Drosophila melanogaster 
suppressed 
neurodegeneration without 
effect on aggregation 
(Warrick et al., 1999) 
ubiquitin chain assembly 
factor E4 
Drosophila 
melanogaster 
promoted ataxin-3 
degradation and 
suppressed 
neurodegeneration 
(Matsumoto et al., 
2004) 
C-terminus of Hsp70-
interacting protein (CHIP) 
mouse 
neuroblastoma cell 
line (Neuro2a) 
suppressed aggregation 
and cell death (Jana et al., 2005) 
Polyglutamine Binding 
Peptide 1 (QBP1) 
Drosophila 
melanogaster 
suppressed aggregation 
and cell death (Nagai et al., 2003) 
chemical chaperones 
(DMSO, cellular 
osmolytes glycerol, 
TMAO) 
mouse 
neuroblastoma cell 
line (Neuro2a) 
reduced aggregation and 
cytotoxicity 
(Yoshida et al., 
2002) 
Ataxin-3 
localization 
CK2 inhibitors (TBB and 
DMAT) 
mouse embryonic 
fibroblasts (MEF) 
decreased ataxin-3 nuclear 
levels and aggregation (Mueller et al., 2009) 
CK2 inhibitor (TBB) and 
GSK3 inhibitor 
(SB216763) 
fibroblast-like 
kidney cell line 
(COS-7) 
decreased ataxin-3 nuclear 
levels (Pastori et al., 2010) 
Ataxin-3 
cleavage 
caspase inhibitor (z-VAD-
fmk) 
fibroblast-like 
kidney cell line 
(COS-7) 
reduced ataxin-3 cleavage 
and aggregation (Berke et al., 2004) 
caspase inhibitor (z-VAD-
fmk) 
Drosophila 
Schneider’s line 2 
(SL2) cells 
reduced ataxin-3 cleavage (Jung et al., 2009) 
calpain inhibitors (ALLN, 
calpeptin and calpastatin) 
mouse 
neuroblastoma cell 
line (Neuro2a) 
suppressed fragmentation 
and aggregation (Haacke et al., 2007) 
calpain inhibitors (ALLN 
and calpeptin) 
patient iPSC-
derived neurons suppressed aggregation (Koch et al., 2011) 
HDAC (histone deacetylase), Hsp (heat shock protein), 17-DMAG [17-(dimethylaminoethylamino)-17-
demethoxygeldanamycin], DMSO (dimethylsulfoxide), TMAO (trimethylamine N-oxide), PNA (peptide 
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nucleic acid), LNA (locked nucleic acid), CK2 (casein kinase 2), TBB (4,5,6,7-tetrabromobenzotriazole), 
DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazol), GSK3 (glycogen synthase kinase 3"), 
ALLN (N-acetyl-leucyl-leucyl-norleucine) 
 
  This thesis delves into mutant ataxin-3 proteolytic cleavage and intranuclear 
localization as pathogenic mechanisms of MJD focusing on proteolysis inhibition as a 
potential therapeutic strategy. 
 
  1.2.1. Ataxin-3 
 
  Non-expanded human ataxin-3 has a molecular weight of approximately 42 kDa 
and is widely distributed, being conserved in the genome of several species, ranging 
from nematodes to human, including plants. Furthermore, despite the localized 
neuronal degeneration observed in MJD patients, ataxin-3 is ubiquitously expressed 
(Costa et al., 2004; Ichikawa et al., 2001; Paulson et al., 1997a; Schmidt et al., 1998; 
Schmitt et al., 1997; Trottier et al., 1998). 
  Ataxin-3 contains a conserved N-terminal Josephin domain, followed by two 
ubiquitin interacting motifs (UIM) and the polyQ region of variable length (Albrecht et 
al., 2003; Burnett et al., 2003; Masino et al., 2003; Nicastro et al., 2005). Alternative 
splicing of the MJD gene results in the production of different isoforms of ataxin-3 with 
a flexible C-terminal tail (Bettencourt et al., 2010; Goto et al., 1997). Notably, the most 
common one expressed in brain has a third UIM domain after the polyQ sequence 
(Harris et al., 2010) (Fig. 1.2). 
 
 
 
  
Figure 1.2. Diagram of the primary structure of ataxin-3. Ataxin-3 is mainly composed of a 
Josephin domain followed by a flexible C-terminal tail containing two or three ubiquitin 
interacting motifs (UIM) and a polyQ sequence of variable length (Qn).  
   
  Multiple lines of evidence implicate ataxin-3 in cellular protein quality control. 
The Josephin domain (residues 1-198 in human protein) belongs to the papain-like 
cysteine protease family, comprising ubiquitin protease activity, with the structurally 
conserved C14, H119, N134 catalytic triad forming the cleavage pocket. Ataxin-3 is 
thus identified as a deubiquitinating enzyme (DUB) (Burnett et al., 2003; Mao et al., 
2005; Nicastro et al., 2005) and as an ubiquitin-binding protein, showing preference for 
chains of no less than four ubiquitin monomers (Burnett et al., 2003). Inhibition of the 
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catalytic activity or ataxin-3 knockout causes ubiquitinated proteins to accumulate in 
cells, suggesting the involvement of ataxin-3 with polyubiquitinated proteins targeted 
for degradation (Berke et al., 2005; Schmitt et al., 2007). A role of ataxin-3 in 
proteasomal protein degradation has been further supported by the identification of its 
interaction partners Rad23 and valosin-containing protein (VCP) (Doss-Pepe et al., 
2003; Wang et al., 2000), suggesting that the protein complex translocates misfolded 
proteins to the proteasome for degradation (Riess et al., 2008). Additionally, ataxin-3 
also appears to be involved in the cellular response to heat or oxidative stress (Araujo 
et al., 2011; Reina et al., 2010; Rodrigues et al., 2011), transcriptional regulation (Evert 
et al., 2006; Li et al., 2002), besides being implicated in aggresome organization and 
important to cytoskeletal organization (Burnett and Pittman, 2005; do Carmo Costa et 
al., 2010; Mazzucchelli et al., 2009; Rodrigues et al., 2010). 
  Although many studies suggest that ataxin-3 participates in many cellular 
pathways, as stated above, knockout models of ataxin-3 orthologs in mouse and 
Caenorhabditis elegans indicate that it is a non-essential protein, as viability or fertility 
were not affected, and no obvious phenotype was displayed (Rodrigues et al., 2007; 
Schmitt et al., 2007). Furthermore, silencing endogenous ataxin-3 in wild-type rat brain 
was not toxic and did not impair the function or integrity of striatal GABAergic neurons 
(Alves et al., 2010). 
 
  1.2.2. Ataxin-3 and its intracellular localization 
 
  In addition to being ubiquitously expressed among peripheral and neuronal 
tissues, ataxin-3 is present both in cytoplasm and nucleus (Paulson et al., 1997a; 
Schmidt et al., 1998; Tait et al., 1998; Trottier et al., 1998), and also in mitochondria 
(Pozzi et al., 2008). As mentioned before, however, when ataxin-3 has an expanded 
polyQ repeat it forms intranuclear inclusions (Fujigasaki et al., 2000; Paulson et al., 
1997b; Warrick et al., 1998), being the nucleus considered an important subcellular 
localization for polyQ pathogenesis (Yang et al., 2002). In fact, Bichelmeier and 
collaborators demonstrated in MJD transgenic mice that nuclear localization of ataxin-3 
is required for the manifestation of symptoms. Directing an expanded ataxin-3 to the 
nucleus revealed a more pronounced phenotype with more inclusions and earlier cell 
death, whereas mice with the same construct but attached to a nuclear export signal 
developed a milder phenotype with less inclusions (Bichelmeier et al., 2007). The 
characterization of what cellular interactions and processes regulate ataxin-3 nuclear 
localization is nowadays under debate. 
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  Soluble ataxin-3 was reported to be highly mobile in the cytoplasm and nucleus, 
with its diffusion rate limited by transport across the nuclear membrane (Chai et al., 
2002). Nuclear transport could then be mediated by recognition of specific nuclear 
localization signals (NLS) or nuclear export signals (NES) (Pemberton and Paschal, 
2005). A putative NLS has been identified upstream to the polyQ sequence (RKRR, 
aminoacid 282-285) (Tait et al., 1998) and is highly conserved among species 
(Albrecht et al., 2004; Antony et al., 2009; Macedo-Ribeiro et al., 2009). Studies show 
that the above NLS sequence is functional and promotes ataxin-3 active import into the 
nucleus in COS-7 cells (Macedo-Ribeiro et al., 2009), but is only weakly functional in 
HEK cells. Two functional NES have also been reported (NES77, I77-Y99; and 
NES141, E141-E158) (Antony et al., 2009), whose export activity appears to integrate 
chromosome region maintenance 1 (CRM1) pathway (Antony et al., 2009; Macedo-
Ribeiro et al., 2009) (Fig. 1.3). Another NES following the Josephin domain (amino 
acids 174-183) was proposed by Albrecht et al. (2004), and a NLS (Q341-E358 for 
human ataxin-3 orthologous protein) was identified in the Caenorhabditis elegans 
homologue of ataxin-3, though without functional consensus (Albrecht et al., 2004; 
Antony et al., 2009; Rodrigues et al., 2007). 
 
 
 
 
Figure 1.3. Functional domains of ataxin-3. Ataxin-3 contains two nuclear export signals 
(NES77 and NES141) in the Josephin domain (Antony et al., 2009) and a nuclear localization 
signal (NLS282) in the region linking the second ubiquitin interacting motif (UIM2) to the polyQ 
region (Qn) (Tait et al., 1998). 
 
  In addition, ataxin-3 nuclear localization was shown to be controlled by protein 
casein kinase 2 (CK2)-dependent phosphorylation of serine residues within the first 
(S236) and third (S340 and S352) UIM in mouse embryonic fibroblasts (MEF) cells, 
independently of the described NLS282 (Mueller et al., 2009). Pastori and collaborators 
further observed that phosphorylation by CK2 and glycogen synthase kinase 3 (GSK3) 
on serine 29, a residue inside the Josephin domain, could also control ataxin-3 nuclear 
uptake in COS-7 cells (Pastori et al., 2010). Furthermore, proteotoxic stress, such as 
heat shock and oxidative stress in human epithelial cervical cancer (HeLa) cells, also 
induced ataxin-3 nuclear accumulation, although the mechanism involved was 
independent of the NLS sequence (Reina et al., 2010). Whether CK2 phosphorylation 
contributes to ataxin-3 nuclear localization upon exposure to elevated temperature is 
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currently uncertain (Mueller et al., 2009; Reina et al., 2010). Phosphorylation of serine 
111 seems to be required for ataxin-3 nuclear localization following heat shock 
although it is not sufficient by itself (Reina et al., 2010).  
  Interestingly, Breuer and co-workers suggested that aggregation in the nuclear 
compartment may be due to a less efficient degradation of the polyQ protein in the 
nucleus than in the cytoplasm. In fact, triggering a cellular stress response by heat 
shock transcription factor #HSF1 abrogated aggregation in the cytoplasm but not in the 
nucleus. Additionally, the cellular site of ataxin-3 aggregation could be directed by 
synthetic localization signals but was not affected by the conserved putative NLS in 
N2a cells (Breuer et al., 2010). 
  Taken together, the current understanding of the nucleocytoplasmic shuttling 
activity of ataxin-3 is not consensual due to the divergent results that have been 
obtained using different cell models, expressing wild-type or expanded ataxin-3 and 
full-length or truncated forms. Cleavage of ataxin-3, discussed in the following section, 
might also contribute to nuclear localization by mediating the separation of the 
proposed NES located at the N-terminus of ataxin-3 from the NLS and the polyQ 
expansion located at the C-terminus, enabling ataxin-3 translocation into the nucleus to 
form intranuclear aggregates. 
 
  1.2.3. Ataxin-3 and its proteolytic cleavage 
 
  Previous work using cell and animal models demonstrated that expression of 
polyQ expanded ataxin-3 fragments resulted in increased aggregation and toxicity as 
compared to the full-length protein (Hara et al., 2001; Ikeda et al., 1996; Paulson et al., 
1997b; Warrick et al., 1998; Yoshizawa et al., 2000), leading to the idea referred to as 
the toxic fragment hypothesis, which suggests that proteolytic cleavage of the polyQ 
protein is required for pathology (Tarlac and Storey, 2003). Such proteolytic events 
have been suggested to be the trigger of the aggregation process (Berke et al., 2004; 
Breuer et al., 2010; Haacke et al., 2006).  
  Interestingly, interaction of the C-terminal fragments with wild-type ataxin-3 
results in a conformational change of its N-terminal Josephin domain and possibly its 
C-terminal as well, which might disturb ataxin-3 normal function or interactions, thus 
perturbing normal cellular mechanisms (Haacke et al., 2006). Furthermore, an ataxin-3 
fragment was detected in Q71 transgenic mice and post mortem brain tissue of MJD 
patients, whose levels increased with disease severity, supporting a relation between 
ataxin-3 cleavage and disease progression (Goti et al., 2004). Therefore, identifying 
protease(s) responsible for human mutant ataxin-3 processing and its cleavage site(s) 
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could contribute to understanding the mechanism of proteolysis involved and reveal 
potential candidates for therapy.  
  In this sense, mutant ataxin-3 has been shown to be a substrate for caspases 
(Berke et al., 2004; Jung et al., 2009; Wellington et al., 1998) and calpains (Haacke et 
al., 2007; Koch et al., 2011), though without consensual results. On one hand, either 
caspase-3 or caspase-1 generated ataxin-3 cleavage products in vitro. Interestingly, 
neither the reversible competitive tetrapeptide aldeyde inhibitor Ac-DEVD-CHO nor Ac-
YVAD-CHO, which inhibit the effector and interleukin-1-" converting enzyme 
(ICE/caspase-1)-like caspases, respectively, were able to inhibit the fragments 
formation, suggesting that other enzymes could generate those products (Wellington et 
al., 1998). However, in cells undergoing apoptosis, proteolysis was mediated 
predominantly by caspase-1. Site-directed mutagenesis experiments narrowed the 
major cleavage event to a cluster of aspartate residues within the UIM2 near the polyQ 
tract (Berke et al., 2004). In a MJD Drosophila model, results suggested that ataxin-3 
cleavage is conserved in the fly and that the process may also be caspase-dependent. 
Nevertheless, even though neuronal loss was aggravated, no significant modifications 
in nuclear inclusion formation were observed (Jung et al., 2009). On the other hand, 
the role of calpains in ataxin-3 proteolysis was first reported by Haacke and 
collaborators in 2007 in mouse neuroblastoma N2a cells (Haacke et al., 2007) and then 
further confirmed, more recently, in L-glutamate-induced excitation of patient-specific 
induced pluripotent stem cell (iPSC)-derived neurons (Koch et al., 2011). In both 
models, calcium-dependent proteolysis of ataxin-3 was followed by the formation of 
SDS-insoluble aggregates, a process abolished by calpain inhibition (Haacke et al., 
2007; Koch et al., 2011). These results are in accordance with deranged calcium 
signalling reported in MJD transgenic mice (Chen et al., 2008), which could contribute 
to calpain activation.  
  In summary, the functional consequences of ataxin-3 proteolysis are still not 
fully elucidated, given the opposing results in literature. While caspase inhibitors had 
no effect on ataxin-3 fragmentation and aggregation in the models referred above 
(Haacke et al., 2007; Koch et al., 2011), calpain inhibition had also no effect in ataxin-3 
cleavage in Drosophila SL2 cells (Jung et al., 2009) and in COS-7 cells (Berke et al., 
2004). These divergent results might be explained by variations in experimental design 
and methods, which lead to different protein cellular contexts. Additionally, one cannot 
exclude that ataxin-3 proteolysis may be a multi-step process, similarly to what has 
been reported for huntingtin (Kim et al., 2001). 
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  Based on work with in vitro models, mutant ataxin-3 has been proposed to have 
proteolytic sites at amino acids 145, 171, 225, 228 (Wellington et al., 1998); 241, 244, 
248 (Berke et al., 2004); 286 (Yoshizawa et al., 2000); 257 (Haacke et al., 2006); and 
60, 200, 260 (Haacke et al., 2007) (Fig. 1.4). Another cleavage site was proposed in a 
mouse model within the N-terminus of amino acid 190 (Colomer Gould et al., 2007; 
Goti et al., 2004). In addition, although only demonstrated for wild-type protein, ataxin-3 
was shown to have autoproteolytic activity, sustained by the same residues responsible 
for the deubiquitinating activity. Cleavage would then occur within the C-terminal 
preserving the Josephin domain from proteolytic attack (Mauri et al., 2006). 
 
 
 
   
 
 
Figure 1.4. Proteolytic cleavage of ataxin-3. Ataxin-3 might be cleaved by calpains at amino 
acids 60, 200, 260 (Haacke et al., 2007). 
 
  Recent in vivo evidences suggest that not only the ataxin-3 C-terminal fragment 
is cytotoxic (Goti et al., 2004; Ikeda et al., 1996), but that the non-polyQ containing 
ataxin-3 N-terminus fragment is also toxic and may contribute to an impaired unfolded 
protein response in the pathogenesis of MJD (Hubener et al., 2011). In contrast, a 
study in COS-7 cells revealed that mutant ataxin-3 was cleaved to a lower extent than 
the wild-type protein, possibly because C-terminal cleavage sites would be masked by 
the expanded polyQ, suggesting that the pathology could arise through the 
accumulation of an uncleaved expanded ataxin-3 (Pozzi et al., 2008). 
  Taken together, further definition of the proteolytic processing of ataxin-3 is 
therefore important to understand the mechanism of MJD pathogenesis and potentially 
reveal new therapeutic targets. 
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  1.2.4. Ataxin-3 intracellular localization and proteolytic cleavage in 
animal models of Machado-Joseph disease 
 
  Many animal models overexpressing specific forms of ataxin-3, either full-length 
or truncated, have been developed to study molecular and related phenotypic aspects 
of MJD, giving the possibility of subsequent employment as valuable tools for 
screening potential therapeutic molecules, as reviewed in table III. Overall, the 
currently used models have been developed in mouse, rat, fruit fly and worm. Although 
rodent models share important molecular, anatomical and physiological similarities with 
humans, invertebrate models of ataxin-3 overexpression, known for their ease of 
maintenance and genetic manipulation, also provided important insights regarding MJD 
pathogenesis (table IV). 
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 Table IV. A
nim
al m
odels of M
achado-Joseph disease 
 
 
M
odel 
Transgene/prom
oter 
Subcellular localization 
O
bservations 
Pathology 
R
eference 
ataxin-3 
inclusions 
nuclear 
localization 
proteolysis 
mouse 
M
JD
1a cD
N
A
 fragm
ent 
w
ith 79 C
A
G
s under L7 
prom
oter 
P
urkinje cells 
no description 
no description 
truncated ataxin-3 
is m
ore potent at 
inducing cell death 
than full-length 
cerebellar atrophy, ataxic 
phenotype, gait disturbance 
(Ikeda et al., 1996) 
full-length M
JD
1 Y
A
C
 w
ith 
76 or 84 C
A
G
s under the 
control of its ow
n 
regulatory elem
ents 
ubiquitous 
ubiquitin-positive N
IIs 
predom
inantly found 
in pontine and 
dentate neurons and 
m
utant ataxin-3 
w
as predom
inantly 
nuclear in pontine 
and dentate 
neurons and 
P
urkinje cells 
proteolytic 
fragm
ents w
ere not 
detected 
cell loss in pons and 
cerebellum
, peripheral 
neuropathy, ataxic phenotype, 
w
ide gait, low
ered pelvis, 
trem
or, reduced activity 
(C
em
al et al., 2002) 
full-length M
JD
1a cD
N
A
 
w
ith 71 C
A
G
s under 
m
ouse prion prom
oter 
brain and spinal cord 
N
IIs 
m
utant ataxin-3 
w
as enriched in 
nucleus 
a m
utant ataxin-3 
fragm
ent of 36 kD
a 
w
as detected 
enriched in nuclear 
fraction and m
ore 
abundant in sick 
m
ice 
decreased TH
-positive 
neurons, progressive postural 
instability, gait and lim
b 
ataxia, w
eight loss, prem
ature 
death 
(G
oti et al., 2004) 
full-length hum
an ataxin-
3c cD
N
A
 w
ith 70 or 148 
C
A
G
s under m
urine prion 
prom
oter 
several brain regions, 
including cortex, 
hippocam
pus, pons 
and cerebellum
 
ubiquitin-positive N
IIs 
directing 148 
C
A
G
s to the 
nucleus revealed 
a m
ore 
pronounced 
phenotype 
no description 
degeneration of P
urkinje cells, 
reduced turnover of D
A
 and 5-
H
T, trem
or, reduced activity, 
prem
ature death 
(B
ichelm
eier et al., 
2007) 
H
A
 tagged full-length 
hum
an M
JD
1a cD
N
A
 w
ith 
79 C
A
G
s under m
ouse 
prion prom
oter 
several brain regions, 
including cerebellum
, 
pontine neurons and 
substantia nigra 
N
IIs in neurons of the 
dentate nucleus, 
pontine neurons and 
substantia nigra 
disruption of 
norm
al gene 
transcription 
suggested nuclear 
toxicity 
no description 
ataxic phenotype, m
otor 
incoordination, reduced 
activity, ataxic gait, abnorm
al 
posture, w
eight loss 
(C
hou et al., 2008) 
H
A
 tagged hum
an ataxin-3 
fragm
ent cD
N
A
 w
ith 69 
C
A
G
s under L7 prom
oter 
P
urkinje cells and 
deep cerebellar nuclei 
ubiquitin-positive N
IIs 
periplasm
ic in 
P
urkinje cells 
diffuse distribution 
of ataxin-3 in the 
nuclei of P
urkinje 
cells 
no description 
im
pairm
ent of dendritic 
differentiation, cerebellar 
atrophy, ataxic phenotype 
(O
ue et al., 2009; 
Torashim
a et al., 
2008) 
full-length hum
an ataxin-
3c cD
N
A
 w
ith 77 C
A
G
s 
using the Tet-O
ff system
 
under the control of a 
ham
ster prion prom
oter 
brain, w
ith a stronger 
im
m
unoreactivity in 
cerebellum
, 
predom
inantly in glial 
cells 
N
IIs in som
e 
neuronal cells of the 
cerebral cortex 
no description 
no description 
neuronal dysfunction in 
cerebellum
, reduced anxiety, 
hyperactivity, m
otor deficits 
(B
oy et al., 2009) 
full-length hum
an ataxin-
3c cD
N
A
 w
ith 148 C
A
G
s 
under the rat huntingtin 
prom
oter 
ubiquitous in brain 
N
IIs in certain brain 
regions, like the red 
nucleus, pons and 
cerebellum
, including 
in hom
ozygous 
m
ice, m
utant 
ataxin-3 w
as 
m
ainly localized in 
no description 
degeneration of P
urkinje cells, 
hyperactivity, m
otor 
incoordination, im
paired m
otor 
learning 
(B
oy et al., 2010) 
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P
urkinje cells 
the nucleus 
full-length hum
an ataxin-
3c cD
N
A
 w
ith 94 C
A
G
s 
under the cytom
egalovirus 
(C
M
V
) prom
oter 
ubiquitous 
m
ainly localized in 
punctuate structures 
in perinuclear region 
of neurons; no large 
N
IIs w
ere observed 
M
JD
-like 
sym
ptom
s w
ere 
not associated to 
N
IIs 
M
JD
-like 
sym
ptom
s w
ere 
not associated to 
ataxin-3 cleavage 
products 
neuronal atrophy, astrogliosis, 
m
otor incoordination, reduced 
locom
otor activity 
(S
ilva-Fernandes et 
al., 2010) 
truncated N
-term
inal 
ataxin-3 cD
N
A
 
brain and spinal cord 
neuronal cytoplasm
ic 
inclusions 
no description 
N
-term
inal 
fragm
ent m
ay 
contribute to 
pathogenesis 
altered endoplasm
ic 
reticulum
-m
ediated unfolded 
response, neuronal death, 
prem
ature death, trem
or, 
clasping, gait ataxia, w
eight 
loss 
(H
ubener et al., 
2011) 
rat 
m
yc tagged full-length 
hum
an M
JD
1a cD
N
A
 w
ith 
72 C
A
G
s under the 
phosphoglycerate kinase 1 
(P
G
K
) prom
oter 
depending on the 
injection site 
ubiquitin-positive N
IIs 
m
utant ataxin-3 
detection in 
punctuate and 
nuclear staining 
possible cleavage 
fragm
ents w
ere 
detected 
in substantia nigra, 
apom
orphine-induced turning 
behaviour and loss of 
dopam
inergic m
arkers; in 
striatum
, loss of neuronal 
m
arkers 
(A
lves et al., 2008b) 
Drosophila 
melanogaster 
H
A
 tagged hum
an M
JD
1 
cD
N
A
 fragm
ent w
ith 78 
C
A
G
s using a glass gene 
prom
oter or elav gene 
prom
oter 
glass: eye cells; elav: 
peripheral and central 
nervous system
 
N
IIs 
as cells m
atured, 
protein becam
e 
redistributed into 
the nucleus 
no description 
glass: late onset eye 
degeneration; elav: lethal or 
early death w
ith loss of 
integrity of the nervous 
system
 
(W
arrick et al., 1998) 
H
A
 or m
yc tagged full-
length ataxin-3 w
ith 78 or 
84 C
A
G
s, respectively, 
using a glass gene 
prom
oter or elav gene 
prom
oter 
glass: eye cells; elav: 
peripheral and central 
nervous system
 
ubiquitin-positive N
IIs 
no description 
truncated form
 of 
ataxin-3 is m
ore 
toxic than the full-
length version 
severe and progressive adult-
onset neural degeneration; 
elav: trem
or and early death 
(W
arrick et al., 2005) 
Caenorhabditis elegans 
full-length and truncated 
M
JD
1 cD
N
A
 w
ith 91 or 
130 C
A
G
s and 63 or 127 
C
A
G
s, respectively, under 
a pan neuronal prom
oter 
ubiquitous 
aggregates m
ay be 
present in cytoplasm
, 
m
ainly in the 
perinuclear region 
and rarely in the 
nucleus 
no description 
truncated peptides 
aggregated faster 
than the full-length 
protein 
neuronal dysfunction, 
interruption of synaptic 
transm
ission, U
P
S
 system
 
im
pairm
ent 
(K
han et al., 2006) 
full-length ataxin-3 cD
N
A
 
w
ith 130 C
A
G
s and 
truncated ataxin-3 w
ith 75 
or 128 C
A
G
s under a pan 
neuronal prom
oter 
through the nervous 
system
 
foci form
ation 
detected in som
e 
neurons in both 
nucleus and 
cytoplasm
 
m
utant ataxin-3 is 
both detected in 
nucleus and 
cytoplasm
 
anim
als w
ith 
truncated protein 
w
ere sm
aller in 
size and m
ore 
lethargic than w
ith 
full-length 
m
otor dysfunction, lethargy, 
slightly reduced life span 
(Teixeira-C
astro et 
al., 2011) 
 R
odent and invertebrate anim
als have been developed as m
odels of M
JD
. In this table, a special focus w
as given to nuclear localization and proteolysis of m
utant 
ataxin-3 as M
JD
 pathogenic m
echanism
s. 
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  In general, the different mouse models currently available display neuronal 
dysfunction and atrophy accompanied by ataxic phenotype with motor incoordination 
(Bichelmeier et al., 2007; Boy et al., 2010; Boy et al., 2009; Cemal et al., 2002; Chou et 
al., 2008; Goti et al., 2004; Ikeda et al., 1996; Silva-Fernandes et al., 2010; Torashima 
et al., 2008), resembling MJD. The presence of intranuclear inclusions (NIIs), 
considered a hallmark of MJD and other polyQ disorders, is also consistent in many of 
the transgenic animals listed in table IV (Alves et al., 2008b; Bichelmeier et al., 2007; 
Boy et al., 2010; Boy et al., 2009; Cemal et al., 2002; Chou et al., 2008; Goti et al., 
2004; Torashima et al., 2008; Warrick et al., 2005; Warrick et al., 1998). Even though 
NIIs were detected in brain regions that are affected in MJD patients (Boy et al., 2010; 
Cemal et al., 2002; Chou et al., 2008) and not in typically spared regions (Cemal et al., 
2002), there is no clear correlation between inclusion formation and MJD-like 
symptoms (Silva-Fernandes et al., 2010). In fact, the presence of NIIs did not appear 
sufficient to cause degeneration (Warrick et al., 1998). Accordingly, motor symptoms 
have been detected before the formation of NIIs, albeit these were observed much 
earlier in homozygous mice (18 months) than heterozygous mice (25 months) (Boy et 
al., 2010), probably due to increased levels of mutant ataxin-3. Nevertheless, the 
contribution of mutant ataxin-3 nuclear localization to pathology was suggested by 
evidence of disruption of normal transcription (Chou et al., 2008) and further elucidated 
in transgenic mouse models, as previously discussed in section 2.2. Targeting ataxin-3 
with 148 glutamines to the nucleus induced an exacerbation of phenotype, as 
compared to mice with the same construct attached to a NES (Bichelmeier et al., 
2007). 
   Several observations related to the toxic fragment hypothesis can be 
addressed from the animal models of MJD. Although the truncated ataxin-3 is more 
aggregation-prone than the full-length protein (Khan et al., 2006; Teixeira-Castro et al., 
2011), and despite the controversy regarding the role of NIIs, which can represent an 
end-stage of the adaptive cellular response to large quantities of misfolded protein, 
evidence suggests that the proteolytic fragments underlie toxic effects. 
  Truncated ataxin-3 has been shown to have a more toxic activity than full-length 
protein in mice, Caenorhabditis elegans and Drosophila: a) while mice expressing 
truncated ataxin-3 were ataxic at four weeks of age, those expressing the full-length 
protein did not manifest an ataxic phenotype even after 23 weeks of age (Ikeda et al., 
1996); b) worms overexpressing truncated 128Q were smaller in size and more 
lethargic than those with full-length 130Q (Teixeira-Castro et al., 2011);  c) crossing 
flies bearing full-length 84Q ataxin-3 with those expressing truncated ataxin-3 78Q 
Introduction 
  23 
improved the eye phenotype relative to those only expressing the truncated protein, an 
effect that was dramatic when compared to flies carrying two copies of truncated 78Q 
(Warrick et al., 2005).  
  The increased toxicity of cleavage fragments was emphasised by the 
observation that such cleavage fragments are endogenously produced. Accordingly, 
increased levels of a 36 kDa fragment of mutant ataxin-3 were detected in post mortem 
brain tissue of MJD patients and in transgenic sick mice (Goti et al., 2004). However, 
some studies have not been able to detect such cleavage fragments (Cemal et al., 
2002; Silva-Fernandes et al., 2010).  
  Until recently, the transgenic animals expressing a truncated form of ataxin-3 
encoded only the C-terminal ataxin-3 fragment with the polyQ stretch (Ikeda et al., 
1996; Khan et al., 2006; Teixeira-Castro et al., 2011; Warrick et al., 2005).  Nowadays, 
a contribution of the N-terminal ataxin-3 fragment to the pathology has also been 
reported. Hubener and colleagues in 2011 showed that the expression of a N-terminal 
ataxin-3 fragment (first 259 amino acids) in a transgenic mouse model caused 
neurological symptoms, endoplasmic reticulum stress and cellular responses to 
unfolded or misfolded proteins (Hubener et al., 2011). 
  Although transgenic animal models do not fully replicate the human disease, 
their importance cannot be questioned. Those models are valuable tools that have 
been contributing to the understanding of ataxin-3 cleavage and cellular localization in 
relation to the MJD pathology, giving the possibility of subsequent employment for 
screening potential therapeutic molecules, such as protease inhibitors, discussed in the 
following section. 
 
 
 
  1.3. Proteases in neurodegeneration 
     
 Proteases can be considered as the executioners of cell death through both 
non-specific and limited proteolysis. These include cytosolic cysteine and aspartyl 
proteases, lysosomal proteases and microglial proteases (Artal-Sanz and 
Tavernarakis, 2005). Due to a crosstalk between different proteolytic mechanisms as 
caspases activate calpains (Wang, 2000) and vice-versa (Blomgren et al., 2001; 
Neumar et al., 2003), the understanding of the molecular pathways involved in 
neurodegeneration through activation of proteases is complex. Focus will be given on 
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the cytosolic cysteine proteases, caspases and calpains, especially on the latter, as the 
main enzymes involved in polyQ proteolysis, as stated on table II. 
 
  1.3.1. Caspases 
 
  Caspases constitute a family of cysteine proteases that are crucial intracellular 
signal transducers and executioners of apoptosis (Hyman and Yuan, 2012). Caspase 
family members can be grouped in initiator caspases (including caspases 1, 2, 4, 5, 8, 
9, 10, 11 and 12) and effector caspases (including caspases 3, 6, 7 and 14), which 
specifically cleave after an aspartate residue in target proteins. Produced as inactive 
zymogens, these enzymes must undergo activation in response to pro-apoptotic and 
pro-inflammatory signals: a) through mitochondrial damage and cytochrome c release, 
b) by extrinsic cell surface receptor-mediated processes as interaction with fas-
activated death domain (FADD), c) following inflammatory stimuli or d) after DNA 
damage (Chan and Mattson, 1999; Hyman and Yuan, 2012). Subsequent cleavage of 
the effector enzymes activates them for the proteolytic cleavage of a broad spectrum of 
cellular targets, including cytoskeletal proteins, enzymes involved in signal 
transduction, cell-cycle proteins and DNA-modulating enzymes (Boatright and 
Salvesen, 2003; Chan and Mattson, 1999). Although a global activation of caspases 
mediates cell death, restricted and localized action may control normal physiology and 
pathophysiology in living neurons (Hyman and Yuan, 2012). Caspases can activate 
calpain proteases by mediating degradation of calpastatin, the endogenous inhibitor of 
calpains (Artal-Sanz and Tavernarakis, 2005; Wang, 2000).  
 
  1.3.2. Calpains 
 
  Calpains constitute a family of calcium-dependent cysteine proteases. The first 
two isoforms of calpain identified – calpain 1 (!-calpain) and calpain 2 (m-calpain) are 
found in most organs, but are particularly abundant in the central nervous system (Liu 
et al., 2008), differing in the calcium concentration required for their activation, being 
activated by micromolar or millimolar calcium concentrations, respectively. Both 
isoforms 1 and 2 are composed of catalytic and small regulatory subunits (Ono and 
Sorimachi, 2012). While genetic deletion of the commonly shared 28-kDa regulatory 
subunit resulted in embryonic lethality (Arthur et al., 2000), deletion of the !-calpain 
large subunit (80-kDa) apparently led to no severe phenotype (Azam et al., 2001), 
whereas genetic deficiency of the m-calpain 80-kDa subunit resulted in a lethal 
phenotype (Dutt et al., 2006), indicating that m-calpain is likely to play an essential role 
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in early developmental processes. Nevertheless, calpains 1 and 2 seem to have similar 
physiological functions, including integrin-mediated cell migration, cytoskeletal 
remodelling, cell differentiation, long-term potentiation and apoptosis, and pathological 
actions, having been implicated in muscular dystrophy, cardiac and cerebral ischemia, 
platelet aggregation, neurodegenerative diseases, aging, rheumatoid arthritis and 
cataract formation (Goll et al., 2003; Khorchid and Ikura, 2002; Liu et al., 2008). Other 
members of the 15 calpain family identified in humans have been implicated in some of 
the disorders described above and in other pathological conditions, including 
susceptibility to type II diabetes (calpain 10), gastric cancer (calpain 9), and may be 
ubiquitous or found only or mainly in certain tissues, including the skeletal muscle-
specific calpain 3, the stomach smooth muscle-specific calpain 8 and the testis-specific 
calpain 11 (Camins et al., 2006; Huang and Wang, 2001). 
 Structural studies of calpains were advanced by the availability of recombinant 
heterodimeric calpain 1 and 2, and their crystal structures indicate that the large 
subunit comprises four domains (I-IV), while the small subunit has two domains (V and 
VI) (Fig. 1.5). Domain I is the site of autolytic cleavage; domain II contains cysteine 
protease activity; domain III might serve as a linker region; domain V may be required 
for interaction with membrane phospholipids; both domains IV and VI contain five sets 
of EF-hand calcium-binding structures (Camins et al., 2006; Goll et al., 2003; Huang 
and Wang, 2001; Khorchid and Ikura, 2002). 
 
 
 
  
 
 
 
 
 
 
Figure 1.5. Schematic diagrams showing calpain 1 and 2 subunits and calpastatin. In 
calpain domain II, C, H and N represent catalytic residues Cys, His and Asn. At the calpain 
COOH-terminal, five sets of EF-hand calcium-binding structures in domains IV and VI are 
shown as vertical bars. Calpastatin contains independent inhibitory domains (CIDs), each one 
composed by three regions, A-C, which bind to different domains of calpain. 
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All calpains can act in two modes: under physiological conditions they undergo 
controlled activation, involving only a few molecules of calpain, whereas during 
sustained calcium overload under pathological conditions they undergo 
hyperactivation, involving all available calpain molecules (Liu et al., 2008). The 
mechanisms by which calpains are activated and identify their protein substrates are 
complex and poorly understood. Calpains are believed to exist in an inactive 
conformation that situates the key active site residues (Cys105, His262, Asn286) too 
far apart to form a catalytic center (Hosfield et al., 1999). Activation of the protease 
requires a conformational change to align these residues, which is modulated by 
different factors, including calcium binding to several sites (Moldoveanu et al., 2002) 
and translocation to membranes (Gil-Parrado et al., 2003). The consequent calpain 
cleavage, to a large extent, depends on higher order structural features, such as 
peptide bond access, backbone conformation, or three-dimensional structure, being 
therefore the cleavage specificity of calpains only weakly dictated by the primary 
sequence of its protein substrates, on the contrary to caspases. However, if the 
cleavage is restricted to an unstructured region, calpains will presumably cleave 
preferentially at positions where the sequences flanking the scissile bond contain the 
most favourable substrate-subsite interactions, which are incompletely understood and 
not consensual (Cuerrier et al., 2005; Tompa et al., 2004). Calpain substrates include 
cytoskeletal proteins and associated proteins, kinases and phosphatases, membrane 
receptors and transporters, and steroid receptors (Chan and Mattson, 1999). 
Deactivation of calpain can come about in several ways: simply the dissipation 
of local high calcium levels, autoproteolytic inactivation, or binding to the endogenous 
calpain inhibitor, calpastatin (Wendt et al., 2004). To date, calpastatin is the only known 
inhibitor that is completely specific for calpain. Calpastatin isoforms in different tissues 
are derived from a single calpastatin gene by a combination of differential mRNA 
splicing (De Tullio et al., 2007; Lee et al., 1992), proteolysis (Nakamura et al., 1989) 
and protein phosphorylation (Adachi et al., 1991; Salamino et al., 1994). Each 
calpastatin molecule contains four regions, the calpastatin inhibitory domains, CIDs I-
IV. Each CID is, in turn, subdivided into three regions (A to C) that are predicted to 
interact with calpain (Mellgren, 2008) (Fig. 5). The consequent calpain inhibition is 
mediated by the intimate contact with three critical regions of calpastatin. Two regions 
target the penta-EF-hand domains of calpain and the third occupies the substrate-
binding, projecting a loop around the active thiol site to evade proteolysis (Moldoveanu 
et al., 2008) (Fig. 1.6). In addition, calpastatin is able to simultaneously bind four 
calpains with different kinetic constants (Hanna et al., 2007). During the calpain 
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inhibition process, calpains can cleave calpastatin, releasing smaller fragments that are 
themselves calpain inhibitors (Averna et al., 2007; Nakamura et al., 1989). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Calpain inhibition mediated by calpastatin.  
When calpain 2 binds to calcium, it adopts an active conformation forming an active site. For 
calpain deactivation by calpastatin, the A region of CID associates with domain IV, whereas the 
C region binds to domain VI. The B region occupies the substrate-binding-cleft, blocking it and 
looping away to avoid proteolysis. Adapted from (Mellgren, 2008). 
 
Despite this important role of calpastatin in modulating calpain activity, mice 
lacking calpastatin have no defect in the development, fertility, morphology, or life span 
under normal conditions, indicating that calpastatin is a negative regulator of calpain 
only under pathological conditions (Takano et al., 2005). In agreement, it is generally 
believed that calpastatin binds and inhibits calpain when calcium levels are high, but 
releases it when calcium levels fall (Hanna et al., 2007). However, Melloni and 
colleagues showed that calpain-calpastatin association can also occur in the absence 
of calcium or at very low calcium concentrations, reflecting the physiological conditions 
under which calpain retains its inactive conformational state (Melloni et al., 2006).  
 In conclusion, the calpain and calpastatin proteins represent a major ubiquitous 
cellular proteolytic system, the imbalance of which has been implicated in necrosis 
associated with several disorders, particularly in neurodegenerative disorders. 
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Understanding the details of calpastatin specificity may aid the design of new 
therapeutic agents. 
 
1.3.2.1. Calpains in Neurodegenerative disorders 
 
 The concept that proteolytic system impairment leads to undesired protein 
cleavage or inefficient protein removal is gaining increasing support within the field of 
neurodegenerative disorders. In opposition to proteasomal and lysosomal systems, the 
impairment of which reduces protein turnover, an imbalanced calpain/calpastatin 
system performs limited cleavage of proteins that modulate many dynamic cellular 
processes (Nixon, 2003). The main mechanisms by which calpain activation 
contributes to several neurodegenerative disorders are discussed hereafter. 
 Elevation of intracellular calcium concentration during the initial stages of cell 
death elicits calpain activation, which can be a critical step in apoptosis by processing 
of the anti-apoptotic Bcl-2 family members (Gil-Parrado et al., 2002), activation of p53 
(Sedarous et al., 2003) and cleavage of Bax (Wood et al., 1998), as well as in necrotic 
neuronal death, in response to excess of glutamate, acidosis or reactive oxygen 
species (Artal-Sanz and Tavernarakis, 2005). There is also evidence of caspase-
independent and calpain-mediated events that accompany excitotoxicity induced by 
overactivation of AMPA (Kieran and Greensmith, 2004) and NMDA receptors 
(Simpkins et al., 2003). The resultant increase of the intracellular calcium concentration 
allows calcium to bind to and activate calpains, which contributes to cell demise by the 
cleavage of scaffolding proteins and several essential cytoskeletal proteins of neuronal 
axons (Liu et al., 2008), such as neurofilaments (Stys and Jiang, 2002), cain/cabin1 
(Kim et al., 2002) and "II-spectrin (Czogalla and Sikorski, 2005), potentially used as 
biomarkers of brain injury (Liu et al., 2008). 
 As previously discussed, calpains have been implicated in polyQ diseases, 
including MJD, particularly in mutant ataxin-3 cleavage (Haacke et al., 2007; Koch et 
al., 2011), and their overactivation may be derived from deranged calcium signalling 
(Chen et al., 2008). Likewise, in Huntington’s disease, it has been shown that polyQ-
expanded huntingtin may also alter calcium homeostasis (Tang et al., 2003), linking 
excitotoxicity to calpain activation (Gafni and Ellerby, 2002; Gafni et al., 2004; Zeron et 
al., 2001). Huntingtin fragments from calpain-mediated proteolysis and increased 
calpain levels were identified in HD tissue culture and transgenic mouse models. 
Moreover, it has been reported that inhibition of calpains reduced huntingtin cleavage 
and toxicity (Gafni et al., 2004). 
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 Besides polyQ diseases, calpains have also been implicated in Alzheimer’s 
disease (AD) and Parkinson’s disease (PD). Impaired calcium homeostasis (Hajieva et 
al., 2009; LaFerla, 2002) and decreased calpastatin levels (Rao et al., 2008; Vaisid et 
al., 2007) might contribute to calpain activation leading to cytoskeletal disruption and 
neurodegeneration in AD (Rao et al., 2008; Vaisid et al., 2007). In fact, alterations in 
calcium content were observed in fibroblasts from patients with familial AD (Peterson 
and Goldman, 1986), and calpain activation could be detected before abnormalities in 
the microtubule-associated protein tau occurred, being the protease later found 
associated with neurofibrillary tangles, a hallmark of AD pathology (Grynspan et al., 
1997). Calpains also appear to cleave the cyclin-dependent kinase 5 (Cdk5) activator 
p35 to produce p25, which accumulates in the brains of patients with AD, causing Cdk5 
activation and mislocalization. The formed p25/Cdk5 complex hyperphosphorylates 
tau, disrupts the cytoskeleton and promotes apoptosis of cultured neurons (Kusakawa 
et al., 2000; Lee et al., 2000; Patrick et al., 1999), a process that can also be mediated 
by calpains through upstream activation of the Erk 1,2 MAPK (mitogen-activated 
protein kinase) pathway (Veeranna et al., 2004). Thus, calpain inhibition may prove to 
be useful in the treatment of AD. Accordingly, it has been shown that inhibition of 
calpains improved memory and synaptic transmission in a mouse model of AD 
(Trinchese et al., 2008). 
  Similarly to AD, increased intracellular calcium in nigral dopamine neurons, 
consequent to secondary excitotoxic mechanisms and depletion of mitochondrial 
calcium pools (Frei and Richter, 1986; Kass et al., 1988), supports a role for the 
involvement of calpains in PD. Postmortem midbrain tissue from human PD cases 
displayed evidence of increased calpain activity (Crocker et al., 2003), consistent with 
increased expression of calpain 2 in dopamine neurons (Mouatt-Prigent et al., 1996). 
Accordingly, inhibition of calpains prevented neuronal and behavioural deficits in a 
MPTP (dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse 
model of PD (Crocker et al., 2003). 
  
1.3.3. Protease inhibitors 
 
The role of calpains in the pathogenesis of neurodegenerative diseases 
suggests that protease inhibitors may offer potential therapeutic compounds. However, 
one important issue is that synthetic protease inhibitors initially thought to be specific 
for a given protease class were subsequently found to have a broader inhibition range. 
In fact, most, if not all, of the synthetic peptidic, peptide-mimetic, and nonpeptidic 
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calpain inhibitors currently available have problems in terms of specificity, metabolic 
stability, water solubility or penetration through the blood-brain barrier (Higuchi et al., 
2005). Further caution should also be exercised in assessing caspase involvement, as 
many synthetic peptide caspase inhibitors are not completely caspase specific, and 
may also effectively inhibit cathepsins (Schotte et al., 1999), a class of lysosomal 
proteolytic enzymes (Artal-Sanz and Tavernarakis, 2005). 
Therefore, one should be cautious when drawing conclusions based on experiments 
with synthetic inhibitors. Nevertheless, a growing understanding of the proteolytic 
mechanisms mediating neurodegeneration holds promise of facilitating the 
development of novel neuroprotective agents in an effort to battle neurodegenerative 
diseases. In agreement, for example, the generation of genetically engineered mice 
overexpressing the endogenous calpain inhibitor calpastatin (Higuchi et al., 2005; 
Morales-Corraliza et al., 2012), as well as the progress in imaging calpain activity in 
living mice (Stockholm et al., 2005), will certainly contribute to enhance the 
understanding of the protease roles and possible major drawbacks of its inhibition. In 
conclusion, issues of bioavailability, low toxicity and selectivity will have to be fully and 
further addressed for future therapeutic application of protease inhibitors. 
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1.4. Objectives 
 
 The general objectives that underlie this thesis were the investigation of the 
central role of calpain-mediated proteolysis of mutant ataxin-3 in the pathogenic 
mechanism of Machado-Joseph disease and the potential of calpain inhibition to 
modify or block the disease progression. 
 
 The specific objectives of this thesis were the following: 
 
- to study mutant ataxin-3 proteolysis in lentiviral (chapter 2) and transgenic mouse 
models of Machado-Joseph disease (chapter 4), 
 
- to investigate the toxic effects of calpain-mediated proteolysis, including its role in 
ataxin-3 translocation to the nucleus (chapter 2), 
 
- to investigate the causes of calpain overactivation, particularly calpastatin levels in 
Machado-Joseph disease (chapter 2), 
 
- to evaluate the effects of calpain inhibition in a lentiviral mouse model of Machado-
Joseph disease by viral transduction (chapter 2) and oral administration (chapter 3) 
regarding ataxin-3 proteolysis, nuclear localization and neuropathology, 
 
- to investigate what is the trigger of ataxin-3 proteolysis in Machado-Joseph 
disease: calpain overactivation or calpastatin depletion (chapter 4), 
 
- to investigate if calpain inhibition in a transgenic mouse model of Machado-Joseph 
disease, by calpastatin overexpression initiated after onset of symptoms, 
suppresses ataxin-3 proteolysis, nuclear localization and ultimately alleviates motor 
incoordination (chapter 4). 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
 
Calpastatin-mediated inhibition of calpains in the 
mouse brain prevents mutant ataxin-3 proteolysis, 
nuclear localization and aggregation, relieving 
Machado-Joseph disease 
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2.1. Abstract 
 
Machado-Joseph disease (MJD) is the most frequent dominantly-inherited 
cerebellar ataxia. Over-repetition of a CAG trinucleotide in the MJD1 gene translates 
into a polyglutamine tract within the ataxin-3 protein, which upon proteolysis may 
trigger MJD. We investigated the role of calpains in generation of toxic ataxin-3 
fragments and MJD pathogenesis. For this purpose, we inhibited calpain activity in 
MJD mouse models by overexpressing the endogenous calpain-inhibitor calpastatin.  
Calpain blockage reduced size and number of mutant ataxin-3 inclusions, 
neuronal dysfunction and neurodegeneration. By reducing fragmentation of ataxin-3, 
calpastatin overexpression modified the subcellular localization of mutant ataxin-3 
restraining the protein in the cytoplasm, reducing aggregation and nuclear toxicity, and 
overcoming calpastatin depletion observed upon mutant ataxin-3 expression.  
Our findings are the first in vivo proof that mutant ataxin-3 proteolysis by 
calpains mediates its translocation to the nucleus, aggregation and toxicity, and that 
inhibition of calpains may provide an effective therapy for MJD. 
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2.2. Introduction 
 
Machado-Joseph disease, also known as spinocerebellar ataxia type 3 
(MJD/SCA3), was originally described in people of Portuguese descent and is now 
considered the most frequent form among the autosomal dominantly inherited 
cerebellar ataxias. MJD is a neurodegenerative disorder characterized by abnormal 
movement (Sudarsky and Coutinho, 1995) and is caused by an unstable and expanded 
polyglutamine repeat of more than 55 CAGs within the coding region of the causative 
gene-MJD1, on chromosome 14q32.1 (Kawaguchi et al., 1994), conferring a toxic gain 
of function to the ubiquitin-binding protein ataxin-3 (Burnett et al., 2003; Chai et al., 
2004; Doss-Pepe et al., 2003; Rubinsztein et al., 1999; Scheel et al., 2003; Wang et al., 
2000).  
 Ataxin-3 is a protein of approximately 42 KDa and is predominantly expressed 
cytoplasmatically (Paulson et al., 1997a; Schmidt et al., 1998), even though it is small 
enough to enter the nucleus through passive diffusion (Marfori et al., 2011). Upon 
polyglutamine expansion, in spite of the increase in its molecular weight which could 
hinder access to the nucleus, mutant ataxin-3 accumulates in ubiquitinated intranuclear 
inclusions (Paulson et al., 1997b). The toxic fragment hypothesis predicts that 
proteolytic cleavage of the full-length polyQ-protein initiates the aggregation process 
associated with inclusion formation and cellular dysfunction (Haacke et al., 2006; 
Takahashi et al., 2008).  
A toxic cleavage fragment of mutant ataxin-3 was first proposed to trigger 
neurodegeneration by Ikeda and col. (Ikeda et al., 1996). Indeed, the C-terminal 
fragment of mutant ataxin-3 is more toxic than the full-length protein (Goti et al., 2004; 
Ikeda et al., 1996; Paulson et al., 1997b). Understanding the proteolytic mechanism 
involved and the cellular protease(s) responsible could unravel the trigger mechanism 
of MJD and reveal potential targets for therapy. Haacke and col. observed in cell 
lysates that upon calcium influx ataxin-3 was proteolyzed by calpains in fragments that 
could escape the cytoplasmic quality control (Breuer et al., 2010; Haacke et al., 2007). 
This observation was recently confirmed in patient – specific induced pluripotent stem 
cell (iPSC)-derived neurons (Koch et al., 2011). Calpain regulation is therefore critical 
and can come about by binding to calpastatin (CAST), the only endogenous calpain-
specific inhibitor ever identified (Takano et al., 2005). How ataxin-3 cleavage fragments 
mediate neurotoxicity has not been evaluated in MJD animal models. Overactivation of 
calpains may contribute decisively to the pathology, by increasing cleavage of ataxin-3 
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into fragments containing the expanded polyglutamine segment, which may be able to 
penetrate the nuclear pore, accumulate in the nucleus and induce neurodegeneration. 
 Here, taking advantage of adeno-associated viral vectors for overexpression of 
calpastatin, we set out to investigate in a lentiviral mouse model of MJD (Alves et al., 
2008) and in transgenic mice overexpressing calpastatin (Takano et al., 2005), whether 
and how are calpains involved in MJD pathogenesis. We provide in vivo evidence that 
a) proteolysis by calpains is required for nuclear localization of mutant ataxin-3, b) 
inhibition of calpains significantly decreases neuronal dysfunction and 
neurodegeneration in a MJD mouse model; c) production of mutant ataxin-3 cleavage 
fragments and the resulting nuclear localization inversely correlates with calpastatin 
levels, in a dose dependent manner; d) calpastatin is depleted from neurons bearing 
mutant ataxin-3 intranuclear inclusions. In conclusion, we provide new insights into 
mutant ataxin-3 proteolysis, nuclear translocation and resultant role in MJD 
pathogenesis, which indicate that calpain inhibition may provide a new therapeutic 
avenue for MJD. 
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2.3. Materials and methods 
 
2.3.1. Animals 
 4-week-old C57BL/6J mice (Charles River) were used. The animals were 
housed in a temperature-controlled room maintained on a 12 h light / 12 h dark cycle. 
Food and water were provided ad libitum. The experiments were carried out in 
accordance with the European Community directive (86/609/EEC) for the care and use 
of laboratory animals. The researchers received adequate training (Felasa-certified 
course), and certification to perform the experiments from the Portuguese authorities 
(Direcção Geral de Veterinária). 
 
2.3.2. Human brain tissue 
 Post mortem human brain tissue from dentate nucleus was obtained from the 
“Tissue donation program of the National Ataxia Foundation, Minneapolis, MN, USA” 
(VA Medical Center and Albany Medical College, Albany, NY, USA): control (female, 
36 years); MJD patient “O” (female, 70 years, 67/23 CAG repeats); MJD patient “W” 
(female, 62 years, 74/22 CAG repeats); MJD patient “K” (male, 53 years, 69/23 CAG 
repeats). 
 
2.3.3. MJD transgenic mice tissue 
 Cerebella of MJD transgenic mice (Torashima, 2008 #62)(Oue, 2009 #61) (n=5), 
5.5 and 15 weeks old, expressing a truncated form of human ataxin-3 with 69 CAG 
repeats, and wild-type mice (n=3), 20 weeks old of an older offspring, were dissected 
and treated for western-blot analysis. 
 
2.3.4. Viral vectors production 
 Lentiviral vectors encoding human wild-type ataxin-3 (ATX-3 27Q) or mutant 
ataxin-3 (ATX-3 72Q) (Alves et al., 2008) were produced in 293T cells with a four-
plasmid system, as previously described (de Almeida et al., 2001). The lentiviral 
particles were resuspended in 1% bovine serum albumin (BSA) in phosphate-buffered 
saline (PBS). The viral particle content of batches was determined by assessing HIV-1 
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p24 antigen levels (RETROtek, Gentaur, Paris, France). Viral stocks were stored at -
80ºC until use. 
 Adeno-associated viral vectors were produced as previously described (Kugler 
et al., 2003; Zolotukhin et al., 1999). 
 
2.3.5. In vivo injection in the striatum 
Concentrated viral stocks were thawed on ice. Lentiviral vectors encoding 
human wild-type (ATX-3 27Q) or mutant ataxin-3 (ATX-3 72Q) were stereotaxically 
injected into the striatum in the following coordinates: antero-posterior: +0.6mm; lateral: 
±1.8mm; ventral: -3.3mm; tooth bar: 0). Animals were anesthetized by administration of 
avertin (10 µl/g, i.p.). 
Wild-type mice and Tg hCAST mice received a single 1 µl injection of 200,000 
ng of p24/ml lentivirus in each side: left hemisphere (ATX-3 27Q) and right hemisphere 
(ATX-3 72Q). Wild-type mice were co-injected with 1 µl of 400,000 ng of p24/ml ATX-3 
72Q lentivirus and 3 µl of AAV1/2-GFP (left hemisphere) or AAV2-CAST (right 
hemisphere). 
For western-blot procedure, Tg hCAST mice received a single 2 µl injection of 
300,000 ng of p24/ml lentivirus in each side: left hemisphere (ATX-3 27Q) and right 
hemisphere (ATX-3 72Q). Wild-type mice were co-injected with 1 µl of 600,000 ng of 
p24/ml ATX-3 72Q lentivirus and 4 µl of AAV1/2-GFP (left hemisphere) or AAV2-CAST 
(right hemisphere). 
Mice were kept in their home cages for 4, 5 or 8 weeks, before being sacrificed 
for immunohistochemical or western-blot analysis. 
 
2.3.6. Immunohistochemical procedure 
 After an overdose of avertin (2.5x 12 µl/g, i.p.), transcardial perfusion of the 
mice was performed with a phosphate solution followed by fixation with 4% 
paraphormaldehyde (PFA). The brains were removed and post-fixed in 4% PFA for 24 
h and cryoprotected by incubation in 25% sucrose/ phosphate buffer for 48 h. The 
brains were frozen and 25 µm coronal sections were cut using a cryostat (LEICA 
CM3050 S) at -21°C. Slices throughout the entire striatum were collected in anatomical 
series and stored in 48-well trays as free-floating sections in PBS supplemented with 
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0.05 µM sodium azide. The trays were stored at 4°C until immunohistochemical 
processing.  
Sections from injected mice were processed with the following primary 
antibodies: a mouse monoclonal anti-ataxin-3 antibody (1H9; 1:5000; Chemicon, 
Temecula, CA), recognizing the human ataxin-3 fragment from amino acids F112-
L249; a rabbit polyclonal anti-ubiquitin antibody (Dako, 1:1000; Cambridgeshire, UK); a 
mouse monoclonal anti-myc tag antibody, clone 4A6 (1:1000; Upstate, Cell signalling 
solutions, Temecula, CA); and a rabbit anti-DARPP-32 antibody (1:1000; Chemicon, 
Temecula, CA), followed by incubation with the respective biotinylated secondary 
antibodies (1:200; Vector Laboratories). Bound antibodies were visualized using the 
Vectastain ABC kit, with 3,3’-diaminobenzidine tetrahydrochloride (DAB metal 
concentrate; Pierce) as substrate.  
Double stainings for Ataxin-3 (1H9; 1:3000), nuclear marker (DAPI, blue) and 
ubiquitin (Dako, 1:1000; Cambridgeshire, UK) or calpastatin (H300, 1:250, Santa Cruz) 
were performed. Free-floating sections from injected mice were at RT for 2 h in 
PBS/0.1% Triton X-100 containing 10% NGS (Gibco), and then overnight at 4°C in 
blocking solution with the primary antibodies. Sections were washed three times and 
incubated for 2 h at RT with the corresponding secondary antibodies coupled to 
fluorophores (1:200; Molecular Probes, Oregon, USA) diluted in the respective blocking 
solution. The sections were washed three times and then mounted in Fluorsave 
Reagent® (Calbiochem, Germany) on microscope slides. 
Staining was visualized using Zeiss Axioskop 2 plus, Zeiss Axiovert 200 and 
Zeiss LSM 510 Meta imaging microscopes (Carl Zeiss Microimaging, Germany), 
equipped with AxioCam HR color digital cameras (Carl Zeiss Microimaging) using 5x, 
20x, 40x and 63x Plan-Neofluar and a 63x Plan/Apochromat objectives and the 
AxioVision 4.7 software package (Carl Zeiss Microimaging). 
Quantitative analysis of fluorescence was performed with a semiautomated 
image-analysis software package (Image J software, USA). 
 
2.3.7. Cresyl violet staining 
Coronal 25-µm-thick striatal sections were cut using a cryostat. Premounted 
sections were stained with cresyl violet for 30 secs, differentiated in 70% ethanol, 
dehydrated by passing twice through 95% ethanol, 100% ethanol and xylene solutions, 
and mounted onto microscope slides with Eukitt® (Sigma). 
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2.3.8. Evaluation of the volume of the DARPP-32 depleted volume 
 The extent of ataxin-3 lesions in the striatum was analyzed by photographing, 
with a x1.25 objective, 8 DARPP-32 stained sections per animal (25 !m thickness 
sections at 200 !m intervals), selected so as to obtain complete rostrocaudal sampling 
of the striatum, and by quantifying the area of the lesion with a semiautomated image-
analysis software package (Image J software, USA). The volume was then estimated 
with the following formula: volume = d(a1+a2+a3 !), where d is the distance between 
serial sections (200 !m) and a1+a2+a3 are DARPP-32 depleted areas for individual 
serial sections. 
 
2.3.9. Cell counts and morphometric analysis of ataxin-3 and 
ubiquitin inclusions 
 Coronal sections showing complete rostrocaudal sampling (1 of 8 sections) of 
the striatum were scanned with a x20 objective. The analyzed areas of the striatum 
encompassed the entire region containing ATX-3 and ubiquitin inclusions, as revealed 
by staining with the anti-ataxin-3 and anti-ubiquitin antibodies. All inclusions were 
manually counted using a semiautomated image-analysis software package (Image J 
software, USA). Inclusions diameter was assessed by scanning the area above the 
needle tract in four different sections, using a x63 objective. At least 100 inclusions 
showing double staining for mutant ataxin-3 and GFP or calpastatin were analyzed 
using LSM Image Browser. 
 
2.3.10. Western-blot analysis 
For assessment of ataxin-3 proteolysis in the lentiviral model of MJD, 
transcardial perfusion of the mice was performed with ice-cold phosphate buffered 
saline containing 10 mM EDTA and 10 mM of the alkylating reagent N-ethylmaleimide, 
to avoid post-mortem calpain overactivation. The injected striata were then dissected 
and immediately sonicated in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 7 
mM EDTA, 1% NP-40, 0.1% SDS, 10 µg/ml DTT, 1mM PMSF, 200 !g/ml leupeptin, 
protease inhibitors cocktail). Equal amounts (30 µg of protein) were resolved on 12% 
SDS-polyacrylamide gels and transferred onto PVDF membranes. Immunoblotting was 
performed using the monoclonal anti-ataxin-3 antibody (1H9, 1:1000, Chemicon, 
Temecula, CA), anti-calpastatin (H300, 1:200, Santa Cruz), anti-calpain-cleaved "-
spectrin (Roberts-Lewis et al., 1994) (Ab38, 1:3000) and anti-actin (clone AC-74, 
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1:5000, Sigma) or anti-tubulin (clone SAP.4G5, 1:15000, Sigma). A partition ratio with 
actin or tubulin was calculated following quantification with Quantity-one 1-D image 
analysis software version 4.5. 
 
2.3.11. Statistical analysis 
 Statistical analysis was performed using Student’s t-test or ANOVA for multiple 
comparisons. Values of p<0.05 were considered statistically significant. 
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2.4. Results 
 
2.4.1. Inhibition of calpains in a lentiviral mouse model of MJD 
reduces the size and number of neuronal intranuclear inclusions of 
mutant ataxin-3  
 In order to investigate the role of calpains in the pathogenesis of SCA3 we 
overexpressed the calpain inhibitor calpastatin in a lentiviral mouse model of MJD 
(Alves et al., 2008). 4-week-old mice were co-injected bilaterally in the striatum with 
lentiviral vectors encoding ATX-3 72Q and AAV vectors encoding GFP (control, left 
hemisphere) or calpastatin (right hemisphere; Fig. 2.1) and were sacrificed 8 weeks 
post-injection. Mice singly injected with CAST and GFP were used as a control of AAV 
transduction. AAV vectors mediate a delayed expression of calpastatin, when 
compared to a quicker onset of ataxin-3 expression upon lentiviral transduction, due to 
the necessity of conversion of the single stranded genome into double stranded DNA, 
especially in non-dividing cells (Shevtsova et al., 2005). Therefore, co-injection of both 
viral vectors in the mouse brain allowed cells co-transduction in a phased manner, 
leading to the development of pathology before maximum expression of the calpain 
inhibitor two weeks later. 
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Figure 2.1. Strategy used to generate an in vivo mouse model of Machado-Joseph disease and 
to inhibit mutant ataxin-3 proteolysis by calpains. Schematic representation of the lentiviral 
constructs used in the development of the mouse model of Machado-Joseph disease. cDNAs 
encoding A, wild-type (27 CAG repeats) or B, mutant ataxin-3 (72 CAG repeats) were cloned in 
the SIN-W transfer vector. C, Scheme of the adeno-associated virus 1/2 encoding green 
fluorescent protein. D, The cDNA encoding calpastatin was inserted into an adeno-associated 
virus serotype 2 backbone, under the control of the human synapsin-1 gene promoter, which 
restrains expression to neurons. E, 4-week-old mice were co-injected bilaterally in the striatum 
with ATX3-72Q and green fluorescent protein (left hemisphere) or calpastatin (right hemisphere) 
vectors and were sacrificed 5 and 8 weeks post-injection for western-blot and 
immunohistochemical analysis, respectively. (injection coordinates: antero-posterior: +0.6mm; 
lateral: ±1,8mm; ventral: -3.5mm; tooth bar:0). F, Diagram of ataxin-3 showing antibodies 
recognition used in Fig. 5. 
 
Calpain inhibition by calpastatin reduced the size and number of mutant ataxin-
3 (ATX-3 72Q) inclusions (Fig. 2.2B, D and K, 2.6E), when compared to the GFP 
transduced hemisphere (Fig. 2.2A, C and K, 2.6E). In this control hemisphere (Fig. 
2.2C) and in cells not infected by calpastatin (Fig. 2.2D; arrowhead), ATX-3 72Q 
accumulated in large intranuclear inclusions with 3.98 !m mean diameter and co-
localized with ubiquitin (Fig. 2.2E-G). On the contrary, upon calpastatin overexpression, 
mutant ATX-3 inclusions became very small, almost undetectable by fluorescence 
immunohistochemistry (Fig. 2.2D), and ubiquitin pattern was diffuse (Fig. 2.2H-J). 
Calpain inhibition promoted a 2.9 fold reduction in inclusions diameter to 1.4 !m (Fig. 
2.2C-D, 2.6E) and reduced to 47% the number of N-terminal ataxin-3 inclusions 
detected with an anti-myc antibody (Fig. 2.2A,B,K), an effect that was less prominent 
when inclusions were counted in brightfield upon imunohistochemistry with the 1H9 
(recognizes amino acids 221-224) or anti-ubiquitin antibodies (Fig. 2.3). This may be 
due to the fact that the C-terminal of ataxin-3, including the polyglutamine tract, is more 
prone to readily aggregate. 
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Figure 2.2. Inhibition of calpains significantly decreases the number of N-terminal mutant 
ataxin-3 inclusions, while changing mutant ataxin-3 and ubiquitin aggregation pattern. A-K, Co-
expression of mutant ataxin-3 and green fluorescent protein (GFP) (left hemisphere) or 
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calpastatin (right hemisphere) in the striatum of adult mice, 2 months post-injection. A,B, 
Immunohistochemistry – peroxidase staining using an anti-myc antibody to the myc tag of the 
N-terminal ataxin-3 (Ab clone 4A6). A significant decrease in the number of N-terminal ataxin-3 
inclusions was observed in calpastatin transduced hemisphere. C, Immunohistochemistry – 
fluorescence staining for mutant ataxin-3 (Ab 1H9, red) localization upon co-expression with 
GFP (green) or D, calpastatin (Ab H300, green). Nuclear marker (DAPI, blue) was used. As 
expected, in the GFP transduced hemisphere mutant ataxin-3 was observed as intranuclear 
inclusions. On the contrary, the cells infected with AAV2-CAST showing calpastatin 
immunoreactivity, presented small inclusions almost not depicted. E-G, Immunohistochemistry – 
fluorescence staining for colocalization (G,J, merge of E and F or H and I with nuclear marker 
DAPI, blue) of mutant ataxin-3 (E,H, Ab 1H9, green) and ubiquitin (F,I, Ab anti-ubiquitin DAKO, 
red). While in the control hemisphere mutant ataxin-3 intranuclear inclusions (E) were 
ubiquitinated (F) particularly within the central core, H-J, ubiquitin pattern upon calpastatin 
overexpression is rather diffuse. K, Quantification of the absolute number of myc-positive cells, 
graph related to panel A-B. Statistical significance was evaluated with Student’s t test (n=4, * 
p=0.05). 
 
Upon co-infection with vectors encoding wild-type ataxin-3 (ATX-3 27Q) and 
GFP (left hemisphere) or calpastatin (right hemisphere), neither ataxin-3 nor ubiquitin 
inclusions were observed. Furthermore, no difference in the subcellular localization of 
ATX-3 27Q was observed between the two hemispheres (Fig. 2.5).  
These results suggest that inhibition of calpain activity in the mouse brain 
prevents accumulation of mutant ataxin-3 in large intranuclear inclusions. 
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Figure 2.3. Mutant ataxin-3 and ubiquitin aggregation. A-F, Co-expression of mutant ataxin-3 
and green fluorescent protein (GFP) (left hemisphere) or calpastatin (right hemisphere) in the 
striatum of adult mice, 2 months post-injection. A-D, Immunohistochemistry – peroxidase 
staining using anti-ataxin-3 (Ab 1H9) or E-F, anti-ubiquitin (Ab Dako) antibody. When compared 
to GFP transduced hemisphere, upon co-injection of mutant ataxin-3, calpastatin promoted a 
decrease in the number of mutant ATX-3-positive inclusions and ubiquitin-positive inclusions. 
Quantification of the absolute number of G, mutant ataxin-3 and H, ubiquitin-positive cells. 
 
2.4.2. Inhibition of calpains in a lentiviral mouse model of MJD 
mediates striatal neuroprotection  
To monitor the effects of calpastatin overexpression over neuronal dysfunction 
induced by mutant ataxin-3 we performed an immunohistochemical analysis for 
DARPP-32, a regulator of dopamine receptor signalling (Greengard et al., 1999) which 
we have previously shown to be down-regulated in the striatum of lentiviral and 
transgenic MJD animal models (Alves et al., 2008). Loss of DARPP-32 
immunoreactivity in the CAST injected striatal hemisphere was reduced to 39% when 
compared to the GFP transduced hemisphere (Fig. 2.4A-D,G), whereas no loss of 
DARPP-32 staining was detected in mice co-injected with ATX-3 27Q and GFP or 
CAST (Fig. 2.5). This is indicative of a neuroprotective effect provided by the selective 
inhibition of calpains. 
 
Chapter 2 
  48   
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Inhibition of calpains prevents cell injury and striatal degeneration. A-H, Co-
expression of mutant ataxin-3 (ATX-3 72Q) and green fluorescent protein (GFP, left 
hemisphere) or calpastatin (CAST, right hemisphere) in the striatum of adult mice, 2 months 
post-injection, A-D, Immunohistochemistry – peroxidise staining using an anti-DARPP-32 
antibody. C, D are a higher magnification of A, B. A ,C A major loss of DARPP-32 
immunoreactivity was observed in the striatum infected with ATX-3 72Q and GFP, B,D, whereas 
minor DARPP-32 loss was observed in the striatum infected with ATX-3 72Q and CAST. E,F, 
Cresyl violet staining of E, ATX-3 72Q + GFP and F, ATX-3 72Q + CAST transduced 
hemispheres of adult mice. G, Quantification analysis of the DARPP-32-depleted region in the 
brains of mice. The lesion volume in the hemisphere infected with ATX-3 72Q and CAST was 
much smaller than that in the hemisphere infected with ATX3-72Q and GFP, indicative of a 
neuroprotective effect conferred by the inhibition of calpains (n=4, * p=0.05). H, Quantification 
analysis of the pycnotic nuclei visible in both hemispheres on cresyl violet-stained sections. 
More pycnotic nuclei were visible in the GFP transduced hemisphere, suggesting that 
calpastatin prevented cell injury and striatal degeneration after co-injection with ATX-3 72Q. All 
the pictures were taken around the injection site area and show representative 
immunohistochemical stainings. Statistical significance was evaluated with Student’s t test (n=4, 
** p<0.01). 
 
Additionally, cresyl violet-stained sections further demonstrated a significant 
reduction in the number of shrunken hyperchromatic nuclei upon calpastatin 
overexpression (Fig. 2.4E,F,H), indicating that calpain inhibition prevents cell injury and 
striatal degeneration induced by mutant ataxin-3 expression in the brain of adult mice. 
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Figure 2.5. Inhibition of 
calpains does not promote 
cell injury and striatal 
degeneration upon wild-
type ataxin-3 
overexpression. A-N, Co-
expression of wild-type 
ataxin-3 (ATX-3 27Q) and 
GFP (left hemisphere) or 
calpastatin (right 
hemisphere) in the 
striatum of adult mice, 2 
months post-injection. No 
differences were observed 
between the two 
hemispheres in terms of 
ataxin-3 and ubiquitin 
localization and its 
distribution pattern. 
Neither GFP nor 
calpastatin promotes cell 
injury and striatal 
degeneration, per se. 
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2.4.3. Calpastatin prevents nuclear translocation of mutant ataxin-3 
in a dose dependent manner   
We further assessed the involvement of calpains in MJD pathogenesis by 
expressing mutant ataxin-3 in the mouse striatum upon three progressively increasing 
levels of calpastatin (Fig. 2.6), as follows: A) wild-type animals, B) transgenic mice 
overexpressing calpastatin (Takano et al., 2005), C) animals injected with AAV vectors 
encoding  calpastatin. 
The mean diameter of mutant ataxin-3 intranuclear inclusions was reduced to 
2.77 !m in transgenic animals (Fig. 2.6B,E), 1.4 fold smaller than the control, but 2 fold 
bigger than the mean inclusion size when calpastatin levels were achieved by viral 
transduction (Fig. 2.6C,E). Fig. 2.6D shows the increasing calpastatin protein levels in 
Tg hCAST and AAV2-CAST injected mice. 
These results suggest that a critical concentration of calpastatin is necessary to 
completely inhibit calpain activity in order to prevent mutant ataxin-3 translocation to 
the nucleus and aggregation. 
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Figure 2.6. Inhibition of calpains prevents nuclear translocation and aggregation of mutant 
ataxin-3 in a dose dependent manner. Subcellular localization of mutant ataxin-3 (ATX-3 72Q, 
Ab 1H9, red) A, when co-injected with green fluorescent protein (GFP, green, n=4), B, in 
transgenic mice overexpressing calpastatin (Tg hCAST, n=8) and C,D, when co-injected with 
calpastatin (CAST, Ab H300, green, n=4). Nuclear marker (DAPI, blue) was used. As the levels 
of calpastatin increased (A to B and B to C),,aggregation in the nucleus was prevented. D, 
Calpastatin immunoreactivity (CAST, Ab H300, green) is lower in wild-type (wt) and transgenic 
mice overexpressing calpastatin (Tg hCAST) than in AAV-2 CAST injected mice. E, Analysis of 
inclusions diameter showing double staining for mutant ataxin-3 with Ab 1H9 and GFP or 
calpastatin (*** p<0.0001). 
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2.4.4. Inhibition of calpains reduces ataxin-3 proteolysis 
 To investigate the mechanism by which calpain inhibition modified the 
subcellular localization of mutant ataxin-3, preventing its nuclear localization, neuronal 
dysfunction and neurodegeneration, we performed western blot analysis of brain 
punches of mice subjected to the previously described experimental paradigm (Fig. 
2.1E) but sacrificed at an earlier time point: 5 weeks post-injection. Striatal punches of 
non-injected and ATX-3 27Q transduced hemispheres were used as controls. 
Importantly, two ataxin-3 fragments of ~26 kDa and ~34 kDa were strongly detected in 
the brain hemispheres expressing mutant ataxin-3 (Fig. 2.7A, arrowheads), but 
sparingly and not detected, respectively, in those overexpressing wild-type and only 
expressing endogenous ataxin-3 (Fig. 2.7D), confirming in vivo that mutant ataxin-3 is 
cleaved into fragments that accumulate in the brain and that a wild-type fragment may 
be more rapidly degraded. Notably, inhibition of calpains activity, confirmed by a 
decreased immunolabeling of calpain-cleaved "-spectrin (Fig. 2.7E, Ab38), a natural 
substrate of calpains, decreased by 39% the production of the ~26 kDa mutant ataxin-3 
fragment (Fig. 2.7A,F), which was also detected using a N-terminal antibody (Ab myc, 
Fig. 2.7C) and a C-terminal antibody specific for the polyglutamine stretch (Ab 1C2, Fig. 
2.7B). In addition, the formation of the ~34 kDa fragment was also decreased by 17%, 
being this fragment only C-terminal and only generated from the mutant protein (Fig. 
2.7G).  
These results are in accordance with the toxic fragment hypothesis and strongly 
support the idea that inhibition of ataxin-3 cleavage by calpains may be the basis of the 
calpastatin neuroprotective mechanism.   
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Figure 2.7. Ataxin-3 proteolysis in the lentiviral mouse model of MJD is decreased upon 
calpastatin overexpression. At 5 weeks post-injection, mice (n=7) co-injected bilaterally with 
mutant ataxin-3 (ATX-3 72Q) and green fluorescent protein (GFP, left hemisphere) or 
calpastatin (CAST, right hemisphere) were sacrificed and punches of the striatum were made to 
perform a western blot analysis with several antibodies to detect different epitopes of ataxin-3 
protein: A, Ab 1H9, which recognizes amino acids E214-L233; B, Ab 1C2, specific for the 
polyglutamine stretch, present at the C-terminal of ataxin-3; and C, Ab myc, which recognizes 
myc tag located at the N-terminal of mutant ataxin-3. Two fragments of ~26kDa and ~34kDa 
were detected (shaded and empty arrowheads, respectively). D, Striatal punches of non-
injected and ATX-3 27Q transduced hemispheres. E, Levels of calpastatin (CAST, Ab H300) 
and of calpain-cleaved "-spectrin (Ab 38) are also shown. F,G, Densitometric quantification of 
~26kDa and ~34kDa fragments levels of mutant ataxin-3 relative to actin, shown in panel A (n=7, 
* p=0.05). The ~26kDa fragment is clearly detected by Ab 1H9, Ab 1C2 and Ab anti-myc in the 
mutant ataxin-3 sample, but faintly in the transgenic wild-type and not detected in the 
endogenous ataxin-3 sample. The ~34kDa fragment is only detected in the mutant ataxin-3 
sample using Ab 1H9 and Ab 1C2. 
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2.4.5. Calpastatin is depleted from cells with mutant ataxin-3 
intranuclear inclusions 
MJD progression could be propelled by depletion of calpastatin, which would 
accelerate calpains dysregulation and lead to neurodegeneration. To investigate this 
hypothesis, we evaluated the immunoreactivity for calpastatin upon expression of 
mutant ataxin-3 in the previously described calpastatin transgenic mice (Takano et al., 
2005). Whereas a strong calpastatin immunoreactivity was observed in the hemisphere 
transduced with lentiviral vectors encoding ATX-3 27Q, a significant reduction of 
calpastatin immunostaining by 18%, was observed in cells where mutant ataxin-3 
inclusions were present (Fig. 2.8A-F,J). Interestingly, in Fig. 2.8F, the cell pointed with 
an arrow, where no ataxin-3 inclusions were observed, presented a similar calpastatin 
immunolabeling to those transduced with ATX3 27Q, contrasting with the reduced 
immunostaining detected in the cells pointed with arrowheads with large ataxin-3 
intranuclear inclusions.  
CAST depletion was further confirmed by immunoblot analysis of brains from 
calpastatin transgenic mice (Fig. 2.8G,K). CAST levels were reduced by 26% in the 
hemisphere where mutant ataxin-3 was overexpressed in comparison to the contra-
lateral hemisphere with wild-type ataxin-3 overexpression. 
To further validate calpastatin depletion in Machado-Joseph disease, using 
western blot, we analyzed calpastatin levels in patient post mortem tissue and in an 
MJD transgenic mouse model (Torashima et al., 2008; Oue et al., 2009). A dramatic 
68% reduction of calpastatin levels was found in the transgenic mouse model of MJD, 
when compared to wild-type mice (Fig. 2.8H,L). Importantly, in human tissue we 
observed that calpastatin levels were reduced by 67%, 25% and 7% in samples from 
dentate nucleus of three MJD patients compared to control (Fig. 2.8I,M). 
These results indicate that upon mutant ataxin-3 expression, calpastatin is 
depleted, which may in turn increase calpain activity, ataxin-3 proteolysis, nuclear 
translocation, aggregation and toxicity, ultimately triggering or at least severely 
aggravating MJD pathogenesis. 
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Figure 2.8. Calpastatin is depleted from cells with mutant ataxin-3 intranuclear inclusions. 
Transgenic mice overexpressing calpastatin (Tg hCAST) were injected bilaterally: wild-type 
ataxin-3 (ATX-3 27Q) in the left hemisphere and mutant ataxin-3 (ATX-3 72Q) in the right 
hemisphere and were sacrificed 4 weeks post-injection for A-G, immunohistochemistry and H,I, 
western blot analysis. A-F, Immunohistochemistry – fluorescence staining for A,D, ataxin-3 (Ab 
1H9, red), B,E, calpastatin (CAST, Ab H300, green) and nuclear marker (DAPI, blue). A-C, 
While cells infected with ATX-3 27Q presented a strong calpastatin immunoreactivity, when D-F, 
ATX-3 72Q was injected, the cells in which intranuclear inclusions were present, nearly no 
calpastatin immunolabeling was observed. F, Even in the same hemisphere, in opposition to the 
cell pointed with an arrow, the cells with intranuclear inclusions (pointed with arrow heads), did 
not overexpress calpastatin, suggesting that the endogenous calpain inhibitor was depleted 
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upon mutant ataxin-3 expression. Western blot analysis with anti-calpastatin antibody (Ab 
H300) revealed a decrease of calpastatin levels in G, mutant ataxin-3 transduced hemisphere in 
comparison to its contra-lateral hemisphere; and also in lysates obtained from H, dissected 
cerebella of a MJD transgenic mouse model (n=5) and from I, dentate nucleus of MJD patients.  
J, Quantitative analysis of CAST immunoreactivity (n=4, ** p<0.01). K,L,M Densitometric 
quantification of calpastatin levels, shown in panel G,H,I, respectively. 
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2.5. Discussion 
 
In this work we provide in vivo evidence that calpains are proteolytic enzymes 
involved in Machado-Joseph disease pathogenesis and that inhibition of calpains 
reduces a) cleavage of mutant ataxin-3, b) its translocation to the nucleus, c) 
aggregation in nuclear inclusions, d) neurotoxicity and e) neurodegeneration. 
 The neurotoxicity associated with MJD has been proposed to be derived from a 
mutant ataxin-3 cleavage fragment (Haacke et al., 2006; Ikeda et al., 1996; Koch et al., 
2011; Takahashi et al., 2008), which above a critical concentration becomes cytotoxic 
(Goti et al., 2004). Based on cell or in vitro models, mutant ataxin-3 has been reported 
to be a substrate for caspases (Berke et al., 2004; Jung et al., 2009), subject to 
autolytic cleavage (Mauri et al., 2006) and a substrate for calpains (Haacke et al., 
2007; Koch et al., 2011). An additional cleavage site was proposed in a mouse model, 
within the N-terminus of amino acid 190, which might not be a caspase nor a calpain 
product (Colomer Gould et al., 2007).  
To clarify this issue, we overexpressed the endogenous calpain-specific 
inhibitor calpastatin in a lentiviral mouse model of MJD, and in transgenic mice 
overexpressing calpastatin (Takano et al., 2005). This approach overcomes the use of 
synthetic peptidic, peptide-mimetic, and nonpeptidic calpain inhibitors currently 
available, which have problems of specificity, metabolic stability, water-solubility, and/or 
penetration through the blood-brain barrier (Higuchi et al., 2005). Instead of using the 
lentiviral model in the rat (Alves et al., 2008) here we generated an analogous model in 
C57BL/6J mice that allows comparing the results with those obtained in the Tg hCAST 
mice also handled, and to previous in vivo studies. 
As expected, upon mutant ataxin-3 expression, the expanded protein 
accumulated as intranuclear inclusions co-localizing with ubiquitin in the mouse brain 
(Fig. 2.2C,E-G). A marked loss of DARPP-32 immunoreactivity and a large number of 
pycnotic nuclei were observed (Fig. 2.4), suggesting cell injury and neurodegeneration. 
On the contrary, when mutant ataxin-3 was co-injected with calpastatin to specifically 
inhibit calpains, a robust and dose-dependent decrease in the size and number of C 
and N-terminal ataxin-3 inclusions, respectively, (Fig. 2.2A-B,K) was observed. In 
addition, the volume of the region depleted of DARPP-32 immunoreactivity and the 
number of pycnotic nuclei were significantly and robustly decreased (Fig. 2.4), 
indicating that calpain inhibition prevents cell injury and provides neuroprotection.  
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Cleavage fragments of mutant ataxin-3, whose existence has been for many 
years the object of controversia, were clearly detected in vivo in this study. While we 
were finalizing the present work, a study in patient – specific induced pluripotent stem 
cell (iPSC)-derived neurons also reported the formation of cleavage fragments of 
mutant ataxin-3 upon L-glutamate or NMDA stimulus (Koch et al., 2011). The two 
studies are concordant on providing compelling evidence of the involvement of calpains 
in MJD, but not on the trigger for calpain activation, as in our study, cleavage of mutant 
ataxin-3 occurred without overstimulation of glutamate receptors. 
Cleavage of mutant ataxin-3 (Fig. 2.7) might occur at amino acid 220 (see figure 
2.1), giving rise to two different fragments of similar molecular weight detected by: a) 
Ab 1H9 (Fig. 2.7A), which recognizes the human ataxin-3 fragment from amino acids 
E214-L233, b) Ab myc (Fig. 2.7C), an antibody for a myc tag located at the N-terminal 
of the protein and c) Ab 1C2 (Fig. 2.7B), an antibody specific for the polyQ stretch, 
present at ataxin-3 C-terminal (Fig. 2.1F). A simultaneous cleavage at amino acids 60 
and 260 proposed by Haacke and col. (Haacke et al., 2007) may lead to the final 
~26kDa fragment, detected by Ab 1H9. Cleavage at amino acid 154 may generate a 
mutant C-terminal ~34kDa fragment only detected by Ab 1H9 (Fig. 2.7A) and Ab 1C2 
(Fig. 2.7B), but not by the Ab myc (Fig. 2.7C).  
These results support the toxic fragment hypothesis indicating that calpastatin 
promotes neuroprotection by decreasing mutant ataxin-3 fragment production, 
suggesting that the pathogenesis of MJD is strongly associated to mutant ataxin-3 
proteolysis by calpains. As evidenced by the decreased cleavage of "-spectrin, a 
potential biomarker for neuronal cell injury (Liu et al., 2008), and ataxin-3 (Fig. 2.7A,E), 
upon calpastatin overexpression, proteolysis of other substrates might also be inhibited 
as well as other functions regulated by calpains under pathological conditions, not 
addressed in our studies. Recent evidences suggest that not only the C-terminal 
fragment is cytotoxic (Goti et al., 2004; Ikeda et al., 1996), but that the non-
polyglutamine containing ataxin-3 N-terminus fragment is also toxic and may contribute 
to an impaired unfolded protein response in the pathogenesis of MJD (Hubener et al. 
2011). Our results show that CAST overexpression leads to a decrease of both 
fragments formation. Further evidences that CAST exerted neuroprotection may also 
be drawn from the subcellular localization of the ataxin-3 species. 
Ataxin-3, when non-expanded is enriched in the cytoplasm (Paulson et al., 
1997a; Schmidt et al., 1998; Cemal et al., 2002; Goti et al., 2004) but upon 
polyglutamine expansion the protein accumulates in the nucleus. This nuclear 
localization is required for the in vivo manifestation of MJD neuropathology. 
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Accordingly, transgenic mice with 148 CAGs but attached to a nuclear export signal 
only develop a milder phenotype with few inclusions (Bichelmeier et al., 2007). 
However, how ataxin-3 enters the nucleus under pathogenic conditions and forms 
aggregates is a matter of debate. It has been proposed that CK2-dependent 
phosphorylation determines cellular localization (Mueller et al., 2009) and that 
proteotoxic stress increases nuclear localization of ataxin-3 (Reina et al., 2010), while 
other reports underline the importance of nuclear localization (NLS 273) and nuclear 
export (NES 77 and NES 141) signals to ataxin-3 intracellular localization (Antony et al., 
2009; Macedo-Ribeiro et al., 2009). Accordingly, we found that the number of 
inclusions detected with the antibody targeting the N-terminal ataxin-3 was significantly 
lower than the amount found when using the 1H9 antibody (aa 221-224) in both GFP 
and CAST-transduced hemispheres. This suggests that the C-terminal fragment, 
including the NLS and the polyQ stretch, is more prone to aggregation and 
accumulates in higher extension in the nucleus as compared to the N-terminal 
fragment carrying the NES sequences (Goti et al., 2004; Koch et al., 2011; Schmidt et 
al., 1998; Walsh et al., 2005). Furthermore, our results show that proteolysis of mutant 
ataxin-3 by calpains is required for its translocation to the nucleus in a dose dependent 
manner (Fig. 2.6). As calpastatin levels increase, the diameter of mutant ataxin-3 
inclusions progressively decreases (A: 3.98 !m, B: 2.77 !m and C: 1.40 !m). Our 
results suggest that calpains cleavage between the nuclear export signals and the 
nuclear localization signal (NLS) discussed above may account for the enhanced 
transport of the C-terminal fragment simultaneously carrying the NLS and the 
expanded polyglutamine tract of ataxin-3 from the cytoplasm to the nucleus. Altogether, 
calpain activity is required for mutant ataxin-3 translocation to the nucleus, and this 
effect is antagonized by the presence of calpastatin.  
Finally, our studies suggest that upon mutant ataxin-3 expression calpastatin is 
depleted (Fig. 2.8), in accordance to what was observed in Alzheimer’s disease models, 
where the progression is propelled by a marked depletion of calpastatin, upstream to 
calpains activation (Rao et al., 2008). Calpastatin depletion was observed not only in 
the lentiviral mouse model, but also in a MJD mouse model (Torashima et al, 2008; 
Oue et al, 2009) and in human brain tissue. Rather than simply its consequence, we 
speculate that CAST depletion may progressively lead to calpain overactivation. Our 
results suggest that calpain activation promotes mutant ataxin-3 cleavage, which in 
turn translocates to the nucleus and aggregates, and that during this process 
calpastatin might also be cleaved, further contributing to calpain overactivation. This 
observation may also explain the larger diameter of mutant ataxin-3 inclusions in Tg 
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hCAST mice than in mice infected with AAV2-CAST (Fig. 2.6). In this experiment, lower 
calpastatin overexpression levels may have been insufficient to overcome calpastatin 
depletion, and to inhibit and prevent nuclear aggregation. 
In conclusion, in this study, we established in vivo the connection between 
mutant ataxin-3 proteolysis by calpains, fragments production and nuclear localization, 
contributing to the elucidation of the pathogenic mechanism of MJD. Furthermore, we 
show that calpastatin, the endogenous calpain-specific inhibitor, is able to block this 
mechanism, preventing nuclear translocation of mutant ataxin-3, consequent 
aggregation and nuclear toxicity. Therefore, these findings indicate that calpains are 
promising targets for therapeutic intervention in MJD. 
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3.1. Abstract 
 
Machado-Joseph disease (MJD) is the most prevalent autosomal dominantly-
inherited cerebellar ataxia. It is caused by an expanded CAG repeat in the ATXN3 
gene, which translates into a polyglutamine tract within the ataxin-3 protein. Present 
treatments are symptomatic and do not prevent disease progression. As calpain 
overactivation has been shown to contribute to mutant ataxin-3 proteolysis, 
translocation to the nucleus, inclusions formation and neurodegeneration, we 
investigated the potential role of calpain inhibition as a therapeutic strategy to alleviate 
MJD pathology. For this purpose, we administered orally the calpain inhibitor BDA-410 
to a lentiviral mouse model of MJD.  
Our data provide evidence that not only the fragments are the toxic species, but 
also that mutant ataxin-3 aggregates of specific size have different toxic properties. 
Western-blot and immunohistochemical analysis revealed the presence of N- and C-
terminal mutant ataxin-3 fragments and the colocalization of large inclusions with 
cleaved caspase-3 in the mice brain. Furthermore, we show that oral administration of 
the calpain inhibitor BDA-410 decreased both fragments formation and full-length 
ataxin-3 levels, reduced aggregation of mutant ataxin-3 and prevented cell injury and 
striatal degeneration. In conclusion, BDA-410 alleviates Machado-Joseph 
neuropathology and may therefore be an effective therapeutic option for MJD. 
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3.2. Introduction 
 
Machado-Joseph disease, also known as spinocerebellar ataxia type 3 
(MJD/SCA3), is the most prevalent autosomal dominantly-inherited cerebellar ataxia 
(Ranum et al., 1995; Schols et al., 2004). The diagnosis of MJD relies on the use of 
molecular genetic testing to detect an abnormal CAG trinucleotide repeat expansion in 
the respective ATXN3 gene located on chromosome 14q32.1 and is suggested in 
individuals with progressive cerebellar ataxia and pyramidal signs as well as 
ophthalmoplegia, dystonia, action-induced facial and lingual fasciculation-like 
movements, and bulging eyes (D'Abreu et al., 2010; Lima and Coutinho, 1980). 
Current treatment is symptomatic without preventing neuronal cell death or delaying 
age of onset (D'Abreu et al., 2010). Therefore, identification of molecular pathways of 
disease is crucial to unravel potential therapeutic targets. 
 Cleavage of mutant ataxin-3 into smaller toxic fragments, that initiate the 
aggregation process associated with inclusion formation and cellular dysfunction 
(Haacke et al., 2006; Takahashi et al., 2008), coupled with mutant ataxin-3 localization 
within the cell nucleus (Bichelmeier et al., 2007; Yang et al., 2002) seem to be key 
issues for the induction of neurodegeneration. The aforementioned proteolytic cleavage 
of mutant ataxin-3 has been associated with calpain activity in mouse neuroblastoma 
cells (Neuro2a) (Haacke et al., 2007), in the abnormalities observed in patient – 
specific induced pluripotent stem cell (iPSC)-derived neurons (Koch et al., 2011) and 
by our group in the lentiviral mouse model by promotion of a) ataxin-3 translocation to 
the nucleus, b) aggregation, c) cell injury, d) neurodegeneration and e) further 
contribution to the depletion of the endogenous calpain inhibitor calpastatin in 
Machado-Joseph disease models and human tissue (Simões et al., 2012)..Together, 
these studies strongly suggest that calpain inhibition may be a promising strategy to 
alleviate MJD. 
 Gene therapy with viral vectors for overexpression of calpastatin is particularly 
adequate and translatable to clinical setting to treat well-defined CNS regions. However, 
as the neuropathology of MJD involves multiple systems such as cerebellar systems, 
substantia nigra, cranial nerve motor nuclei (Durr et al., 1996; Sudarsky and Coutinho, 
1995), and the striatum (Alves et al., 2008; Klockgether et al., 1998; Taniwaki et al., 
1997; Wullner et al., 2005), a strategy able to reach broader distribution, while 
minimizing invasiveness, such as an orally-administered low molecular weight drug is 
also needed either as a single or complementary therapy. Therefore, in this study, we 
investigated whether a novel and highly specific cysteine protease inhibitor termed 
BDA-410 (Li et al., 2007; Subramanian et al., 2012; Trinchese et al., 2008) would 
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alleviate MJD. Using a lentiviral mouse model of MJD (Alves et al., 2008; Simões et al., 
2012), we investigated whether this orally-administered compound mediated 
neuroprotection.  
Our results show that BDA-410 inhibited calpain mediated proteolysis, and 
decreased mutant ataxin-3 aggregation. In addition, this calpain inhibitor prevented cell 
injury and degeneration in the mouse brain, suggesting that it may provide a new 
therapeutic choice for MJD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
  66     
3.3. Materials and Methods 
 
3.3.1. Calpain inhibitor BDA-410 
BDA-410 was kindly provided by Dr. Narihiko Yoshi and Dr. Hisako Yamaguchi 
from Mitsubishi Pharma Corporation, Yokohama, Japan. The chemical name of this 
compound is (2S)-N-(1S)-1-[(S)-Hydroxy(3-oxo-2-phenyl-1-cyclopropen-1yl)methyl]-2-
methylpropyl-2-benzenesulfonylamino-4-methylpentanamide (C26H32N2O5S; MW 
484.61). BDA-410 has a potent and selective inhibitory action against calpains: calpain 
1/calpain 2, IC50 = 21.4 nM; papain, IC50 = 400 nM; cathepsin B, IC50 = 16 !M; thrombin, 
IC50 >100 !M; cathepsin G, IC50 >100 !M; cathepsin D, IC50 = 91.2 !M; proteasome 
20S, IC50 >100 !M. 
 
3.3.2. Cultures of cerebellar granule neurons 
Primary cultures of rat cerebellar granule neurons were prepared from P7 post-
natal Wistar rat pups. Cerebella were dissected and dissociated with trypsin (0.01%, 15 
min, and 37ºC, Sigma, T0303) and DNase (0.045 mg/ml, Sigma, D5025) in Ca2+- and 
Mg2+- free Krebs buffer (120 mM NaCl, 5 mM KCl, 1.2 mM KH2PO4, 13 mM glucose, 15 
mM HEPES, 0.3% BSA, pH 7.4). Cerebella were then washed with Krebs buffer 
containing trypsin inhibitor (0.3 mg/ml, Sigma, T9128) to stop trypsin activity. The cells 
were dissociated in this solution, centrifuged and then resuspended in Basal Medium 
Eagle supplemented with 25 mM KCl, 30 mM glucose, 26 mM NaHCO3, 1% penicillin-
streptomycin (100 U/ml, 100 !g/ml) and 10% fetal bovine. Cells were plated on 6 or 12-
well plates (1x106 or 5x105 cells/well) coated with poly-D-lysine. Cultures were 
maintained for 3 weeks in a humid incubator (5% CO2/ 95% air at 37ºC). 
 
3.3.3. Animals 
 4-week-old C57BL/6J mice (Charles River) were used. The animals were 
housed in a temperature-controlled room maintained on a 12 h light / 12 h dark cycle. 
Food and water were provided ad libitum. The experiments were carried out in 
accordance with the European Community directive (86/609/EEC) for the care and use 
of laboratory animals. 
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3.3.4. Viral vectors production 
 Lentiviral vectors encoding human wild-type ataxin-3 (ATX-3 27Q) or mutant 
ataxin-3 (ATX-3 72Q) (Alves et al., 2008) were produced in 293T cells with a four-
plasmid system, as previously described (de Almeida et al., 2001). The lentiviral 
particles were resuspended in 1% bovine serum albumin (BSA) in phosphate-buffered 
saline (PBS). The viral particle content of batches was determined by assessing HIV-1 
p24 antigen levels (RETROtek, Gentaur, Paris, France). Viral stocks were stored at -
80ºC until use. 
 
3.3.5. Lentiviral infection of cerebellar granule neurons 
 The cell cultures were infected with lentiviral vectors at ratio of 10 ng of p24 
antigen/ 105 cells 1 day after plating (1 DIV) (Zala et al., 2005). At 2 DIV, medium was 
replaced with freshly prepared culture medium and calpain inhibitor BDA-410 was 
added in two different concentrations (50 and 100 nM in DMSO). DMSO was used as a 
control. Medium plus inhibitor or DMSO was replaced every three days. 
 
3.3.6. In vivo injection in the striatum 
Concentrated viral stocks were thawed on ice. Lentiviral vectors encoding 
human wild-type (ATX-3 27Q) or mutant ataxin-3 (ATX-3 72Q) were stereotaxically 
injected into the striatum in the following coordinates: antero-posterior: +0.6mm; lateral: 
±1.8mm; ventral: -3.3mm; tooth bar: 0). Animals were anesthetized by administration of 
avertin (10 µl/g, i.p.). 
For immunohistochemical procedure, wild-type mice received a single 1 µl 
injection of 400,000 ng of p24/ml lentivirus in each side: left hemisphere (ATX-3 27Q) 
and right hemisphere (ATX-3 72Q). For western-blot procedure and RNA extraction, 
wild-type mice received a single 2 µl injection of 300,000 ng of p24/ml lentivirus in each 
side: left hemisphere (ATX-3 27Q) and right hemisphere (ATX-3 72Q). Mice were kept 
in their home cages for 4 or 8 weeks, before being sacrificed for western-blot analysis 
and RNA extraction or immunohistochemical analysis, respectively. BDA-410 was 
orally administered (30 mg/kg in 1% Tween 80 saline in a volume equal to 5 ml/kg), 
with a 20G gavage needle, every day since two days before stereotaxic injection until 
sacrifice. 
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3.3.7. Immunohistochemical procedure 
 After an overdose of avertin (2.5x 12 µl/g, i.p.), transcardial perfusion of the 
mice was performed with a phosphate solution followed by fixation with 4% 
paraphormaldehyde (PFA). The brains were removed and post-fixed in 4% PFA for 24h 
and cryoprotected by incubation in 25% sucrose/ phosphate buffer for 48 h. The brains 
were frozen and 25 µm coronal sections were cut using a cryostat (LEICA CM3050 S) 
at -21°C. Slices throughout the entire striatum were collected in anatomical series and 
stored in 48-well trays as free-floating sections in PBS supplemented with 0.05 µM 
sodium azide. The trays were stored at 4°C until immunohistochemical processing.  
Sections from injected mice were processed with the following primary 
antibodies: a mouse monoclonal anti-ataxin-3 antibody (1H9; 1:5000; Chemicon, 
Temecula, CA), recognizing the human ataxin-3 fragment from amino acids F112-
L249; a rabbit polyclonal anti-ubiquitin antibody (Dako, 1:1000; Cambridgeshire, UK); 
and a rabbit anti-DARPP-32 antibody (1:1000; Chemicon, Temecula, CA), followed by 
incubation with the respective biotinylated secondary antibodies (1:200; Vector 
Laboratories). Bound antibodies were visualized using the Vectastain ABC kit, with 
3,3’-diaminobenzidine tetrahydrochloride (DAB metal concentrate; Pierce) as substrate.  
Double stainings for Ataxin-3 (1H9, 1:3000), nuclear marker (DAPI, blue) and 
ubiquitin (Dako, 1:1000; Cambridgeshire, UK) or cleaved caspase-3 (Asp175, 1:2000; 
Cell Signaling) were performed. Free-floating sections from injected mice were at RT 
for 2 h in PBS/0.1% Triton X-100 containing 10% NGS (Gibco), and then overnight at 
4°C in blocking solution with the primary antibodies. Sections were washed three times 
and incubated for 2 h at RT with the corresponding secondary antibodies coupled to 
fluorophores (1:200; Molecular Probes, Oregon, USA) diluted in the respective blocking 
solution. The sections were washed three times and then mounted in Fluorsave 
Reagent® (Calbiochem, Germany) on microscope slides. 
Staining was visualized using Zeiss Axioskop 2 plus, Zeiss Axiovert 200 and 
Zeiss LSM 510 Meta imaging microscopes (Carl Zeiss Microimaging, Germany), 
equipped with AxioCam HR color digital cameras (Carl Zeiss Microimaging) using 5x, 
20x, 40x and 63x Plan-Neofluar and a 63x Plan/Apochromat objectives and the 
AxioVision 4.7 software package (Carl Zeiss Microimaging). 
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3.3.8. Cresyl violet staining 
Coronal 25-µm-thick striatal sections were cut using a cryostat. Premounted 
sections were stained with cresyl violet for 30 secs, differentiated in 70% ethanol, 
dehydrated by passing twice through 95% ethanol, 100% ethanol and xylene solutions, 
and mounted onto microscope slides with Eukitt® (Sigma). 
 
3.3.9. Evaluation of the volume of the DARPP-32 depleted volume 
 The extent of ataxin-3 lesions in the striatum was analyzed by photographing, 
with a x1.25 objective, 8 DARPP-32 stained sections per animal (25 !m thickness 
sections at 200 !m intervals), selected so as to obtain complete rostrocaudal sampling 
of the striatum, and by quantifying the area of the lesion with a semiautomated image-
analysis software package (Image J software, USA). The volume was then estimated 
with the following formula: volume = d(a1+a2+a3 !), where d is the distance between 
serial sections (200 !m) and a1+a2+a3 are DARPP-32 depleted areas for individual 
serial sections. 
 
3.3.10. Cell counts and morphometric analysis of ataxin-3 and 
ubiquitin inclusions 
 Coronal sections showing complete rostrocaudal sampling (1 of 11 sections) of 
the striatum were scanned with a x20 objective. The analyzed areas of the striatum 
encompassed the entire region containing ATX-3 and ubiquitin inclusions, as revealed 
by staining with the anti-ataxin-3 and anti-ubiquitin antibodies. All inclusions were 
manually counted using a semiautomated image-analysis software package (Image J 
software, USA). Inclusions diameter was assessed by scanning the area above the 
needle tract in four different sections, using a x63 objective. At least 100 inclusions per 
animal were analyzed using LSM Image Browser. Inclusions diameter was further 
assessed by double staining of ataxin-3 inclusions with cleaved caspase-3 by scanning 
the area above the needle tract in three different sections, using a x63 objective. At 
least 100 inclusions per animal were analyzed using LSM Image Browser.  
 
 
 
 
Chapter 3 
  70     
3.3.11. Western-blot analysis 
For assessment of ataxin-3 proteolysis in the lentiviral model of MJD, 
transcardial perfusion of the mice was performed with ice-cold phosphate buffered 
saline containing 10 mM EDTA and 10 mM of the alkylating reagent N-ethylmaleimide, 
to avoid post-mortem calpain overactivation. The injected striata were then dissected 
and immediately sonicated in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 7 
mM EDTA, 1% NP-40, 0.1% SDS, 10 µg/ml DTT, 1mM PMSF, 200 !g/ml leupeptin, 
protease inhibitors cocktail).  
One week before cell lysis, cerebellar granule neurons were treated with 200 
!M NMDA plus 2.5 mM CaCl2 in Krebs buffer without MgCl2 for one hour for excitatory 
stimulation and subsequently cultured in fresh medium plus inhibitor or DMSO until 
harvest and sonication in RIPA buffer, as described above. 
Equal amounts (20 µg of protein) were resolved on 12% SDS-polyacrylamide 
gels and transferred onto PVDF membranes. Immunoblotting was performed using the 
monoclonal anti-ataxin-3 antibody (1H9, 1:1000; Chemicon, Temecula, CA), 
monoclonal anti-polyglutamine antibody (1C2, MAB1574, 1:1000; Chemicon), 
monoclonal anti-myc tag (clone 4A6, 1:1000; Cell Signaling), monoclonal anti-spectrin 
antibody (MAB1622, 1:1000; Chemicon) and monoclonal anti-"-actin (clone AC-74, 
1:5000; Sigma) or monoclonal anti-"-tubulin I (clone SAP.4G5, 1:15000; Sigma). Semi-
quantitative analysis was carried out using Quantity-one 1-D image analysis software 
version 4.5. A partition ratio with actin or tubulin was calculated. 
 
3.3.12. Purification of total RNA from striata of mice and cDNA 
synthesis 
Mice were sacrificed by cervical dislocation and injected striata were dissected 
and stored overnight at 4ºC in tubes containing RNAlater RNA stabilization reagent 
(QIAGEN). Samples were then kept at #80°C until extraction of RNA. Total RNA was 
isolated using the RNeasy Mini Kit (QIAGEN) according to the manufacturer's 
instructions. Briefly, after cell lysis, the total RNA was adsorbed to a silica membrane, 
washed with the recommended buffers and eluted with 30 !l of RNase-free water by 
centrifugation. Total amount of RNA was quantified by optical density (OD) using a 
Nanodrop 2000 Spectrophotometer (Thermo Scientific) and the purity was evaluated 
by measuring the ratio of OD at 260 and 280 nm. cDNA was then obtained by 
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conversion of 1 !g of total RNA using the iScript Select cDNA Synthesis Kit (Bio-Rad) 
according to the manufacturer's instructions and stored at #20°C. 
 
3.3.13. Quantitative real-time polymerase chain reaction (qRT-PCR) 
 Quantitative PCR was performed in an iQ5 thermocycler (Bio-Rad) using 96-
well microtitre plates and the QuantiTect SYBR Green PCR Master Mix (QIAGEN). The 
primers for the target human gene (ATXN3, NM_004993) and the reference mouse 
genes (Hprt, NM_013556  and Gapdh, NM_008084) were pre-designed and validated 
by QIAGEN (QuantiTect Primers, QIAGEN). A master mix was prepared for each 
primer set containing the appropriate volume of QuantiTect SYBR Green PCR Master 
Mix (QIAGEN), QuantiTect Primers (QIAGEN) and template cDNA. All reactions were 
performed in duplicate and according to the manufacturer's recommendations: 95°C for 
15 min, followed by 40 cycles at 94°C for 15 sec, 55°C for 30 sec and 72°C for 30 sec. 
The amplification efficiency for each primer pair and the threshold values for threshold 
cycle determination (Ct) were determined automatically by the iQ5 Optical System 
Software (Bio-Rad). The mRNA fold increase or fold decrease with respect to control 
samples was determined by the Pfaffl method, taking into consideration different 
amplification efficiencies of all genes. 
 
3.3.14. Statistical analysis 
 Statistical analysis was performed using unpaired Student’s t-test or one-way 
ANOVA followed by Bonferroni test for selected pairs comparison. Values of p<0.05 
were considered statistically significant; p<0.01 very significant; and p<0.001 extremely 
significant. 
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3.4. RESULTS 
 
3.4.1. BDA-410 inhibits calpain activity and decreases mutant 
ataxin-3 levels in vitro   
 Several evidences indicate that calpains cleave ataxin-3 producing proteolytic 
fragments that trigger MJD pathology (Haacke et al., 2007; Koch et al., 2011; Simões 
et al., 2012), suggesting that calpain inhibition may provide an effective therapy for 
MJD. Therefore, we first investigated whether calpains could be inhibited by the novel 
oral calpain inhibitor BDA-410 (Fig. 3.1A) (Li et al., 2007; Subramanian et al., 2012; 
Trinchese et al., 2008), in cultures of cerebellar granule neurons. 
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Figure 3.1. BDA-410 inhibits calpains activity and decreases mutant ataxin-3 levels in vitro. A, 
Chemical structure of BDA-410. Representative western-blot analysis (out of n=4) of cerebellar 
granule neurons three weeks after infection with lentiviral vectors encoding for wild-type ataxin-
3 (ATX-3 27Q) or mutant ataxin-3 (ATX-3 72Q). One day after infection, cells were incubated 
with BDA-410 (50 or 100 nM) or DMSO. Membrane was incubated with B, spectrin antibody 
(MAB1622) or C, ataxin-3 antibody (Ab 1H9). D, Densitometric quantification of calpain cleaved 
spectrin (150/145 kDa fragments) level relative to tubulin (clone SAP.4G5), shown in panel B. E, 
Densitometric quantification of full-length ataxin-3 level relative to actin (clone AC-74), shown in 
panel C. 
 
When calcium concentration increases in the intracellular compartment, a 
subset of axonal structural proteins is vulnerable to calpain activity, including $II-
spectrin, a potential biomarker for neuronal cell injury (Liu et al., 2008). Interestingly, 
levels of the calpain-generated 150/145 kDa fragments of $II-spectrin were increased 
when cerebellar granule neurons were transduced with lentiviral vectors encoding the 
mutant ataxin-3 (ATX-3 72Q) in opposition to wild-type ataxin-3 (ATX-3 27Q) and non-
infected cultures. Importantly, BDA-410 (50 and 100 nM) mediated a decrease of the 
$II-spectrin fragments in cultures expressing mutant ataxin-3 (Fig. 3.1B,D). 
Furthermore, this calpain inhibition translated into a 30% decrease in immunolabeling 
of full-length mutant ataxin-3 (Fig. 3.1C,E). 
 Since the concentration of BDA-410 used in this experiment was much below 
the threshold of inactivation of other proteases than calpains, we conclude that the 
decreased levels of mutant ataxin-3 are due to a specific calpain inhibitory action, as a 
reduced calpain-mediated cleavage of ataxin-3 might prevent the full-length protein and 
its fragments from escaping the cytoplasmic quality control mechanisms.  
 
3.4.2. BDA-410 reduces cleavage of mutant ataxin-3 in a lentiviral 
mouse model of MJD 
 Therefore, in order to investigate whether orally-administered BDA-410 would 
inhibit ataxin-3 cleavage in vivo, we administered daily by oral gavage the compound 
BDA-410 (30 mg/kg in 1% Tween80 saline in a volume equal to 5 ml/kg) to a lentiviral 
mouse model, in which lentiviral vectors encoding for wild-type ataxin-3 (ATX-3 27Q) 
were injected in the left striatum hemisphere and mutant ataxin-3 (ATX-3 72Q) in the 
right hemisphere, a strategy that we use to generate models of disease (Alves et al., 
2008; de Almeida et al., 2002; Nascimento-Ferreira et al., 2011; Simões et al., 2012). 
As a control, a group of animals received only the vehicle in which BDA-410 was 
Chapter 3 
  74     
ressuspended for the treated group.  After 4 weeks of treatment, mice were sacrificed 
and striatal tissue processed for western blot analysis. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. BDA-410 decreased fragmentation in vivo. Western-blot and RT-PCR analysis of 
mice four weeks post-injection of lentiviral vectors encoding for wild-type ataxin-3 (ATX-3 27Q; 
left hemisphere) and mutant ataxin-3 (ATX-3 72Q; right hemisphere) after daily gavage of 
vehicle (1% Tween80 saline; n=4) or BDA-410 (n=4). Depicted are blots of a pool of 4 animals 
for each condition using several antibodies to detect different epitopes of ataxin-3 protein: A, Ab 
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1H9, which recognizes amino acids E214-L233; B, Ab 1C2, specific for the polyglutamine 
stretch, present at the C-terminal of ataxin-3; and C, Ab myc, which recognizes myc tag located 
at the N-terminal of mutant ataxin-3. D-F, Densitometric quantification of ~26kDa fragment, 
~34kDa fragment and full-length levels of ataxin-3, using Ab 1H9, relative to actin (n=4). G, 
Levels of mRNA expression of human ataxin-3, relative to mouse GAPD (n=4). Results with 
hPRT mouse gene as reference were comparable. 
 
Two ataxin-3 fragments of ~26 kDa and ~34 kDa were detected at high levels in 
the brain hemispheres expressing mutant ataxin-3, or less and not detected, 
respectively, in the brain hemispheres expressing wild-type protein (Fig. 3.2A-C, 
arrowheads). In addition, the ~26 kDa fragment was detected using any of the 3 
antibodies tested: a) Ab 1H9 (Fig. 3.2A), which recognizes the human ataxin-3 
fragment from amino acids E214-L233, b) Ab 1C2 (Fig. 3.2B), an antibody specific for 
the polyQ stretch, present at ataxin-3 C-terminal, and c) Ab myc (Fig. 3.2C), an 
antibody for a myc tag located at the N-terminal of the protein. On the contrary, the ~34 
kDa fragment was only detected for the mutant protein and when using Ab 1H9 and Ab 
1C2 (Fig. 3.2A-B), suggesting that while the ~26 kDa might be both a N or C-terminal 
fragment, the ~34 kDa fragment is only C-terminal and produced only upon mutant 
ataxin-3 proteolysis. Notably, calpains inhibition by BDA-410 administration significantly 
decreased by 50% and 37.6% the formation of the 26 kDa fragment of the wild-type 
and mutant ataxin-3, respectively (Fig. 3.2A-D). Furthermore, upon calpains inhibition, 
the formation of the ~34 kDa fragment was also decreased by 22.5% (Fig. 3.2A-C,E). 
 However, as we observed a general decrease of the different ataxin-3 species: 
aggregates (Fig. 3.2A, 3.3G), fragments (Fig. 3.2D-E) and even a slight decrease of 
full-length (Fig. 3.2F), we asked whether inhibition at transcription level could be 
occurring. RNA extraction was then performed using the same experimental paradigm. 
Surprisingly, even though BDA-410 administration was able to drastically reduce 
ataxin-3 proteolysis, the mRNA levels of human ataxin-3 were significantly increased 
by three fold for the mutant gene and not altered for the wild-type gene, indicating that 
the reduction of mutant ataxin-3 fragment levels was not due to inhibition of 
transcription (Fig. 3.2G). 
 
3.4.3. BDA-410 inhibits mutant ataxin-3 aggregation in vivo by 
decreased fragmentation 
To investigate if reduced calpain-mediated production of fragments by BDA-410 
would prevent the subsequent phenomena predicted by the “toxic fragment hypothesis”, 
namely seeding of intranuclear inclusions and neurodegeneration (Haacke et al., 2006; 
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Haacke et al., 2007; Ikeda et al., 1996; Koch et al., 2011; Simões et al., 2012; 
Takahashi et al., 2008), we performed a new experiment using a similar paradigm but 
sacrificing the mice at a later time point (8 weeks post-injection) and processing the 
brains for immunohistochemistry. As a control, a group of animals received only the 
vehicle in which BDA-410 was ressuspended for the treated group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. BDA-410 inhibits mutant ataxin-3 aggregation in vivo. Immunohistochemical 
analysis of mice eight weeks post-injection of lentiviral vectors encoding for mutant ataxin-3 
(ATX-3 72Q) after daily gavage of vehicle (1% Tween80 saline; n=6) or BDA-410 (n=6) using an 
A-D, anti-ataxin-3 antibody (Ab 1H9) or E-F, anti-ubiquitin antibody (Dako). Quantification of the 
absolute number of G, ataxin-3 intranuclear inclusions and H, ubiquitin inclusions; graphs 
related to panel A-F. Values are expressed as mean ± standard error of the mean. 
 
Daily oral gavage of the calpain inhibitor during 8 weeks promoted a 38% 
significant decrease in the number of mutant ataxin-3 inclusions (Fig. 3.3A-D,G) and a 
26% reduction of ubiquitin inclusions (Fig. 3.3E-F,H). No alteration was observed 
between treated and vehicle groups when ATX-3 27Q was expressed (Fig. 3.6A-F). 
These results support the idea that ataxin-3 cleavage by calpains is required for the 
subsequent aggregation process and that calpain inhibition can reduce mutant ataxin-3 
aggregation by suppressing the formation of ~26 kDa and ~34 kDa cleavage fragments. 
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3.4.4. Mutant ataxin-3 aggregates of specific size have different 
toxic properties 
 To further investigate these findings, we analyzed the size of mutant ataxin-3 
aggregates and cytotoxicity by evaluation of cleaved caspase-3 immunoreactivity in 
treated and vehicle groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Mutant ataxin-3 aggregates of specific size have different toxic properties. 
Immunohistochemical analysis of mice eight weeks post-injection of lentiviral vectors encoding 
for mutant ataxin-3 (ATX-3 72Q) after daily gavage of vehicle (1% Tween80 saline; n=6) or 
BDA-410 (n=6). Upper panel: Coronal sections were stained for A,D, mutant ataxin-3 (ATX-3 
72Q, Ab 1H9, green), B,E, ubiquitin (Dako, red), nuclear marker (DAPI, blue). C,F, merge 
images of A and B or D and E, respectively. Lower panel: Coronal sections were stained for H,K, 
mutant ataxin-3 (ATX-3 72Q, Ab 1H9, red), I,L, cleaved caspase-3 (Asp 175, green), nuclear 
marker (DAPI, blue). J,M, merge images of H and I or K and L, respectively. G, Analysis of 
mutant ataxin-3 intranuclear inclusions diameter. Graph related to upper panel. N, Analysis of 
mutant ataxin-3 intranuclear inclusions diameter, with (+) or without (-) colocalization with 
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cleaved caspase-3. Graph related to lower panel. O, Cytotoxicity, measured by cleaved 
caspase-3. Results are presented as a percentage of mutant ataxin-3 positive cells co-
expressing cleaved caspase-3. Graph related to lower panel. 
 
Calpains inhibition by BDA-410 administration mediated a small decrease in 
aggregate size of 0.22 !m (Fig. 3.4A-G). Even though fragments and soluble oligomers 
are thought to be the toxic species and contribute to aggregation (Takahashi et al., 
2008), we found that larger aggregates (mean diameter: 4 !m) colocalized significantly 
more with cleaved caspase-3 than smaller aggregates (mean diameter: 1.6 !m) (Fig. 
3.4H-N) for both groups. However, upon calpains inhibition, the number of mutant 
ataxin-3 positive cells co-expressing cleaved caspase-3 significantly decreased by 14% 
(Fig. 3.4H-M,O). Interestingly, in common cases where mutant ataxin-3 remained 
perinuclear, such as the representative cell pointed with an arrow in Fig. 3.4M, no 
cleaved caspase-3 immunoreactivity was observed suggesting that ataxin-3 nuclear 
localization is necessary for caspase-3 activation. These results show that mutant 
ataxin-3 aggregates of specific size have different toxic properties and suggest that 
BDA-410-mediated calpain inhibition decreases fragmentation, mutant ataxin-3 
seeding and aggregation, with a small effect in aggregates size but promoting an 
important decrease in cytotoxicity. 
 
3.4.5. BDA-410 mediates neuroprotection 
 To confirm that BDA-410 mediates neuroprotection, we monitored the effects of 
its oral administration over neuronal dysfunction, which may precede degeneration and 
clinical symptoms induced by mutant ataxin-3 (Yen et al., 2002). In this sense, we 
performed an immunohistochemical analysis for DARPP-32, a regulator of dopamine 
receptor signaling (Greengard et al., 1999), as we have previously shown that it is a 
sensitive marker to detect early neuronal dysfunction (Alves et al., 2008; de Almeida et 
al., 2002). Accordingly, loss of DARPP-32 immunoreactivity was robustly and 
significantly reduced by 46% in the treated group when compared to the vehicle group 
(Fig. 3.5A-D,G). 
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Figure 3.5. BDA-410 prevents cell injury and striatal degeneration. Immunohistochemical 
analysis of mice eight weeks post-injection of lentiviral vectors encoding for mutant ataxin-3 
(ATX-3 72Q) after daily gavage of vehicle (1% Tween80 saline; n=6) or BDA-410 (n=6) A-D, 
using an anti-DARPP-32 antibody. C,D are a higher magnification of A,B. E,F, Cresyl violet 
staining using the same experimental paradigm. G, Quantification analysis of the DARPP-32 
depleted volume in the mice brains. H, Quantification analysis of the pycnotic nuclei visible in 
treated and vehicle groups on cresyl violet-stained sections. 
 
Additionally, cresyl violet-stained sections further demonstrated that calpain 
inhibition promoted a significant reduction of 30% in the number of shrunken 
hyperchromatic nuclei (Fig. 3.5E-F,H), induced by mutant ataxin-3 expression in the 
brain of adult mice. No loss of DARPP-32 staining or increase of degenerated 
shrunken hyperchromatic nuclei was observed in the hemispheres of mice expressing 
ATX-3 27Q treated or not with the calpains inhibitor compound (Fig. 3.6G-J). 
 Overall, these results are indicative of a neuroprotective effect provided by 
BDA-410 in a genetic mouse model of Machado-Joseph disease. 
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Figure 3.6. BDA-410 does not promote subcellular alteration or cell injury and striatal 
degeneration upon wild-type ataxin-3 expression. Immunohistochemical analysis of mice eight 
weeks post-injection of lentiviral vectors encoding for wild-type ataxin-3 (ATX-3 27Q) after daily 
gavage of vehicle (1% Tween80 saline; n=6) or BDA-410 (n=6) using an A-D, anti-ataxin-3 
antibody (Ab 1H9); E,F, anti-ataxin-3 antibody (Ab 1H9, green), ubiquitin (Dako, red), nuclear 
marker (DAPI, blue); G,H, anti-DARPP-32 antibody; I,J, cresyl violet staining. 
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3.5. DISCUSSION 
 
Present treatment of Machado-Joseph disease is only supportive and no 
medication has been able to slow the course of disease (D'Abreu et al., 2010). There is 
an urgent need for a disease-modifying therapy. The recent identification of the role of 
calpains in Machado-Joseph disease pathogenesis provided the rationale to the use of 
the calpain inhibitor BDA-410, which we show in the present work to robustly alleviate 
the neuropathology of this disorder.  
Growing evidence suggests that calcium signalling is deranged in MJD (Chen et 
al., 2008), which coupled to decreased levels of the endogenous inhibitor of calpains – 
calpastatin, creates favourable conditions for activation of these calcium-dependent 
cysteine proteases, proteolysis of mutant ataxin-3, generation of toxic fragments, 
translocation to the nucleus, aggregation  and neurodegeneration (Haacke et al., 2007; 
Koch et al., 2011; Simões et al., 2012). We have recently shown that calpastatin 
overexpression by viral gene therapy alleviated MJD neuropathology, providing the 
proof of principle that inhibition of calpains may be a potential new target for therapy of 
MJD (Simões et al., 2012). Therefore, in this study we investigated whether the oral 
compound BDA-410 (Li et al., 2007; Subramanian et al., 2012; Trinchese et al., 2008) 
would be able to block calpain-mediated cleavage of ataxin-3 and alleviate MJD.  
We found that BDA-410 reduced cleavage of the calpain natural substrate $-
spectrin in cultures of cerebellar granule neurons (Fig. 3.1B,D), confirming its calpain 
inhibitory activity. Interestingly, in the same in vitro model, calpain inhibition was 
translated into a decrease in immunolabeling of full-length ataxin-3 (Fig. 3.1C,E), which 
might be explained by a better clearance of mutant ataxin-3 by normal quality control 
mechanisms, preventing further accumulation of the non-cleaved full-length ataxin-3 
through clearance by the UPS and autophagy-lysossomal pathways (Breuer et al., 
2010; Nascimento-Ferreira et al., 2011). 
According to the toxic fragment hypothesis, the aggregation process associated 
with inclusion formation and cellular dysfunction is initiated by the proteolytic cleavage 
of the full-length polyQ-protein (Haacke et al., 2006; Ikeda et al., 1996; Takahashi et al., 
2008). We have therefore analyzed ataxin-3 fragmentation upon BDA-410 
administration and we observed a significant reduction of the ~26 kDa and ~34 kDa 
fragments formation (Fig. 3.2A-F). Real time PCR confirmed that the decreased 
fragmentation is not a consequence of a decreased mRNA expression. In fact, BDA-
410 was able to suppress mutant ataxin-3 proteolysis by calpains despite mediating 
increase of mRNA levels of mutant ataxin-3 (Fig. 3.2G). Our studies demonstrate that a 
~26 kDa fragment is also produced for the wild-type protein (Fig. 3.2), being BDA-410 
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able to reduce more effectively its formation, when compared to the mutant protein. 
This might be explained by the fact that not only the wild-type fragment may be more 
easily degraded, but also that mRNA levels are not altered for the wild-type human 
ataxin-3 gene (Fig. 3.2G), on the contrary to the mutant gene. Nevertheless, the 
reduction of both the N- (Hubener et al., 2011) and C- (Goti et al., 2004; Ikeda et al., 
1996) terminal fragments formation of mutant ataxin-3 may have a contributive effect to 
neuroprotection mediated, in this study, by the calpain inhibitor BDA-410. 
BDA-410 mediated a reduction within the mouse brain of the number of mutant 
ataxin-3 intranuclear inclusions (Fig. 3.3), which are a hallmark of the pathology 
(Paulson et al., 1997; Schmidt et al., 1998; Yamada et al., 2001). We have previously 
shown that the diameter of mutant ataxin-3 inclusions decreased, as calpastatin levels 
increased (Simões et al., 2012). Even though BDA-410 had a minor effect in inclusions 
size (Fig. 3.4A-G), the number of mutant ataxin-3 positive cells co-expressing cleaved 
caspase-3 significantly decreased upon its administration, suggesting a 
neuroprotective role for the drug (Fig. 3.4H-O). Neuroprotection was further confirmed 
by a dramatic 46% decrease of the volume of the region depleted of DARPP-32 
immunoreactivity and of the number of pycnotic nuclei in the treated group, when 
compared to the control group (Fig. 3.5). 
On one hand, our results suggest that the fragments are the toxic species (Fig. 
3.3) and that intranuclear inclusions might have a protective function, in agreement with 
the toxic fragment hypothesis (Haacke et al., 2006; Ratovitski et al., 2009; Takahashi et 
al., 2008). On the other hand, intranuclear inclusions do not solely comprise the 
polyglutamine protein. Functionally relevant proteins are sequestered such as ubiquitin 
(Fig. 3.4A), chaperones and proteasome components that are involved in quality 
control of protein surveillance machinery (Chai et al., 2004; Chai et al., 1999; Schmidt 
et al., 2002). Furthermore, inclusions might compromise cell integrity and disrupt 
axonal transport, through motor protein titration or physical interruption (Gunawardena 
et al., 2003). Our studies thus demonstrate that despite being the fragments pernicious, 
larger aggregates present increased colocalization with cleaved caspase-3 (Fig. 3.4H-
O) suggesting increased cytotoxicity as compared to smaller aggregates. Therefore, 
our results suggest that both theories might coexist. Nevertheless, BDA-410 is able to 
suppress fragmentation decreasing consequent aggregation. 
Calpain inhibition might affect their physiological function and be consequently a 
matter of concern causing adverse side effects. However, calpastatin-deficient mice did 
not present any defect in development, fertility, morphology or life span (Takano et al., 
2005). Moreover, under normal conditions, calpains cleave substrates at a limited 
number of sites leaving large and often catalytically active fragments, indicating that 
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prior to a digestive function, calpains display a regulatory or signaling role (Goll et al., 
2003). Thus, the occurrence of adverse side effects may be restricted. In fact, our 
results show neither alteration in subcellular localization of wild-type ataxin-3, nor cell 
injury or striatal degeneration (Fig. 3.6), upon BDA-410 administration. 
In conclusion, the oral calpain inhibitor BDA-410 reduced fragmentation of 
mutant ataxin-3, decreased inclusion number and prevented cell injury and 
neurodegeneration in a model of MJD. This study shows for the first time that a low 
molecular weight drug orally administered may provide a viable therapeutic option to 
block progression of MJD. 
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4.1. Abstract 
 
 Machado-Joseph disease (MJD) is caused by an abnormal expanded CAG 
repeat in the coding region of MJD1 gene which is translated into a polyglutamine tract 
within ataxin-3 protein. MJD is the most common autosomal dominantly-inherited 
cerebellar ataxia and no causative treatment is presently available. 
 Calpain-mediated mutant ataxin-3 proteolysis has been implicated in ataxin-3 
translocation to the nucleus, aggregation and neurodegeneration in MJD. Moreover, we 
have previously shown that calpain activation could be propelled by a marked depletion 
of the endogenous calpain inhibitor, calpastatin (CAST). Nevertheless, information is 
lacking on a time-line basis and whether rescue of CAST levels can restrain the 
proteolytic process in transgenic mice that exhibit MJD-like pathology. Therefore, we 
studied proteolysis in CAMKII-MJD77 mice and their wild-type littermates. 
 We found that proteolysis in transgenic mice is an early event, being increased 
in the regions of ataxin-3 expression (forebrain in the present model) relatively to wild-
type littermates at the age of two months, and that CAST depletion emerges 
downstream, with significant depletion in transgenic mice at the age of eight and half 
months. CAST overexpression at the age of seven months preserved normal levels of 
ataxin-3 proteolysis, increased the number of cells with ataxin-3 perinuclear localization 
and decreased ataxin-3 full-length levels and aggregation. We conclude that to 
alleviate phenotypic behaviour characteristic of MJD, calpain inhibition should be 
promoted as soon as two months old in respect to the present MJD transgenic mouse 
model and translation into clinical approach should also favour an early intervention. 
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4.2. Introduction 
 
 Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 
(SCA3), is an autosomal dominantly-inherited cerebellar ataxia (Sudarsky and 
Coutinho, 1995), caused by an expanded CAG repeat in the coding region of MJD1 
gene, resulting in an abnormal expanded polyglutamine tract at the C-terminus of 
ataxin-3 protein (Kawaguchi et al., 1994; Takiyama et al., 1993). MJD is characterized 
by progressive cerebellar ataxia, pyramidal signs as well as ophthalmoplegia and 
dystonia, being the current treatment available purely symptomatic (D'Abreu et al., 
2010; Riess et al., 2008). 
 Previously generated mouse models of MJD (Bichelmeier et al., 2007; Boy et 
al., 2010; Boy et al., 2009; Cemal et al., 2002; Chou et al., 2008; Goti et al., 2004; 
Hubener et al., 2011; Ikeda et al., 1996; Silva-Fernandes et al., 2010; Torashima et al., 
2008) have been developed to study molecular and related phenotypic aspects of the 
disease, urging the screening of potential therapeutic molecules. Conditional mouse 
models have also been developed. A Tet-Off system under the control of a prion 
protein promoter (PrP), was first reported allowing the reversibility of motor symptoms 
after blocking ataxin-3 expression with five months of doxycycline treatment (Boy et al., 
2009). More recently, another inducible Tet-Off model for MJD based on the calcium/ 
calmodulin-dependent protein kinase II (CamKII) promoter, instead of PrP has been 
developed (unpublished data). CamKII is a forebrain specific promoter, with neuron 
specific activity and not reported in glia, while PrP promoter activity is mainly distributed 
in the brainstem and cerebellum and observed in both neuronal and glia cell 
populations (Odeh et al., 2011). As the onset of expression occurs at a relatively late 
developmental stage, usually the first to second postnatal week (Kojima et al., 1997), 
the CamKII promoter line is likely suited for generating transgenic models for late-onset 
diseases (Odeh et al., 2011), such as Alzheimer’s disease (Jankowsky et al., 2005) 
and Huntington’s disease (Yamamoto et al., 2000). In this sense, we used the full-
length human ataxin-3 cDNA with 77 repeats transgenic mouse model (Boy et al., 
2009), under the control of CamKII promoter, with the Tet-Off system (Mayford et al., 
1996) to evaluate calpain-mediated proteolysis in MJD. 
 Consistent with the toxic fragment hypothesis, evidence suggests that the 
soluble species including the proteolytic fragments underlie toxic effects (Ikeda et al., 
1996). Furthermore, an ataxin-3 fragment was detected in the brains of MJD patients, 
Q71 transgenic mice, whose levels increased with disease severity (Goti et al., 2004), 
supporting a relation between ataxin-3 cleavage and disease progression. Though 
without consensus, mutant ataxin-3 has been shown to be a substrate for caspases 
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(Berke et al., 2004; Jung et al., 2009; Wellington et al., 1998) and calpains (Haacke et 
al., 2007; Koch et al., 2011; Simões et al., 2012). More recently, we showed that 
mutant ataxin-3 is cleaved into fragments of ~26 and ~34 KDa, and that calpain 
inhibition decreases neuronal dysfunction and neurodegeneration in a lentiviral mouse 
model (Simões et al., 2012).  
Here, we present the first studies addressing the proteolytic event in a timeline 
basis and its inhibition as an attempt to alleviate motor deficits characteristic of MJD. 
We provide evidence that proteolysis in transgenic mice is an early event and that 
calpastatin depletion is age-dependent. Although calpastatin overexpression solely in 
striatum could not alter motor coordination, we were able to decrease mutant ataxin-3 
full-length levels and inhibit its translocation to the nucleus within the calpain inhibitory 
transduced area of seven months old transgenic mice, suggesting that a strategy that 
could inhibit calpains at a younger age reaching all affected regions should be 
considered for MJD therapeutical application. 
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4.3. Materials and methods 
 
4.3.1. Animals 
 A transgenic mouse model was generated by crossbreeding the promoter line 
expressing the tetracycline transactivator (tTA) combined with calcium/ calmodulin-
dependent kinase II (CamKII) promoter, to achieve both regional and temporal control 
of the transgene expression (Mayford et al., 1996), with the stable responder mouse 
line number 2904, containing the full-length human ataxin-3c isoform (GenBank 
accession number: U64820), which has an additional ubiquitin-interacting motif at its C-
terminus and 77 CAG repeats (Boy et al., 2009). 
The animals were housed in a temperature-controlled room maintained on a 12 
h light / 12 h dark cycle. Food and water were provided ad libitum. The experiments 
were carried out in accordance with the European Community directive (86/609/EEC) 
for the care and use of laboratory animals. 
 
4.3.2. Viral vectors production 
Adeno-associated viral vectors, under the control of the human synapsin-1 gene 
promoter, which restrains expression to neurons, were produced as previously 
described (Kugler et al., 2003; Zolotukhin et al., 1999). 
 
4.3.3. In vivo injection in the striatum 
Concentrated viral stocks were thawed on ice. Adeno-associated viral vectors 
(AAV) encoding green fluorescent protein (GFP) or mouse calpastatin (CAST) were 
stereotaxically injected into the mouse striatum in the following coordinates: antero-
posterior: +0.6mm; lateral: ±1.8mm; ventral: -3.3mm; tooth bar: 0). Animals were 
anesthetized by administration of avertin (10 µl/g, i.p.). 
Both seven months old transgenic mice of Machado-Joseph Disease and wild-
type mice littermates were injected with 1.2 !l of 1.0 x 108 transducing units (TU)/ml of 
either AAV1/2-GFP or AAV1/2-CAST in the striatum of both hemispheres. 
Mice were kept in their home cages for 3 months before being sacrificed for 
immunohistochemical or western-blot analysis. 
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4.3.4. Rotarod 
 To measure the motor coordinative abilities and balance of the transgenic mice, 
rotarod analyses were performed. Mice were tested on an accelerating rotarod (Letica 
Scientific Instruments, Panlab, Barcelona, Spain) starting at 4 rpm and accelerating to 
40 rpm over a period of 5 min. Three trials per test day, in which the latency to fall off 
the rotating rod was recorded, were carried out with 15 min rest between trials (Boy et 
al., 2009). The tests were repeated every 4 weeks. The mean of the best two trials of 
each week was considered for graphic representation. 
 
4.3.5. Open field analysis 
 For assessment of the mice explorative behaviour, open field tests were 
performed. Mice were placed in a 50 x 50 cm arena with 50 cm high walls and their 
movement activity was recorded for 15 min (Boy et al., 2009) using the ActiTrack 
System (Panlab, Barcelona, Spain). 
 
4.3.6. Immunohistochemical procedure 
 After an overdose of avertin (2.5x 12 µl/g, i.p.), transcardial perfusion of the 
mice was performed with a phosphate solution followed by fixation with 4% 
paraphormaldehyde (PFA). The brains were removed and post-fixed in 4% PFA for 24 
h and cryoprotected by incubation in 25% sucrose/ phosphate buffer for 48 h. The 
brains were frozen and 25 µm coronal sections were cut using a cryostat (LEICA 
CM3050 S) at -21°C. Slices throughout the entire striatum were collected in anatomical 
series and stored in 48-well trays as free-floating sections in PBS supplemented with 
0.05 µM sodium azide. The trays were stored at 4°C until immunohistochemical 
processing.  
Free-floating sections from injected mice were processed overnight at 4ºC with 
double stainings for ataxin-3 (1H9; 1:3000; Chemicon, Temecula, CA) and calpastatin 
(H300, 1:250, Santa Cruz), after incubation in blocking solution at RT for 2 h in 
PBS/0.1% Triton X-100 containing 10% NGS (Gibco). Sections were washed three 
times and incubated for 2 h at RT with the corresponding secondary antibodies coupled 
to fluorophores (1:200; Molecular Probes, Oregon, USA) diluted in the respective 
blocking solution. The sections were washed three times, incubated with nuclear 
marker (DAPI, blue) and then mounted in Fluorsave Reagent® (Calbiochem, Germany) 
on microscope slides. 
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Staining was visualized using Zeiss Axioskop 2 plus and Zeiss LSM 510 Meta 
imaging microscopes (Carl Zeiss Microimaging, Germany) and the AxioVision 4.7 and 
Zeiss LSM510 software packages (Carl Zeiss Microimaging). 
 
4.3.7. Cell counts of ataxin-3 perinuclear staining 
 Coronal sections showing complete rostrocaudal sampling (8 sections) of the 
striatum were visualized with a x20 objective. The analyzed areas of the striatum 
encompassed the entire region containing ATX-3 perinuclear immunoreactivity. All cells 
were manually counted using a cell counter. 
 
4.3.8. Western-blot analysis 
For assessment of ataxin-3 proteolysis in the transgenic mouse model of MJD, 
transcardial perfusion of the mice was performed with ice-cold phosphate buffered 
saline containing 10 mM EDTA and 10 mM of the alkylating reagent N-ethylmaleimide, 
to avoid post-mortem calpain overactivation. The different brain regions (cortex, 
striatum, cerebellum and brainstem) were then dissected and sonicated in RIPA buffer 
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 7 mM EDTA, 1% NP-40, 0.1% SDS, 10 µg/ml 
DTT, 1mM PMSF, 200 !g/ml leupeptin, protease inhibitors cocktail). 
Equal amounts (20 µg of protein) were resolved on 12% SDS-polyacrylamide 
gels and transferred onto PVDF membranes. Immunoblotting was performed using the 
monoclonal anti-ataxin-3 antibody (1H9, 1:1000; Chemicon, Temecula, CA), 
monoclonal anti-polyglutamine antibody (1C2, MAB1574, 1:1000; Chemicon), 
polyclonal anti-calpastatin antibody (H300, 1:200; Santa Cruz) and monoclonal anti-"-
actin (clone AC-74, 1:5000; Sigma) or monoclonal anti-"-tubulin I (clone SAP.4G5, 
1:15000; Sigma). Semi-quantitative analysis was carried out using Quantity-one 1-D 
image analysis software version 4.5. A partition ratio with actin or tubulin was 
calculated. 
 
4.3.9. Statistical analysis 
 Statistical analysis was performed using one-way ANOVA or two-way ANOVA 
followed by Bonferroni test for selected pairs comparison. Values of p<0.05 were 
considered statistically significant; p<0.01 very significant; and p<0.001 extremely 
significant. 
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4.4. Results 
 
4.4.1. Inhibition of calpains increases perinuclear ataxin-3 
localization 
 In order to investigate whether calpain inhibition would mitigate the phenotype 
of a MJD transgenic mouse model, seven months old mice were injected bilaterally in 
the striatum with adeno-associated viral vectors (AAV) encoding for either calpastatin 
(CAST), an endogenous calpain-specific inhibitor (Takano et al., 2005), or green 
fluorescent protein (GFP), as a control. Wild-type littermates were also subjected to 
stereotaxic injection following the same experimental paradigm.  
The presence of intranuclear inclusions is considered a hallmark of 
polyglutamine disorders, including MJD (Paulson et al., 1997b). However, in the 
transgenic MJD mouse model used in this study, only cytoplasmic inclusions were 
observed in the cortex and in the striatum of older mice. Nevertheless, a more diffuse 
nuclear immunoreactivity of ataxin-3 was observed in the striatum of ten months old 
transgenic mice (Fig. 4.1G-I), and not in their wild-type littermates (Fig. 4.1A-C). Upon 
calpastatin overexpression, although without co-localization of calpastatin with ataxin-3, 
the number of cells with perinuclear ataxin-3 localization increased significantly in the 
viral transduced area. This significant increase was only observed when calpain 
inhibition was promoted in transgenic mice, but not in their wild-type littermates (Fig. 
4.1M), suggesting that calpains are the proteases required for mutant ataxin-3 
translocation to the nucleus. 
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Figure 4.1. Calpain inhibition suppressed intranuclear localization of mutant ataxin-3, mediating 
perinuclear localization. Immunohistochemical analysis of A-F, wild-type and G-L, transgenic 
MJD mice littermates twelve weeks post-injection of adeno-associated viral vectors encoding for 
A-C,G-I, green fluorescent protein (GFP) or D-F,J-L, calpastatin (CAST) using an A,D,G,J, anti-
ataxin-3 antibody (Ab 1H9, red) and E,K, anti-calpastatin (H300, green). Nuclear marker (DAPI, 
blue) was used. M, Quantification of the absolute number of cells with perinuclear ataxin-3 
localization in both transgenic mice of MJD (MJD, related to panel G-L) and their wild-type (wt, 
related to panel A-F) littermates either injected with AAV-GFP or AAV-CAST (n=4). 
 
4.4.2. Inhibition of calpains decreases full-length mutant ataxin-3 
levels, stabilizing the fragments formation 
 To better understand the mechanism through which calpain inhibition modified 
the subcellular localization of mutant ataxin-3, preventing its nuclear localization, we 
performed western-blot analysis of striata dissected from ten months old transgenic 
mice of MJD and their wild-type littermates injected twelve weeks before with either 
AAV-CAST or AAV-GFP. Western blotting with the anti-ataxin-3 antibody Ab 1H9, 
which recognizes amino acids E214-L233, allowed detection of different ataxin-3 
species: mouse endogenous ataxin-3 at 42 kDa, transgenic full-length protein at 61 
kDa, aggregates in the stacking gel, and fragments at ~24, 31 and 35 kDa (Fig. 4.2A). 
Importantly, the 24 kDa fragment, but not the 31 and 35 kDa species, was also 
detected with the antibody Ab 1C2 (Fig. 4.2B), which is specific for the polyglutamine 
stretch present at the C-terminal of ataxin-3. These results suggest a N-terminal 
position for the ~31 and 35 kDa fragments, and a C-terminal for the ~24 kDa fragment 
of ataxin-3. 
 Calpastatin overexpression promoted a decrease of the transgenic full-length 
protein levels and aggregates by 43% and 35%, respectively. Unexpectedly, when 
comparing the two transgenic mice groups: the control (MJD-GFP) and the calpain 
inhibition group (MJD-CAST), we observed that the 24 kDa fragment level was 
increased by 53% when calpastatin was overexpressed (Fig. 4.2C). However, when 
the four groups of both wild-type and transgenic mice were compared, results suggest 
that what happened was not an increase, but a stabilization of the proteolytic process 
in the MJD-CAST group, and a decrease of the fragment level in the MJD-GFP group 
(Fig. 4.2D), possibly due to the consequent ataxin-3 aggregation in the latter one (Fig. 
4.1G-I, 4.2A,C). 
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Figure 4.2. Calpastatin overexpression in striatum promoted a decrease of full-length mutant 
ataxin-3 levels and aggregation, maintaining ataxin-3 proteolysis. Western-blot analysis of 
dissected striata of transgenic mice of MJD (MJD) and their wild-type (wt) littermates twelve 
weeks post-injection of either adeno-associated viral vectors encoding for green fluorescent 
protein (GFP) or calpastatin (CAST).  A, Representative blot using an anti-ataxin-3 antibody (Ab 
1H9), which recognizes amino acids E214-L233. B, Depicted is a blot of a pool of 4 animals for 
each condition using Ab 1C2, specific for the polyglutamine stretch, present at the C-terminal of 
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ataxin-3. C, Densitometric quantification of different ataxin-3 species (fragment, full-length and 
aggregates), using Ab 1H9, relative to actin (n=4). Graph related to part of panel A. D, 
Densitometric quantification of ataxin-3 fragment, using Ab 1H9, relative to actin (n=4). Graph 
related to panel A. 
 
4.4.3. Proteolysis is an early event in transgenic mice of Machado-
Joseph disease 
 According to the toxic fragment hypothesis, proteolytic fragments of expanded 
polyglutamine proteins show a great propensity for aggregation and may trigger 
pathogenesis (Haacke et al., 2006; Ikeda et al., 1996; Tarlac and Storey, 2003). 
Previously, we have shown that calpain inhibition suppressed fragmentation and 
consequent aggregation in a lentiviral mouse model of MJD (Alves et al., 2008; Simões 
et al., 2012). However, in the transgenic mouse model here used, even though we 
could detect an increased number of cells with mutant ataxin-3 perinuclear localization 
(Fig. 4.1) and a decreased aggregation (Fig. 4.2), upon calpastatin overexpression, 
these processes were not accompanied by a decreased fragmentation, but instead a 
maintenance of the fragment formation (Fig. 4.2D). As the transgenic mice were 
injected when they were seven months old, we wondered if the proteolytic process 
could be an early event. To answer this question, we sacrificed two and seven months 
old non-injected transgenic mice, and performed a western-blot analysis of specific 
dissected brain regions: cortex (Fig. 4.3A), striatum (Fig. 4.3B), cerebellum and 
brainstem (Fig. 4.4). Our studies show that proteolysis of both wild-type and mutant 
ataxin-3 increased with age in cortex, striatum (Fig. 4.3C) and cerebellum (Fig. 4.4C). 
Interestingly, when relative levels of ataxin-3 fragments of transgenic MJD mice were 
compared to fragments levels of their age-matched wild-type littermates, we observed 
that although proteolysis increased with age, the distinction of this event between wild-
type and transgenic mice occurred when mice were two months old, exhibiting a 1.8 
fold increase in cortex and 2.5 fold in striatum of transgenic mice (Fig. 4.3D). 
Furthermore, while proteolysis of wild-type ataxin-3 was increased with age, from two 
to seven months old, by 4.3 fold in cortex and 2.8 fold in striatum, proteolysis of mutant 
ataxin-3 with age was only increased by 2.7 fold in cortex and 1.3 fold in striatum (Fig. 
4.3C), possibly due to an early proteolysis followed by aggregation. Our results suggest 
that the key event in Machado-Joseph disease pathogenesis is an early and enhanced 
proteolytic cleavage of mutant ataxin-3, although with age there is an increase in 
proteolysis independently of genotype, possibly due to an impaired efficiency of 
endogenous proteolytic regulators. 
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Figure 4.3. Proteolysis is an early event in MJD transgenic but not wild-type mice, increasing 
with age in a genotype-independent manner. Western-blot analysis of dissected A, cortex and 
B, striatum of two (2M) and seven (7M) months old non-injected transgenic mice of MJD (MJD) 
and their wild-type (wt) littermates, using an anti-ataxin-3 antibody (Ab 1H9). C-D, Densitometric 
quantification of ataxin-3 fragments using Ab 1H9, relative to actin (n=3). Both graphs are 
related to panels A-B. C, Relative levels of ataxin-3 fragments were compared to levels of two 
months old wild-type mice. D, Relative levels of ataxin-3 fragments of transgenic mice of MJD 
were compared to levels of their age-matched wild-type littermates. 
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Figure 4.4. Proteolysis in cerebellum and brainstem. Western-blot analysis of dissected A, 
cerebellum and B, brainstem of two (2M) and seven (7M) months old non-injected transgenic 
mice of MJD (MJD) and their wild-type (wt) littermates, using an anti-ataxin-3 antibody (Ab 1H9). 
C-D, Densitometric quantification of ataxin-3 fragments using Ab 1H9, relative to actin (n=3). 
Both graphs are related to panels A-B. C, Relative levels of ataxin-3 fragments were compared 
to levels of two months old wild-type mice. D, Relative levels of ataxin-3 fragments of transgenic 
mice of MJD were compared to levels of their age-matched wild-type littermates. 
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4.4.4. Calpastatin depletion in transgenic mice of Machado-Joseph 
disease is age-dependent 
 We previously showed that calpain mutant ataxin-3 proteolysis and consequent 
neurodegeneration could be propelled by calpastatin depletion but the contribution of 
aging to the levels of this endogenous calpain inhibitor remains unknown. Therefore, in 
this study, we investigated whether calpastatin levels are depleted with age, in a late 
onset and slowly progressive transgenic mouse model expressing full-length ataxin-3 
with 77 glutamines. For this purpose, we sacrificed non-injected two, seven and eight 
and a half months old transgenic mice and performed western-blot analysis of four 
different brain dissected regions - cortex, striatum, cerebellum and brainstem, and 
compared calpastatin levels to wild-type littermates (Fig. 4.5A-B). In two months old 
mice, no difference in calpastatin levels was observed between the two genotypes. 
However, as mice became older, a 17% and 44% decrease in the relative levels of 
calpastatin was detected at ages seven and eight and a half months, respectively, in 
the transgenic mice of MJD, when compared to their wild-type littermates (Fig. 4.5C), 
independently of the brain region analysed. These results suggest that calpastatin 
levels decrease with age presumably contributing to calpain dysregulation and MJD 
pathogenesis. Nevertheless, this may be a downstream event to the previously 
described enhancement of proteolysis. 
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Figure 4.5. Calpastatin depletion in transgenic MJD mice is age-dependent. Western-blot 
analysis of different brain regions (cortex, striatum, cerebellum, brainstem) of A, two, seven and 
B, eight and a half months old non-injected transgenic mice of MJD (MJD) and their wild-type 
(wt) littermates, using an anti-calpastatin antibody (H300). C, Densitometric quantification of 
calpastatin levels relative to actin (n=3). Mean of the four brain regions for each animal was 
considered as n=1. Graph related to panels A-B.  
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 4.4.5. Striatum calpain inhibition was not sufficient to alter 
phenotypic symptoms due to a broader mutant ataxin-3 expression 
 Age-dependent calpastatin depletion and contribution of calpain-mediated 
proteolysis to nuclear localization of ataxin-3 and aggregation prompted us to 
investigate if calpain inhibition through calpastatin overexpression could mitigate 
behavioural phenotype and alter motor coordination through rescue of calpastatin 
levels. In agreement, and as mice expressed the transgene predominantly in the 
forebrain, we transduced the mouse model of MJD bilaterally in the striatum with AAV 
vectors encoding either for calpastatin (CAST) or for green fluorescent protein (GFP), 
as a control. Wild-type littermates were also injected following the same experimental 
paradigm to evaluate possible negative effects of calpain inhibition. To determine the 
motor activity of mice, accelerating rotarod and open field tests were performed before 
injection and four, eight and twelve weeks after injection. 
 Transgenic mice exhibited a minor deficit in the accelerating rotarod test, as 
they could not equilibrate as long as wild-type mice on the rotating rod (Fig. 4.6A) and 
were less active than wild-type littermates (Fig. 4.6B). No differences were observed 
between CAST or GFP overexpression. Furthermore, calpain inhibitory and control 
effects were similar in both genotypes, being parallel over time after injection (Fig. 
4.6A-B). This might be explained by the fact that although the mutant ataxin-3 
transgene is expressed preferentially in the forebrain, mutant ataxin-3 expression was 
also found in cerebellum and brainstem (Fig. 4.2A, 4.6C), regions that were not 
transduced with the vectors and that might be determinant for mice behavioural 
phenotype. Therefore the approach used in this model, should also target these 
regions, preferably at a young age to prevent proteolysis.  
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Figure 4.6. Calpain inhibition in striatum was not sufficient to alter phenotypic behaviour due to 
mutant ataxin-3 expression in other brain regions than forebrain. A, Rotarod analysis and B, 
open field test of transgenic mice of MJD (MJD) and their wild-type (wt) littermates zero, four, 
eight and twelve weeks post-injection of either adeno-associated viral vectors encoding for 
green fluorescent protein (GFP) or calpastatin (CAST) (n=8 for each condition). C, 
Representative western-blot analysis of dissected cortex, cerebellum and brainstem of mice 
(sacrificed after the behavioural tests of panels A-B) using Ab 1C2, specific for the 
polyglutamine stretch, present at the C-terminal of ataxin-3 (n=4). 
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4.5. Discussion 
 
 In this work we provide evidence in a mouse model of MJD expressing human 
ataxin-3 with 77 CAG repeats under the control of the calcium/ calmodulin-dependent 
protein kinase II promoter that a) calpains are the proteases involved in mutant ataxin-3 
translocation to the nucleus and consequent aggregation, b) mutant ataxin-3 cleavage 
is an early event, and c) calpastatin depletion is age dependent. 
 Ataxin-3 is present in both cytoplasm and cell nucleus (Paulson et al., 1997a; 
Schmidt et al., 1998; Tait et al., 1998; Trottier et al., 1998). Nevertheless, the 
importance of nuclear localization has been demonstrated for polyglutamine 
pathogenesis (Yang et al., 2002), and for the MJD manifestation of symptoms in 
particular (Bichelmeier et al., 2007). Therefore, understanding how ataxin-3 enters the 
nucleus under pathogenic conditions is highly relevant to understand and modify MJD 
pathogenesis. Nuclear transport may be mediated by recognition of specific nuclear 
localization signals (NLS) (Albrecht et al., 2004; Antony et al., 2009; Macedo-Ribeiro et 
al., 2009; Rodrigues et al., 2007; Tait et al., 1998) or nuclear export signals (NES) 
(Albrecht et al., 2004; Antony et al., 2009). In addition, phosphorylation of serine 
residues within ataxin-3 (Mueller et al., 2009; Pastori et al., 2010) or proteotoxic stress, 
such as heat shock and oxidative stress (Reina et al., 2010), could also determine 
cellular localization. More recently, we have shown that calpains contribute to nuclear 
localization and aggregation through ataxin-3 mediated proteolysis in a lentiviral mouse 
model of MJD: as calpastatin levels increased, the size and number of mutant ataxin-3 
inclusions decreased (Simões et al., 2012). Here, we further assessed calpains 
involvement in ataxin-3 translocation to the nucleus in a transgenic mouse model of 
MJD, by overexpressing the endogenous calpain-specific inhibitor calpastatin. Upon 
calpain inhibition, the number of cells with perinuclear ataxin-3 localization significantly 
increased within the viral transduced area (Fig. 4.1). As this significant increase was 
only observed when calpain inhibition was promoted in transgenic mice, but not in their 
wild-type littermates (Fig. 4.1M), our studies suggest that calpain proteases are 
required for mutant ataxin-3 translocation to the nucleus and that this process may be 
specific for the mutant protein. This might be explained by the different conformation 
the mutant protein bears due to the expanded polyglutamine stretch in comparison to 
the wild-type protein, as calpain cleavage is only weakly dictated by the primary 
sequence of its protein substrates, depending to a large extent on higher order 
structural features, such as peptide bond access, backbone conformation, or three-
dimensional structure (Cuerrier et al., 2005; Tompa et al., 2004). 
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 In addition to nuclear localization, growing evidence suggests that neurotoxicity 
of MJD may derive from proteolytic cleavage of the mutant ataxin-3, an idea referred to 
as the toxic fragment hypothesis (Ikeda et al., 1996). Furthermore, the proteolytic 
events were reported to be the trigger of the aggregation process (Haacke et al., 2006), 
being either caspases (Berke et al., 2004; Jung et al., 2009; Wellington et al., 1998) or 
calpains (Haacke et al., 2007; Koch et al., 2011; Simões et al., 2012) the executioner 
proteases involved in this process. In the present study, we were able to show that the 
promotion of calpain inhibition when transgenic mice were already seven months old 
was still efficacious in decreasing the mutant full-length protein levels and aggregates 
by 43% and 35%, respectively (Fig. 4.2A,C). Nevertheless, calpastatin overexpression 
only succeeded in maintaining and not decreasing fragments formation (Fig. 4.2D), 
which led us to investigate if the proteolytic process could be an early event. 
Accordingly, the sacrifice of two and seven months old non-injected transgenic mice 
and their wild-type littermates revealed that proteolysis of ataxin-3 increased with age, 
independently of genotype (Fig. 4.3A-C). However, distinction between the two 
genotypes occurred at an early time point, revealing that transgenic mice proteolysis is 
an early event, being significantly increased in the forebrain at the age of two months 
(Fig. 4.3D), suggesting that mutant ataxin-3 is a preferred substrate for proteolysis 
when compared to the wild-type protein. Nevertheless, even though transgenic mice 
exhibited at both ages a higher level of proteolysis, the increase of proteolysis 
observed when transgenic mice were two and later seven months old was not as 
pronounced as for the wild-type protein (Fig. 4.3C), probably due to the aggregation 
process observed in the mutant case. A previous study in COS-7 cells reported that 
mutant ataxin-3 was cleaved to a lesser extent than the wild-type protein (Pozzi et al., 
2008). In the present study, using the CamKII-MJD77 mouse model at a late time-point 
(7 months), both proteins were cleaved at similar extent, but proteolysis was increased 
for mutant ataxin-3 at an earlier time suggesting that mutant ataxin-3 in the transgenic 
mice is submitted to a prior increase in proteolysis that may trigger pathogenesis.  
 Previously, we have shown that calpastatin was depleted in human brain tissue, 
in the lentiviral mouse model and in a MJD mouse model containing a truncated form of 
ataxin-3 bearing 69 glutamines (Simões et al., 2012), in accordance to what was 
observed in Alzheimer’s disease models (Rao et al., 2008; Vaisid et al., 2007). 
Calpains are activated in the presence of increased calcium (Goll et al., 2003), whose 
signalling has been reported to be deranged in MJD (Chen et al., 2008). As calpastatin 
binding to calpain deactivates this protease (Goll et al., 2003), a depletion of the 
endogenous inhibitor might promote an imbalance of the system, leading to calpain 
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overactivation and consequent neurodegeneration. Here, we were able to establish a 
time line of the proteolytic mechanism in MJD. To achieve it, we compared calpastatin 
levels of non-injected two, seven and eight and a half months old CamKII-MJD77 mice 
with their wild-type littermates. Our results show that as mice became older, the relative 
levels of calpastatin decrease, being significantly diminished at the oldest age analysed 
(Fig. 4.5). Interestingly, calpastatin depletion appears to be developed downstream to 
mutant ataxin-3 cleavage. Calpastatin depletion may come about either by calpains or 
caspases activation, accelerating a cascade involving calpain-mediated activation of 
specific MJD pathogenic processes, particularly ataxin-3 proteolysis, translocation to 
the nucleus and aggregation, as well as unspecific death processes involving apoptosis 
or necrosis, cytoskeleton disruption and excitotoxicity (Goll et al., 2003). 
 Calpain inhibition through calpastatin overexpression in the striatum could not 
alter motor incoordination observed in CamKII-MJD77 mice (Fig. 4.6A), probably 
because its inhibition in striatum was not sufficient to overcome the toxic effects 
derived from ataxin-3 expression in other brain regions, such as the cerebellum and 
brainstem, where expression of mutant ataxin-3 was not expected in this model (Fig. 
4.6C). Another possibility could be the fact that calpain inhibition was only promoted 
when mice were seven months old. Therefore, even though mutant ataxin-3 nuclear 
localization was suppressed (Fig. 4.1) and full-length levels and aggregation were 
decreased, no reduction of the levels of proteolytic fragments were observed (Fig. 4.2), 
as this event may have occurred at a very early time point (Fig. 4.3), suggesting that it 
may have been too late to prevent the toxic fragments formation. Nevertheless, we 
speculate that if a broader approach at a younger age had been used reaching calpain 
inhibitory effects to all brain regions affected, before the beginning of the proteolytic 
process, a successful behavioural observation would have been achieved. 
 In conclusion, this study implicates calpains in ataxin-3 translocation to the 
nucleus, an involvement only detected for the mutant protein, when no other study had 
made a distinction between the nucleocytoplasmic shuttling between the two protein 
species. Furthermore, we show that proteolysis is an early event and that calpastatin 
depletion is age-dependent. In addition, our results indicate that calpastatin 
overexpression at a late stage of the proteolytic process can still decrease mutant 
ataxin-3 full-length levels and aggregation. Therefore, these findings suggest that 
calpains should be considered for MJD therapeutic intervention and that treatment 
should be initiated early in the neurodegeneration process. 
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5. Final conclusions and future perspectives 
 
 This thesis provides evidence that calpains are the proteases involved in 
proteolytic cleavage of mutant ataxin-3 in MJD. Calpain cleavage mediates mutant 
ataxin-3 translocation to the nucleus with consequent neurotoxicity, aggregation, and 
neurodegeneration, a pathogenic mechanism that is shown in this dissertation to be 
amenable to blockage through gene transfer or pharmacological calpain inhibition. 
  
According to the toxic fragment hypothesis, neurotoxicity might derive from the 
proteolysis of the host protein to liberate a polyQ fragment (Tarlac and Storey, 2003). 
In fact, an ataxin-3 fragment was detected in Q71 transgenic mice and post mortem 
brain tissue of MJD patients, whose levels increased with disease severity, supporting 
a relation between ataxin-3 proteolysis and disease progression (Goti et al., 2004). 
Either caspases (Berke et al., 2004; Jung et al., 2009; Wellington et al., 1998) or 
calpains have been reported to cleave ataxin-3 (Haacke et al., 2007; Koch et al., 2011). 
Independently of the proteases involved, recent studies suggest that not only the 
ataxin-3 C-terminal fragment is cytotoxic (Goti et al., 2004; Ikeda et al., 1996), but that 
the non-polyQ N-terminal fragment may also contribute to pathology through an 
impaired unfolded protein response (Hubener et al., 2011). Overall, such proteolytic 
events have been suggested to be the trigger of the aggregation process, a hallmark of 
pathology. However, while the N-terminal fragment promotes the formation of 
cytoplasmic aggregates (Hubener et al., 2011), the C-terminal fragment bearing the 
polyQ stretch leads to the formation of intranuclear inclusions (Berke et al., 2004; 
Haacke et al., 2006), being the nucleus considered a more important subcellular 
localization site than the cytoplasm for polyQ pathogenesis (Yang et al., 2002). 
Therefore, despite the toxicity of the cytoplasmatic N-terminal ataxin-3, a more 
pronounced phenotype is observed upon ataxin-3 nuclear localization (Bichelmeier et 
al., 2007), suggesting a determinant contribution of the nuclear-localized C-terminal 
fragment of mutant ataxin-3. 
Ataxin-3 nucleocytoplasmic shuttling activity was shown to be promoted by a) 
recognition of specific nuclear localization signals (NLS) or nuclear export signals 
(NES) (Albrecht et al., 2004; Antony et al., 2009; Macedo-Ribeiro et al., 2009; 
Rodrigues et al., 2007; Tait et al., 1998), b) phosphorylation on serine residues within 
ataxin-3 (Mueller et al., 2009; Pastori et al., 2010) and c) proteotoxic stress, such as 
heat shock and oxidative stress (Reina et al., 2010). 
 In the present work, building on prior knowledge, we investigated the role of 
mutant ataxin-3 proteolysis  in ataxin-3 subcellular localization and MJD pathology. Our 
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findings demonstrate for the first time in vivo, without external protease activation, that 
calpain-mediated proteolysis has a determinant role in ataxin-3 toxic fragments 
formation, ataxin-3 translocation to the nucleus and MJD pathogenesis. In addition, we 
have shown that calpain inhibition mediated by its endogenous specific inhibitor 
calpastatin and by the synthetic compound BDA-410 is effective through either in situ 
viral transduction in the brain or oral administration, respectively. Both calpain inhibitors 
decreased neurotoxicity and neurodegeneration in vivo, suggesting their potential use 
as a therapeutic approach for MJD. 
 
 In a CamKII-MJD77 mouse model of MJD and wild-type littermates we 
observed that proteolysis of both wild-type and mutant ataxin-3 increased with age in 
cortex, striatum and cerebellum. However, when mice were two but not seven months 
old, the levels of ataxin-3 fragments were increased 1.8 fold in the cortex and 2.5 fold 
in the striatum of transgenic mice bearing 77 glutamines as compared to wild type 
mice. These results suggest that activation of proteolysis by mutant ataxin-3 is an early 
event within the pathogenic mechanism of MJD (chapter 4). 
 The endogenous calpain specific inhibitor calpastatin (Goll et al., 2003) is 
depleted in the post mortem dentate nucleus of MJD patients, in the lentiviral mouse 
model, in the L7-MJDtr69 mouse model and in the CamKII-MJD77 mouse model 
(chapter 2,4). In the latter model, we have observed that calpastatin depletion in 
transgenic mice in comparison to their wild-type littermates is age-dependent in all 
brain regions analysed: cortex, striatum, cerebellum and brainstem. As mutant ataxin-
3-associated increased proteolysis is an early event and calpastatin depletion reaches 
statistical significance between mutant and wild-type genotypes later in age, these 
results suggest that calpastatin depletion is a downstream event to mutant ataxin-3 
cleavage (chapter 4). Nevertheless, subsequent decreased calpastatin levels 
contribute to an imbalance of the calpain-calpastatin system, which might lead to a 
continuous calpain overactivation exacerbating a cascade involving calpain-mediated 
mutant ataxin-3 proteolysis, translocation to the nucleus, aggregation, neurotoxicity and 
neurodegeneration (chapter 2,3,4). 
 The aforementioned cascade was observed initially in the lentiviral mouse 
model (chapter 2,3) and later confirmed in the CamKII-MJD77 mouse model (chapter 
4). When calcium concentration increases in the intracellular compartment, a subset of 
axonal structural proteins appears to be vulnerable to calpain activity, including !II-
spectrin, a potential biomarker for neuronal cell injury (Liu et al., 2008). Levels of the 
calpain-generated 150/145 kDa fragments of !II-spectrin were increased when rat 
cerebellar granule neurons were transduced with lentiviral vectors encoding for mutant 
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ataxin-3 in opposition to wild-type ataxin-3 and non-infected cultures, suggesting that 
mutant ataxin-3 expression leads to calpain activation (chapter 3). We have shown that 
both calpastatin and BDA-410 reduce the cleavage of the calpain natural substrate !-
spectrin, confirming that these calpain inhibitors are able to mitigate calpain activity in 
the lentiviral mouse model (chapter 2,3). The implications of the observed calpain 
overactivation in MJD were elucidated as described next. 
In agreement to the toxic fragment hypothesis as a pathogenic mechanism for 
MJD, we have identified mutant ataxin-3 cleavage fragments with two molecular 
weights:  
a) ~26 kDa, detected using Ab 1H9, which recognizes the human ataxin-3 from 
amino acids E214-L233; Ab myc, an antibody for a myc tag located at the N-terminal of 
the protein; and Ab 1C2, an antibody specific for the polyQ stretch, present at ataxin-3 
C-terminal;  
b) and ~34 kDa, only detected by Ab 1H9 and Ab 1C2.  
Cleavage of mutant ataxin-3 at amino acid 220 might lead to the formation of a 
N and a C-terminal fragment of ~26 kDa. A simultaneous cleavage at amino acids 60 
and 260 may also give rise to the observed ~26 kDa fragment, while cleavage at 
aminoacid 154 may generate a mutant C-terminal ~34 kDa fragment (chapter 2). Wild-
type ataxin-3 cleavage also results in the formation of a ~26 kDa fragment, but not in 
the formation of a ~34 kDa fragment (chapter 3). Notably, calpain inhibition upon 
calpastatin overexpression by AAV transduction and oral administration of BDA-410 
promotes a decrease of both fragments formation in the lentiviral mouse model 
(chapter 2,3). As proteolysis is an early event, calpastatin overexpression in the 
CamKII-MJD77 mouse model at a late time-point leads to a stabilization of the 
proteolytic process (chapter 4). In conclusion, our results confirm the cleavage sites at 
amino acids 60 and 260 proposed by Haacke and collaborators in 2007 and bring two 
new possibilities at amino acids 154 and 220 (see Fig. 5.1). We have also shown that 
calpains are the proteases responsible for the proteolytic cleavage of ataxin-3 and that 
calpain inhibition blocks this process. Whether calpain inhibitors could promote 
neuroprotection was further evaluated by analysis of ataxin-3 species levels and 
subcellular localization. 
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Figure 5.1. Calpain-mediated proteolysis of ataxin-3. Mutant ataxin-3 cleavage at amino acid 
220 and simultaneously at amino acids 60 and 260 (right side of the figure) generates a ~26 
kDa fragment (let side of the figure), while cleavage at amino acid 154 leads to the formation of 
a ~34 kDa fragment, only detected for mutant ataxin-3. Cleavage of wild-type ataxin-3 at 
position 154 and simultaneous cleavage at amino acids 60 and 260 may generate a ~26kDa 
fragment. Left side of the figure represents a western blot stained with either Ab 1H9 or Ab 1C2. 
 
Upon polyglutamine expansion, ataxin-3 accumulates in the nucleus as 
intranuclear inclusions. In the lentiviral mouse model, calpastatin overexpression 
decreases the number of mutant ataxin-3 inclusions. Furthermore, as calpastatin levels 
increase, the diameter of those inclusions progressively decreases (chapter 2). Daily 
oral administration of BDA-410 promotes a decrease of full-length ataxin-3 levels in rat 
cerebellar granule neurons and a reduction of mutant ataxin-3 intranuclear inclusions 
formation in the lentiviral mouse model (chapter 3). In the CamKII-MJD77 mouse 
model, despite late calpastatin overexpression, the number of cells with perinuclear 
ataxin-3 localization still increased significantly in the viral transduced area, while the 
mutant full-length protein levels and aggregates decreased (chapter 4). We confirmed 
that the observed decreased fragmentation and aggregation is not a consequence of 
decreased mRNA expression. In fact, calpain inhibition by BDA-410 administration is 
able to suppress ataxin-3 proteolysis despite a three-fold increase in mRNA levels of 
mutant human ataxin-3 without alteration for the wild-type gene (chapter 3). These 
results suggest that calpain-mediated proteolysis of mutant ataxin-3 between the NES 
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and the NLS discussed above is required for its translocation to the nucleus and 
consequent aggregation. Calpain cleavage might therefore be considered a new 
mechanism that modulates ataxin-3 nucleocytoplasmic shuttling activity. 
Although our study supports the toxic fragment hypothesis, whereby smaller 
proteolytic fragments are considered the toxic species, our results also provide 
evidence that mutant ataxin-3 aggregates of specific size have different toxic 
properties. Accordingly, larger aggregates of a mean diameter of 4 "m colocalize more 
with cleaved caspase-3 than smaller aggregates of mean diameter of 1.6 "m (chapter 
3). Calpain inhibition by calpastatin overexpression decreases aggregates diameter 
and number, while BDA-410 administration reduces the number of mutant ataxin-3 
positive cells co-expressing cleaved caspase-3, decreasing cytotoxicity (chapter 2,3).  
The observation that both fragments and large aggregates are pernicious to 
brain cells in MJD and that calpain inhibition can prevent their formation has 
implications in neuroprotective therapies. In agreement, both calpastatin 
overexpression and BDA-410 administration reduce loss of DARPP-32 
immunoreactivity, a regulator of dopamine receptor signaling, and the number of 
shrunken hyperchromatic nuclei in the lentiviral mouse model. No loss of DARPP-32 
staining or increase of degenerated shrunken hyperchromatic nuclei was observed in 
mice expressing wild-type ataxin-3 treated or not with the calpain inhibitors (chapter 
2,3). Overall, these results are indicative of a neuroprotective effect provided by 
calpastatin and BDA-410 when calpains are overactivated. 
As an effective treatment for MJD is still lacking, our results suggest that calpain 
inhibitors are good candidates as therapeutic compounds. Unfortunately, we could not 
show in the CamKII-MJD77 mouse model that calpain inhibition through calpastatin 
overexpression in the striatum could alter motor incoordination, probably due to a) 
mutant ataxin-3 expression in other brain regions, such as the cerebellum and 
brainstem; b) and late calpain inhibition, considering a time line within the proteolytic 
process (chapter 4). Therefore, we speculate that if a broader approach at a younger 
age had been used providing calpain inhibitory effects to all brain regions affected, a 
successful behavioural observation would have been achieved. How mutant ataxin-3 
expression leads to initial calpain activation and whether calpain inhibition modifies 
ataxic behaviour remain to be clarified. 
 
In conclusion, we have shown that calpains are the proteases involved in MJD 
formation of ataxin-3 toxic fragments, which can translocate to the nucleus and lead to 
the formation of large toxic inclusions. Further calpastatin depletion may exacerbate 
this pathogenic mechanism. Calpain inhibiton can block this process even after late 
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administration and promote neuroprotection, without compromising wild-type ataxin-3 
localization (see Fig. 5.2). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Calpain-mediated proteolysis in Machado-Joseph disease. Calpain-mediated 
proteolysis of mutant ataxin-3, predicted at amino acids 220, 154, 60 and 260, leads to the 
formation of toxic fragments of ~26 kDa and ~34 kDa, whose translocation to the nucleus and 
consequent aggregation leads to neurodegeneration. Calpastatin depletion exacerbates this 
mechanism. Therefore, calpain inhibition might be a promising therapeutic approach for MJD. 
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